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ABSTRACT 
 
Malaria,  caused  by  an  intracellular  Plasmodium  parasite,  remains  a  devastating  disease,  
having  claimed  approximately  655000  lives  worldwide  in  2010.  The  Medicines  for  
Malaria  Venture  suggests  a  ―single-dose  radical  cure‖  as  the  ideal  malaria  treatment  
since  rapid  clearance  of  blood-stage  parasites  and  symptom  relief  improves  patient  
compliance  and  limits  drug  resistance.  Thus,  novel  antimalarials  should  be  rapid-acting  
and  assessing  their  rate  of  activity  is  critical  to  drug  discovery.  Traditional  evaluation  
of  this  rate  by  morphological  assessments  is  flawed  by  highly  subjective,  operator-
specific  interpretations,  mainly  due  to  heterogeneous  parasite  morphology  under  routine  
culture  conditions.  This  study  aimed  to  develop  an  alternative,  quantitative  assay.  
Energy  is  vital  for  the  growth  and  maintenance  of  all  living  organisms.  Commercially  
available  kits  allow  rapid  quantification  of  the  cell‘s  energy  currency,  ATP.  Therefore,  
quantification  of  parasite  ATP  shows  potential  for  diagnosing  abnormal  parasite  
metabolism  and  the  kinetics  of  drug  action.  In  this  study,  a  rapid  protocol  for  
detecting  ATP  in  Plasmodium  falciparum  parasites  using  a  luminescence-based  kit  was  
developed  and  optimised.  Furthermore,  luciferase-expressing  transgenic  parasites,  in  
which  luciferase  activity  is  detected  using  a  similar  kit,  were  acquired.  The  utility  of  
both  methods  for  evaluating  the  rate  of  drug-induced  stress  was  explored  using  
antimalarials  with  varying  modes  of  action  and,  presumably,  rates  of  activity.  Results  
showed  that  parasite  ATP  remained  unchanged,  increased  or  decreased  during  drug  
exposure.  Morphological  examinations  by  light  microscopy  and  a  Recovery  assay,  
aided  interpretation  of  the  drug-induced  changes  in  parasite  ATP.  These  investigations  
suggested  that  unchanged  parasite  ATP  levels  reflect  poor  drug  action,  increased  ATP  
levels  indicate  a  stress  response  and  partially  compromised  viability,  while  
significantly  reduced  ATP  reflects  severely  compromised  viability.  Concerning  the  
Luciferase  assay,  parasite  luciferase  activity  decreased  during  drug  exposure,  even  in  
the  presence  of  proteasome  inhibitors.  Changes  in  parasite  ATP  and  luciferase  activity  
occurred  at  rates  which  suggested  that  chloroquine  is  slow-acting,  mefloquine  has  a  
moderate  rate  of  activity  and  artemisinin  is  rapid-acting.  These  findings  are  compatible  
with  the  expected  rates  of  activity  of  these  established  antimalarials.  Hence,  
measurement  of  parasite  ATP  and/or  luciferase  activity  may  support  assessments  of  
parasite  health  and  the  kinetics  of  antimalarial  action  during  drug  discovery. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1.    MALARIA 
Malaria is caused by an obligate intracellular protozoan parasite of the genus Plasmodium 
and transmitted by the female Anopheles mosquito (Francis et al., 1997). This potentially 
fatal parasitic disease targets several vertebrate hosts including humans, monkeys and birds 
(Cox, 2010). Humans have been victims of the disease since ancient times, with reports 
detailing signs and symptoms of malaria dating back to as early as 2700 BC (Cox, 2010).  
 
The parasites responsible for the disease were discovered in 1880 by Charles Louis Alphonse 
Laveran, a French army surgeon, while working in Algeria (Cox, 2010). On the basis of 
reports that a pigment was observed in the spleens of malaria patients, Laveran used light 
microscopy to search for the pigment in fresh, unstained blood samples of malaria patients. 
His efforts were rewarded when he observed the pigment in leucocytes and in, or on, 
erythrocytes. Upon closer examination, Laveran noticed that the parasite took on several 
different forms including crescents, and motile and motionless spherical forms that contained 
pigment. He described a course of events that started with clear spots which grew, obtained 
pigment and filled the erythrocyte before rupturing at a point which coincided with fever, a 
well-known symptom of malaria. Laveran‘s description of events, though based solely on 
light microscopy without the use of stains or an oil immersion lens, is still compatible with 
the currently accepted description of the intra-erythrocytic development of the malaria 
parasite. After carefully examining the blood of 200 patients, Laveran noted that the crescent-
shaped bodies were present in all malaria-infected individuals but not in uninfected patients. 
Despite the leading theory at the time which suggested that malaria was caused by a 
bacterium, Laveran realised that the erythrocytic bodies which he had discovered were in fact 
protozoan parasites which he named Oscillaria malariae, and proposed were the cause of 
malaria.  
 
Laveran‘s theory initially received much scepticism, with leading malariologists and 
microbiologists not convinced that what Laveran was describing was anything more than 
disintegrating erythrocytes (Cox, 2010). However, he persevered and by 1884, had convinced 
leading Italian malariologists that the causative agent of malaria was a protozoan and not a 
bacterium (Cox, 2010). The development of novel staining techniques and the oil immersion 
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lens allowed for more detailed investigations of the parasite and by 1890 it was widely 
accepted that malaria was caused by a protozoan parasite that invaded and replicated within 
erythrocytes (Cox, 2010). In addition, after much debate, three species which cause human 
malaria were identified, Laverania malariae, Haemamoeba vivax and Haemamoeba 
malariae, currently now known as Plasmodium falciparum, P. vivax and P. malariae, 
respectively (Cox, 2010). A fourth species, P. ovale, was discovered later by John Stephens 
while working in Africa (Cox, 2010). In 1897, mosquitoes were identified as vectors of avian 
malaria by Dr. Ronald Ross, a British medical officer stationed in India (Cox, 2010; Tuteja, 
2007). Italian scientists, including Prof. Giovanni Battista Grassi, later showed that human 
malaria was transmitted solely by Anopheles mosquitoes (Cox, 2010; Tuteja, 2007). It was 
initially believed that only the four abovementioned Plasmodium species could cause human 
malaria. However, Singh et al. (2004) recently showed that almost a third of severe human 
malaria infections in the Malaysian Borneo region, were misdiagnosed as P. malariae, but 
were actually caused by P. knowlesi. Thus, P. knowlesi, which usually causes malaria in 
long-tailed macaque monkeys, has been identified as the fifth human malarial parasite. 
 
1.2.    THE LIFE CYCLE OF P. FALCIPARUM 
Of the five species of Plasmodium that cause malaria in humans, Plasmodium falciparum is 
the most prevalent and virulent, accounting for the large majority of deaths (Francis et al., 
1997). The life cycle of P. falciparum is quite complex (Figure 1.1) with the asexual stage of 
development occurring within a vertebrate host and the sexual stage occurring in a female 
Anopheles mosquito (Francis et al., 1997). 
 
The asexual developmental phase (reviewed by (Chiang et al., 2006; Cowman & Crabb, 
2006; Francis et al., 1997; Tuteja, 2007; van Agtmael et al., 1999)) begins when a malaria-
infected anopheline mosquito feeds on a human, thereby transferring infectious sporozoites in 
its saliva to the human bloodstream. The sporozoites travel through the blood ultimately 
reaching the liver and infecting hepatocytes. This liver stage of parasite development lasts 9-
16 days and is asymptomatic as the sporozoites mature into schizonts within the hepatocytes. 
The schizonts eventually burst, releasing thousands of liver merozoites into the blood where 
they proceed to infect erythrocytes. This intra-erythrocytic developmental stage is an asexual, 
48-hour cycle and is the cause of the clinical manifestations of malaria. Following invasion of 
the erythrocyte, the merozoites progress to the ring stage of parasite growth which lasts 
approximately 24 hours and is characterised by limited metabolic activity. The rings develop 
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into trophozoites which display marked metabolic activity that includes import and glycolysis 
of vast amounts of glucose, endocytosis of host cytoplasm and subsequent digestion of 
haemoglobin, as well as the synthesis of DNA, RNA and proteins. The trophozoites mature 
into schizonts which, in turn, go through four to five rounds of binary divisions to produce 
16-32 daughter merozoites. The pathophysiology of falciparum malaria is believed to be due 
to the adherence of trophozoite- and schizont-infected erythrocytes to the endothelium of 
small blood vessels, a process known as sequestration. The schizonts rupture, releasing the 
merozoites back into the bloodstream to infect other erythrocytes and begin a new cycle of 
asexual development. This intra-erythrocytic developmental phase is highly synchronised 
with the majority of the parasite population in the bloodstream being in the same 
developmental stage at any one time (Tuteja, 2007; van Agtmael et al., 1999). Thus, rupture 
of schizont-infected erythrocytes occurs at roughly the same time and is believed to release 
malaria toxins which are proposed to initiate a cytokine response by the host, resulting in the 
classic malaria symptoms of fever, malaise and chills (Tuteja, 2007; van Agtmael et al., 
1999). 
 
Apart from asexual development, some intra-erythrocytic stages of the parasite may 
differentiate into male and female sexual forms known as gametocytes, thereby initiating the 
sexual stage of development (reviewed by (Chiang et al., 2006; Cowman & Crabb, 2006; 
Cox, 2010; Ghosh et al., 2000; Tuteja, 2007)). When a female Anopheles mosquito feeds on a 
malaria-infected individual, the gametocytes enter the insect gut where they develop into 
gametes and eventually fuse to produce zygotes. The zygote transforms into a motile ookinete 
which forces its way into the epithelial lining of the midgut where it differentiates into an 
oocyst. After a complex developmental process which lasts several days, the oocyst releases 
thousands of sporozoites into the mosquito‘s body cavity. The sporozoites migrate to the 
salivary glands and, during the mosquito‘s next blood meal, can be transmitted via the saliva 
to another human host where the cycle begins again. 
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Figure 1.1: Life cycle of the Plasmodium falciparum malaria parasite (van Agtmael et 
al., 1999). 
 
1.3.    PATHOGENESIS AND CLINICAL SYMPTOMS OF P. FALCIPARUM  
          MALARIA 
Most malaria-infected individuals present with uncomplicated malaria which is characterised 
by non-specific, flu-like symptoms such as fever, headache, vomiting and diarrhoea and is 
often easily resolved either via host immune responses or antimalarials (Beeson & Brown, 
2002; Mackintosh et al., 2004). About 1% of malaria-infected individuals exhibit severe 
malaria (Mackintosh et al., 2004), a life-threatening form of the disease which was previously 
thought to manifest as either cerebral malaria or severe anaemia but is now recognised as a 
complex disorder that affects multiple organs, similar to sepsis (Mackintosh et al., 2004; 
Miller et al., 2002). Severe malaria arises when the parasite progresses to the intra-
erythrocytic stage of development (Rasti et al., 2004) and a unique feature of this 
developmental phase of P. falciparum malaria, relative to other human malarias, is 
sequestration (Beeson & Brown, 2002; Mackintosh et al., 2004; Miller et al., 2002; Rasti et 
al., 2004). 
 
Sequestration is the ability of mature parasitised red blood cells (RBCs) to adhere to 
uninfected RBCs, endothelial cells and the placental cells of pregnant women (Beeson & 
Brown, 2002; Mackintosh et al., 2004; Miller et al., 2002; Rasti et al., 2004; Tuteja, 2007). 
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The parasite achieves sequestration by trafficking parasite proteins, such as P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) to the surface of the host RBC, and these proteins 
mediate adherence by interacting with receptors on the surface of various host cells (Beeson 
& Brown, 2002; Mackintosh et al., 2004; Miller et al., 2002; Rasti et al., 2004; Tuteja, 2007). 
Sequestration prevents parasite-infected RBCs from being destroyed in the spleen of the host, 
however, it also threatens the life of the host by blocking the small blood vessels of vital 
organs and tissues, thereby directly contributing to the pathogenesis of severe malaria 
(Beeson & Brown, 2002; Mackintosh et al., 2004; Miller et al., 2002; Rasti et al., 2004). For 
example, sequestration of the parasite-infected RBCs in the small vessels of the brain may 
result in cerebral malaria which causes unrousable coma and convulsions in the patient and is 
believed to be the cause of the majority of malaria deaths (Beeson & Brown, 2002; Tuteja, 
2007). 
 
Severe anaemia in malaria-infected individuals is also a key feature of severe malaria and is 
primarily due to parasite-mediated rupture of infected RBCs and increased destruction of 
infected and non-infected RBCs by the spleen and macrophages of the host (Beeson & 
Brown, 2002; Mackintosh et al., 2004; Miller et al., 2002; Rasti et al., 2004). Furthermore, 
free radicals produced by host macrophages in response to pro-inflammatory cytokines, and 
the release of malaria pigment following rupture of infected RBCs, may impair RBC 
production in the bone marrow thereby contributing to anaemia during malaria infection 
(Rasti et al., 2004). Interestingly, severe anaemia may have a beneficial effect on the host 
during malaria infection by reducing blood viscosity and thus improving circulation in small 
vessels, hence allowing for increased oxygen and nutrient supply to tissues (Rasti et al., 
2004).  
 
Metabolic acidosis, which leads to respiratory distress, is the strongest indicator of imminent 
death in severe malaria, and even though the pathogenesis of this acidosis is still unclear, 
lactic acidosis is proposed to play a central role (Mackintosh et al., 2004; Miller et al., 2002). 
Hypovolemia and dehydration are observed in patients with severe malaria and together with 
microvascular blockage and severe anaemia may reduce tissue perfusion and thus give rise to 
anaerobic metabolism and hence lactic acidosis (Mackintosh et al., 2004; Miller et al., 2002). 
Metabolic acidosis has also been implicated in a reduction of the deformability of uninfected 
RBCs, and though the pathogenesis of this effect remains unclear, it may further compromise 
tissue perfusion in individuals with severe malaria (Miller et al., 2002; Rasti et al., 2004). 
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Other contributors to metabolic acidosis in severe malaria are the cytokine-mediated failure 
of oxygen utilisation and parasite-mediated production of lactic acid (Mackintosh et al., 
2004; Miller et al., 2002). Renal dysfunction and failure, spontaneous bleeding and 
hypoglycaemia have also been observed in cases of severe malaria (Beeson & Brown, 2002). 
Thus, current knowledge suggests that severe malaria results from a combination of key 
pathogenic processes, namely microvascular obstruction, the destruction of infected and 
uninfected RBCs and host inflammatory responses which together decrease tissue perfusion 
(Miller et al., 2002). This may subsequently cause downstream cellular events which 
aggravate the situation further. 
 
Multiple infections with malaria lead to the development of partial immunity which protects 
against severe disease and only mild infections occur with little or no clinical symptoms 
(Beeson & Brown, 2002). Hence, due to a lack of acquired immunity, children are 
particularly susceptible to the disease and the prognosis is often very poor (Rasti et al., 2004). 
Pregnant women are at a greater risk of contracting the disease than non-pregnant women, 
and are also exceptionally vulnerable to the disease (Beeson & Brown, 2002; Tuteja, 2007). 
Lindsay et al. (2000) suggested that the increased risk of infection in pregnant women, 
relative to non-pregnant women, is due to an increased attractiveness to the vectors of the 
disease (i.e. mosquitoes) as a result of physiological and behavioural changes that occur 
during pregnancy. Pregnant women were found to have heightened exhalation and body 
temperature relative to non-pregnant women, and this was believed to result in a greater 
release of chemicals that likely attract mosquitoes. The pregnant women were also found to 
be at a greater risk of exposure to the mosquitoes since they left the safety of their bednet, in 
order to urinate, twice as often as non-pregnant women. Key characteristics of P. falciparum 
infection in pregnant women are sequestration and accumulation of parasites in the placental 
blood cavities, and maternal anaemia (Beeson & Brown, 2002; Tuteja, 2007). These 
pathogenic events are believed to be the cause of maternal deaths, low birthweight, premature 
delivery, miscarriages and stillbirths in malaria-infected pregnant women (Beeson & Brown, 
2002; Tuteja, 2007). 
 
1.4.    IMPACT OF MALARIA 
Malaria remains one of the world‘s most serious parasitic infections with approximately half 
the world‘s population in 109 countries at risk of contracting the disease (WHO, 2010a). 
Approximately 216 million malaria cases and 655000 deaths were reported in 2010 alone and 
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an estimated 81% and 91% of these cases and deaths, respectively, occurred in Africa (WHO, 
2011) which carries the majority of the world malaria burden (Figure 1.2). These estimates 
make malaria the second leading cause of death from infectious diseases on the African 
continent, after HIV/AIDS (Sachs & Malaney, 2002). The primary victims are pregnant 
women and children younger than five, with 86% of global malaria deaths in 2010 affecting 
the latter group (WHO, 2011). The disease can also affect the immune system and alter the 
body‘s response to vaccines, thereby increasing susceptibility to other infections (Sachs & 
Malaney, 2002). 
 
 
Figure 1.2: World malaria risk areas, 2010. , countries or areas experiencing malaria 
transmission; , countries or areas where risk of malaria transmission is limited (WHO, 2010b). Note: The map 
is intended as a visual aid only and not as a definitive source of information for malaria endemicity.  
 
Over and above its effects on global health, malaria exacerbates poverty in many areas and is 
severely detrimental to the rate of economic growth in countries where it is endemic (Sachs 
& Malaney, 2002; Vitoria et al., 2009; WHO, 2010c). In general, in areas where malaria 
thrives, human societies have had the least success (Sachs & Malaney, 2002). For instance, in 
Africa alone, malaria-related illness, treatment and premature death incur costs of no less 
than 12 billion US dollars every year, with even greater losses to economic growth (Tuteja, 
2007; WHO, 2010c). In addition, with almost 25% of household incomes spent on malaria 
treatment in the majority of African endemic countries, access to preventative measures and 
lifesaving services is limited (Vitoria et al., 2009). Thus, while malaria aggravates poverty, 
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the relationship is also reversible in that poverty promotes malaria transmission in cases 
where preventative measures, such as bednets or insecticides, are too costly. The scourge of 
malaria also discourages tourism, trade and foreign investment in countries in which it is 
endemic and this is severely detrimental to economic growth (Sachs & Malaney, 2002). 
Children are particularly susceptible to malaria morbidity and mortality since, unlike adults, 
they lack acquired immunity (Rasti et al., 2004). As a result, school absenteeism is increased 
and this leads to higher failure rates, drop-out rates and repetition of school years (Sachs & 
Malaney, 2002). In addition, malaria-infected children suffer from poor nutritional status 
which can be detrimental to cognitive development (Sachs & Malaney, 2002).  
 
1.5.    EFFORTS AT MALARIA ERADICATION 
Until the 1850s, malaria was prevalent in most countries reaching as far north as the Arctic 
Circle with approximately 90% of the world‘s population at risk of contracting the disease 
(Mendis et al., 2009; WHO, 2010c). During the latter half of the 19th century, much of North 
America and Europe became malaria-free, likely due to changes in the agricultural use of 
land and better housing (Mendis et al., 2009). Discovery of the malaria parasite and its 
mosquito vector led to further suppression of the disease through the implementation of focal 
mosquito control and widespread availability of malaria diagnosis and treatment (Mendis et 
al., 2009). In 1955, the availability of DDT (dichlorodiphenyltrichloroethane) and 
chloroquine, a potent insecticide and antimalarial, respectively, led the World Health 
Organisation (WHO) to initiate the Global Malaria Eradication Programme in endemic areas 
outside of sub-Saharan Africa (Mendis et al., 2009; WHO, 2010c). This African region was 
excluded since its substantial burden of malaria and limited infrastructure made the 
programme unfeasible (Tanner & de Savigny, 2008). By 1978, the programme had 
successfully eradicated malaria in North America, the Caribbean, Europe and parts of south-
central America and Asia (Tanner & de Savigny, 2008). The campaign also significantly 
reduced malaria cases and deaths in many other countries, including India and Sri Lanka 
(Mendis et al., 2009). However, poor maintenance of the programme and the appearance of 
chloroquine-resistant parasites and DDT-resistant vectors led to resurgence of the disease and 
by 1969, efforts to eradicate malaria were replaced by attempts to control the disease (Mendis 
et al., 2009). Furthermore, the eradication of malaria in developed countries led to a loss of 
interest in the disease and developing African countries, which were struggling to set up 
primary healthcare and broad-based health systems, received little global support for malaria 
control and continued to carry a heavy malaria burden (Tanner & de Savigny, 2008). By 
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1992, the deteriorating malaria situation and promising technical innovations sparked 
renewed global interest in malaria control (Tanner & de Savigny, 2008).  
 
The Roll Back Malaria (RBM) initiative was launched by the WHO in 1998 with the goal of 
halving malaria deaths by 2010 and again by 2015 by improving the availability of effective 
treatment and prevention measures (Nabarro & Tayler, 1998). The World Malaria Report 
2011 (WHO, 2011) indicated that in 46% of the countries experiencing malaria transmission, 
reports of malaria cases had decreased by over 50% between 2000 and 2010. In addition, the 
number of global cases and deaths had decreased by 17% and 26%, respectively, between 
2000 and 2010. While these rates of decline fail to meet the goals set by the RBM initiative, 
they still reflect a major accomplishment in the fight against malaria. Taking into account the 
progress made by 2010, the goals of the RBM initiative were revised and the possibility of 
malaria eradication is back on the agenda (WHO, 2010c). Current goals of the RBM initiative 
are to achieve the following by 2015: (i) reduce global malaria cases from 2000 levels by 
75% (ii) decrease global malaria deaths to close to zero, (iii) eliminate malaria in 10 new 
countries. The measures currently being employed to meet these goals include vector control, 
vaccine development, and therapeutic and prophylactic drugs (WHO, 2010c). 
 
1.6.    CURRENT COUNTERMEASURES 
Malaria is a completely preventable and treatable disease, as long as the currently 
recommended interventions are correctly employed (WHO, 2011). These include vector 
control, chemoprophylaxis and timely diagnosis and treatment. 
 
1.6.1.    Vector control 
The severity and pattern of transmission of malaria parasites, and hence the epidemiology of 
infection and disease, are heavily dependent on the abundance, seasonality and feeding habits 
of the anopheline mosquito vector (Greenwood et al., 2008). Malaria vector control has been 
a key element of successful malaria elimination strategies, such as those employed in the 
United States and Europe, and continues to play a leading role in current strategies 
(Greenwood et al., 2008). Malaria vector control is aimed at protecting the individual from 
malaria infection and decreasing the severity of local malaria transmission (WHO, 2011). The 
most effective and widely used forms of vector control are indoor residual spraying (IRS) of 
insecticides and insecticide-treated bednets (ITNs) (Greenwood et al., 2008; WHO, 2011).  
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Currently, four chemical classes of insecticides are used for vector control, i.e. pyrethroids, 
organophosphates, carbamates and organochlorines (WHO, 2011). The pyrethroids are the 
most commonly used due to their affordability, low toxicity and rapid, long-lasting effects 
(WHO, 2011). Any of the abovementioned insecticide classes can be used for IRS, however, 
only the pyrethroids are approved for use in ITNs (Greenwood et al., 2008; WHO, 2011). In 
addition, in cases where mosquito breeding sites are minimal and easily identifiable, IRS and 
ITNs may be supplemented with larval control (WHO, 2011). In 2010, 82 countries, 
including 38 African countries, provided ITNs either free or at a subsidised price, and a total 
of 185 million individuals were protected from malaria vectors by IRS (WHO, 2011). 
However, the widespread use of a single class of insecticide (i.e. the pyrethroids) has 
enhanced the risk of mosquitoes acquiring resistance and, to date, 27 African countries have 
reported cases of resistance (WHO, 2011). Given the significant role of vector control in the 
fight against malaria, maintaining the susceptibility of malaria vectors to currently available 
insecticides through controlled use, and the development of novel vector control measures, is 
crucial (Greenwood et al., 2008; WHO, 2011). Novel vector control measures under 
investigation are sterile insect technique and transgenic techniques. The former technique 
involves the sterilisation of male mosquitoes via gamma radiation or chemical sterilants 
(Damodaran et al., 2011). The rationale being that since female anopheline mosquitoes mate 
only once in their lifetime, the release of vast numbers of sterile male mosquitoes would 
significantly decrease reproduction rates of the mosquito population (Damodaran et al., 
2011). Transgenic vector control involves the expression of a dominant lethal gene in male 
mosquitoes which can be passed on to the offspring and cause embryonic death (Damodaran 
et al., 2011). 
 
1.6.2.    Vaccine development 
Vaccines have the potential to generate long term immunity and thus only one or two doses 
can impart life-long protection against a particular infection (Chiang et al., 2006). Vaccines 
are also the most affordable health intervention for a variety of infectious diseases (Todryk & 
Hill, 2007) and the development of a successful malaria vaccine would be a major step 
towards eradication of the disease. The idea that it may be possible to produce a malaria 
vaccine is supported by numerous observations such as the fact that immunity to the disease 
can develop naturally after repeated exposures or through immunisation with irradiated 
sporozoites (Todryk & Hill, 2007). However, the exact mechanisms by which these immune 
responses decrease or prevent malaria are still a mystery and humans display remarkable 
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heterogeneity in their immune responses to the disease (Richie & Saul, 2002). In addition, the 
various parasite stages express different antigens and thus a vaccine directed against liver-
stage parasites will likely have little effect on blood-stage parasites (Todryk & Hill, 2007). 
These factors make the development of a malaria vaccine quite challenging, but not 
impossible. 
 
Malaria vaccines currently under development fall into three categories (Richie & Saul, 2002; 
Todryk & Hill, 2007): (i) pre-erythrocytic vaccines which target the sporozoite and/or liver 
stages of the parasite thereby preventing progression to blood-stage infection and 
circumventing all manifestations of the disease, (ii) erythrocytic vaccines that reduce the 
clinical severity of malaria since they are directed against the asexual blood-stage parasites 
which cause the clinical manifestations of the disease, and (iii) transmission-blocking 
vaccines which block development of the sexual stages of the parasite in the mosquito. SPf-
66 was the first malaria vaccine developed against P. falciparum to be assessed in clinical 
trials in the 1990s and preliminary results of this pre-erythrocytic vaccine in South America 
were promising, however, later studies in Africa indicated decreased efficacy (Damodaran et 
al., 2011). To date, there are still no licensed malaria vaccines, however, several are under 
development, with the RTS,S/AS01 vaccine already undergoing phase III clinical trials and 
an estimated 20 other projects in phase I or phase II trials (WHO, 2011). 
 
The RTS,S/AS01 vaccine was developed by GlaxoSmithKline and the Program for 
Appropriate Technology in Health Malaria Vaccine Initiative mainly for use in infants and 
young children in sub-Saharan Africa (White, 2010; WHO, 2011). It is a pre-erythrocytic 
vaccine which blocks parasite invasion of liver hepatocytes (Todryk & Hill, 2007). It consists 
of a hepatitis B surface antigen fused to a recombinant antigen derived from a portion of the 
malaria parasite‘s circumsporozoite protein (Todryk & Hill, 2007; White, 2010; WHO, 
2011). This protein coats the sporozoite stage of the parasite which is injected into the human 
host by the anopheline mosquito before proceeding to infect the liver hepatocytes (Todryk & 
Hill, 2007). The adjuvant AS01, which consists of the immunostimulants monophosphoryl 
lipid A and QS-21, is also included in the vaccine (Richie & Saul, 2002). Preliminary results 
of phase III clinical trials with RTS,S/AS01 have indicated that during the 12 months post-
vaccination, incidences of clinical malaria were reduced by approximately 50% in children 
aged between 5 and 17 months (WHO, 2011). If the vaccine continues to perform well it may 
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soon be included as one of the WHO-recommended measures for malaria prevention (WHO, 
2011). 
 
1.6.3.    Therapeutic and prophylactic drugs  
With mosquito vectors developing resistance to insecticides and malaria vaccines still under 
development, therapeutic and prophylactic drugs are currently the primary means of 
combating malaria (Dubey et al., 2009; Grimberg & Mehlotra, 2011). During the last six to 
seven decades, since the development of synthetic antimalarials, only a few compounds have 
been identified as suitable for clinical use and fall into three broad categories known as the 
quinolines, antifolates and artemisinins (Dubey et al., 2009; Grimberg & Mehlotra, 2011).  
 
1.6.3.1.    Quinolines 
In the early 17th century, Jesuit priests introduced the Peruvian Cinchona bark into Europe as 
a treatment for periodic malaria-like fevers known as the ague (Meshnick & Dobson, 2001). 
Thus, quinine and its quinoline derivatives, which occur naturally in the bark of Cinchona 
trees, were recommended by physicians long before malaria was recognised as a distinct 
disease (Meshnick & Dobson, 2001). These antimalarials are believed to exert their 
antimalarial action by targeting the food vacuoles of blood-stage parasites (Dubey et al., 
2009; Grimberg & Mehlotra, 2011). The quinine derivative, chloroquine, is the most 
successful, affordable and thus the most extensively used antimalarial since the 1940s, 
effective for both therapy and prophylaxis (Dubey et al., 2009; Grimberg & Mehlotra, 2011; 
Meshnick & Dobson, 2001). However, the emergence of chloroquine-resistant strains of the 
malaria parasite has significantly reduced the usefulness of this drug (Dubey et al., 2009; 
Grimberg & Mehlotra, 2011; Meshnick & Dobson, 2001). Mefloquine is a quinoline 
methanol derivative used as both a therapeutic and prophylactic antimalarial, while 
primaquine is a therapeutic quinoline antimalarial active against the liver stages of the 
parasite (Dubey et al., 2009). Halofantrine and lumefantrine are structural analogs of quinine 
used to treat multidrug-resistant P. falciparum malaria (Grimberg & Mehlotra, 2011).  
 
1.6.3.2.    Antifolates         
Unlike the quinolines, the antifolate class of antimalarials is not plant-derived and originated 
from synthetic compounds generated via knowledge of synthetic medicinal chemistry and 
cell biology (Ridley, 2002). These antimalarials target nucleic acid synthesis in the parasite 
and consist of various combinations of dihydropteroate synthase inhibitors (e.g. dapsone and 
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sulphadoxine) and dihydrofolate reductase enzyme inhibitors (e.g. proguanil and 
pyrimethamine) (Dubey et al., 2009; Grimberg & Mehlotra, 2011). Atovaquone, an inhibitor 
of the parasite‘s electron transport chain, is used in combination with proguanil for malaria 
prophylaxis. As with chloroquine, parasite resistance to the antifolates, particularly the 
sulphadoxine-pyrimethamine combination, has limited the usefulness of these antimalarials in 
many malaria endemic regions.  
 
1.6.3.3.    Artemisinins 
Artemisinins are sesquiterpene lactone endoperoxides derived from the Chinese herb 
Artemisia annua and are the latest and most effective addition to the antimalarial drug arsenal 
(Klayman, 1985; Liao, 2009). In the 1980s, worldwide attention was drawn to China where 
artemisinin and its derivatives were being used for the successful treatment of thousands of 
malaria patients (Liao, 2009). The discovery of artemisinin has since been lauded as a major 
breakthrough in the fight against malaria (Liao, 2009). This extraordinary class of 
antimalarials has several advantages over other established antimalarials. The broad range of 
activity of artemisinins encompasses both sexual and asexual stages of P. falciparum, as well 
as strains which are no longer sensitive to conventional drugs such as chloroquine (White, 
2008; Woodrow et al., 2005). Efficacy of artemisinins against the sexual stages of the 
parasite (i.e. gametocytes) reduces the transmission potential of infected individuals 
(Grimberg & Mehlotra, 2011; WHO, 2010a). A key feature of artemisinin treatment is its 
prompt onset of action, with parasite numbers in the blood being reduced by a factor of 
10000 in each 48-hour cycle of asexual development of the parasite, which is far more 
efficient than other established antimalarials (van Agtmael et al., 1999; WHO, 2010a). 
Artemisinins are the only established antimalarials to which the parasite has not yet 
developed widespread resistance and they form the cornerstone of the current antimalarial 
treatment regimens known as artemisinin-based combination therapies (ACTs) (Grimberg & 
Mehlotra, 2011). 
 
1.6.3.4.    Antibiotics 
In 1997, a plastid-like organelle, now known as an apicoplast, was identified in apicomplexan 
parasites including P. falciparum (Kohler et al., 1997). The apicoplast is believed to have 
originated via secondary endosymbiosis of an alga and subsequent preservation of the algal 
plastid (Kohler et al., 1997). It carries out housekeeping processes such as DNA replication, 
transcription and translation, as well as anabolic processes such as the synthesis of fatty acids, 
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haem and isoprenoid precursors (Ralph et al., 2004). Due to its endosymbiotic origin, the 
metabolic processes of the apicoplast are prokaryotic in nature and are therefore distinct from 
those of the eukaryotic host thereby providing ideal drug targets for malaria drug discovery 
(Ralph et al., 2004). Antibiotics which target protein synthesis in the apicoplast, such as 
clindamycin, tetracycline and doxycycline, have been shown to display slow-acting but 
effective antimalarial activity (Dahl et al., 2006; Goodman et al., 2007). These antibiotics are 
recommended by the WHO as second-line antimalarial treatments to be used in combination 
with fast-acting counterparts such as quinine and artesunate (WHO, 2010a). Thus far, there 
have been no reported cases of resistance to this form of antimalarial therapy in malaria-
endemic areas (Ekland et al., 2011).  
 
1.6.4.    The current treatment strategy: combination therapies  
Resistance of P. falciparum to all conventional antimalarials, particularly chloroquine and 
sulphadoxine-pyrimethamine, has been a major contributor to the current malaria crisis 
(WHO, 2010a). Extensive and indiscriminate usage of antimalarials as monotherapies has 
caused the parasites to develop resistance in response to strong selective pressure (WHO, 
2010a). Thus, to circumvent resistance of P. falciparum to monotherapies and enhance 
treatment outcomes, antimalarial combination therapies are currently the preferred form of 
treatment (WHO, 2010a). Antimalarial combination therapy is the concurrent use of two or 
more blood schizonticides with different mechanisms of action and thus independent 
biochemical targets (WHO, 2010a). The rationale being that a drug combination is usually 
more effective than monotherapies and, in the rare event that the parasite does develop 
resistance to one of the drugs, it can still be killed by the partner drug (WHO, 2010a).  
 
Artemisinin-based combination therapies are currently recommended by the WHO as the 
first-line treatment for uncomplicated P. falciparum malaria (WHO, 2010a). This treatment 
strategy uses artemisinin or one of its derivatives (e.g. artesunate, artemether, 
dihydroartemisinin) in combination with partner drugs such as mefloquine, amodiaquine or 
lumefantrine (WHO, 2010a). The choice of ACTs used in a particular region depends on the 
existing level of parasite resistance to the partner drug in that area. The ACTs have been, and 
continue to be, highly successful against malaria with cure rates comparable to those of 
chloroquine three decades ago (Malenga et al., 2005). An added advantage is that ACTs can 
diminish gametocyte transmissibility, thereby reducing the risk of infectiousness in 
individuals taking ACT (Grimberg & Mehlotra, 2011; Malenga et al., 2005; WHO, 2010a). 
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All African countries with extensive P. falciparum malaria have replaced older, less effective 
antimalarials with ACTs as a frontline treatment (WHO, 2009). Over the last decade, ACTs 
together with other malaria control measures, have played a major role in reducing the 
number of malaria cases and deaths throughout the world (Dondorp et al., 2011).  
 
1.7.    MALARIA DRUG DISCOVERY 
Successful malaria elimination programmes of the past have all relied on the concurrent use 
of effective therapeutic drugs and vector control measures, and the development of resistance 
to one or both of these control measures makes the goal of malaria elimination unachievable 
(Dondorp et al., 2011). A prime example is the Global Malaria Eradication Programme of the 
1960s which failed partly as a result of malaria parasites and vectors developing resistance to 
the respective antimalarial and insecticide used at the time (i.e. chloroquine and DDT) 
(Mendis et al., 2009; Tanner & de Savigny, 2008). Thus, in order for current plans to 
eliminate malaria to be successful, the long-term availability of effective antimalarials is 
crucial. Consequently, the ongoing development of novel antimalarials is vital in order to 
circumvent resistance and ensure a continued supply of reliable malaria therapies. 
 
1.7.1.    Emerging resistance to ACTs and the need for novel antimalarials 
The ACTs, together with increased mosquito control measures, have made a significant 
contribution to decreasing the world malaria burden since their introduction in 2001 (WHO, 
2011). There is no evidence, thus far, of artemisinin-resistant strains of P. falciparum 
parasites in Africa (Grimberg & Mehlotra, 2011; Kachur et al., 2010). However, there are 
fears that reduced susceptibility to artemisinins in Southeast Asia may lead to resistant strains 
which would spread to Africa and hamper the success of ACTs (Kachur et al., 2010). The 
south-eastern border of Thailand with Cambodia has long been recognised as the epicentre of 
drug-resistant malaria (Dondorp et al., 2009; Kachur et al., 2010; WHO, 2007). It began with 
chloroquine-resistant malaria several years ago, followed by resistance to sulphadoxine-
pyrimethamine and recently, resistance to mefloquine (WHO, 2007). Thai and Cambodian 
malaria control programmes which routinely monitor these areas and assess therapeutic 
efficacy have led to the discovery that ACTs are failing on both sides of the border (WHO, 
2007). Delayed parasite clearance and abnormally high failure rates have been observed with 
both artemether-lumefantrine and artesunate-mefloquine combinations (WHO, 2007). In 
addition, in vitro tests have shown that susceptibility to artemisinin derivatives and their 
partner drugs have diminished in this area (WHO, 2007). The alarmingly high failure rate of 
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artemisinins in these regions amounts to a local and global emergency due to the fact that 
these drugs are currently the only established group of antimalarials with significant efficacy 
against malaria (WHO, 2007). Even though parasite sensitivity to artemisinins appears to be 
reduced, the clinical and parasitological efficacy of ACTs has not yet been affected (WHO, 
2011). Nevertheless, the ever-evolving malaria parasite may develop resistance to either 
component of the drug combination at any time.  
 
The risk of artemisinin resistance developing in Southeast Asia and spreading to other 
countries is disturbingly high and Africa, which carries the majority of the world malaria 
burden and already experiences resistance to other antimalarials, would be particularly 
susceptible (WHO, 2007). A high prevalence of artemisinin-resistant malaria parasites in 
Africa would not only halt malaria eradication efforts, but would also cause a large number of 
childhood deaths, as was the case in the previous century when chloroquine-resistant 
parasites emerged (Dondorp et al., 2011). Hence, while ACTs are making a major 
contribution to alleviating the malaria burden, there are constant fears that resistance to ACTs 
may develop in the foreseeable future as well as concerns regarding side-effects during 
prolonged use (Jambou et al., 2005). Malaria research worldwide is therefore constantly 
focussed on the development of new antimalarials to supplement ACTs, in order to improve 
efficacy and pharmacokinetic properties and circumvent resistance (Greenwood et al., 2008).  
 
1.7.2.    Current approaches to malaria drug discovery 
There is an urgent need for new antimalarials to supplement the ACTs in order to circumvent 
resistance and ensure their continued success in the fight against malaria. Ideally, novel 
antimalarials should be safe, exhibit efficacy that extends to drug-resistant strains, allow for 
oral administration as well as for parenteral use during coma, cure malaria within 3 days, be 
suitable for use in young children and pregnant women and, of particular importance, be 
inexpensive (Na-Bangchang & Karbwang, 2009; Nwaka & Ridley, 2003). It may take more 
than 5 years to discover a truly new antimalarial drug, however, approaches using existing 
antimalarials may produce a new drug within 3-5 years (Dubey et al., 2009). Six major drug 
discovery approaches are currently employed in the search for novel, effective malaria 
treatments. 
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(i) Re-optimising the use of existing antimalarials 
The first means of re-optimising the use of existing antimalarials is drug replacement or 
rotation. This involves the withdrawal of a drug to which parasites have developed resistance 
in the hopes that drug-sensitive strains will replace the drug-resistant strains in the majority of 
the parasite population, thereby restoring the efficacy of the drug in question (Grimberg & 
Mehlotra, 2011). The rationale behind this approach is that drug-resistant parasite strains will 
probably be less fit than their wildtype counterparts in the absence of the drug selection 
(Grimberg & Mehlotra, 2011). This approach was successful with sulphadoxine-
pyrimethamine in Peru and with chloroquine in Malawi, however, sensitivity to the respective 
drugs took 5 and 10 years to return (Grimberg & Mehlotra, 2011; Hobbs & Duffy, 2011). In 
contrast, the withdrawal of sulphadoxine-pyrimethamine from Venezuela and Cambodia, for 
8 and 20 years, respectively, was unsuccessful in restoring sensitivity to this drug (Grimberg 
& Mehlotra, 2011). An alternative strategy for re-optimising existing antimalarials involves 
combining drugs. The rationale is that since the activity of antimalarials is usually 
pleiotropic, drug resistance may be a result of various mechanisms, each open to reversal by 
drug combination (Grimberg & Mehlotra, 2011). Thus, resistance to a particular drug may be 
reversed by co-administration with a second drug which chemosensitises the parasite to the 
first drug (Grimberg & Mehlotra, 2011). For example, chloroquine-resistance in patients was 
found to be reversed in the presence of chlorpheniramine (Hobbs & Duffy, 2011; Na-
Bangchang & Karbwang, 2009; Rosenthal, 2003). 
 
(ii) Repurposing drugs that are presently used to treat other diseases 
The rationale behind this approach is that a compound which displays activity against a 
particular organism may be active against orthologs of its target in another organism, such as 
the malaria parasite (Rosenthal, 2003). In most developing countries malaria is co-endemic 
with human immunodeficiency virus (HIV), hence many malaria-infected individuals are 
exposed to antiretrovirals (Grimberg & Mehlotra, 2011; Skinner-Adams et al., 2004). This 
prompted Skinner-Adams et al. (2004) to investigate the in vitro effects of antiretroviral 
protease inhibitors on P. falciparum, and ritonavir, saquinavir and indinavir were found to be 
highly effective antimalarials. However, the high cost, potential toxicity and limited 
knowledge with regard to interactions with established antimalarial drugs means that these 
antiretrovirals are unlikely to become first-line antimalarials in the near future (Skinner-
Adams et al., 2004). Anticancer drugs are also under investigation as potential antimalarials. 
For example, the anticancer agents, SU-11274 and Bay 43-9006, have shown potent activity 
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against P. falciparum (Grimberg & Mehlotra, 2011). As with the antiretrovirals, the major 
limitation in using anticancer drugs as antimalarials is their high level of toxicity (Grimberg 
& Mehlotra, 2011). 
  
(iii) Chemical modification of existing antimalarial compounds 
Derivatisation is a widely used strategy in drug discovery and involves chemical alteration of 
an existing drug in the hope of preserving or increasing potency whilst simultaneously 
ameliorating adverse traits of the parent compound (Na-Bangchang & Karbwang, 2009; 
Rosenthal, 2003). This strategy has produced several of the currently available antimalarials, 
such as mefloquine and chloroquine which are derivatives of quinine (Na-Bangchang & 
Karbwang, 2009; Rosenthal, 2003). Another route for producing new antimalarials from 
existing compounds is through hybridisation which involves the covalent binding of two 
compounds (Rosenthal, 2003). These hybrid molecules have the potential to postpone or 
circumvent the development of resistance and lower the risk of drug-drug interaction, the 
latter of which is often seen with combination therapies (Rosenthal, 2003). An example of a 
potent hybrid antimalarial is the artemisinin-quinine hybrid which showed potent in vitro 
activity against both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum 
(Rosenthal, 2003). The activity was greater than that of the individual drugs alone or a 1:1 
combination of the drugs.  
 
(iv) Exploring natural products 
Historically, antimalarial drug discovery efforts have greatly benefited from investigating 
natural compounds and the most successful antimalarials to date, chloroquine and 
artemisinin, are plant-derived (Grimberg & Mehlotra, 2011; Rosenthal, 2003). This approach 
uses indigenous knowledge of medicinal plants to identify a plant product with clinical 
activity against malaria which can then be used as a starting point for a medicinal chemistry 
effort (Rosenthal, 2003). However, a disadvantage of this approach is that the mechanism of 
action of plant-derived antimalarials is usually unknown (Grimberg & Mehlotra, 2011). 
Additional challenges include screening procedures, species selection criteria and 
fractionation processes (Grimberg & Mehlotra, 2011). Nonetheless, it is hoped that once the 
activity of a natural compound in humans is characterised, it can be used to identify novel 
molecular scaffolds upon which the next generation of antimalarials can be based (Grimberg 
& Mehlotra, 2011). 
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(v) High-throughput screening of diverse chemical libraries 
Recent years have seen numerous drug-screening groups producing a plethora of compounds 
which may provide novel starting points for potential antimalarials with new modes of action 
(Grimberg & Mehlotra, 2011). Consequently, a powerful approach used currently in malaria 
drug discovery is the large-scale screening of these diverse chemical libraries using high-
throughput assays (Grimberg & Mehlotra, 2011; Hobbs & Duffy, 2011). For example, 
Plouffe et al. (2008) used a high-throughput cell-based method to screen ~1.7 million 
compounds and identified ~6000 small molecules with strong antimalarial activity. Gamo et 
al. (2010) used a similar approach to screen ~2 million compounds from GlaxoSmithKline‘s 
chemical library and found that ~13500 of these displayed antimalarial activity. Virtual 
screening is an in silico, speedier approach for screening these libraries (Grimberg & 
Mehlotra, 2011). It involves the rapid evaluation of large libraries of chemical structures in 
order to identify those which are most likely to bind a pre-selected drug target, typically an 
enzyme or protein receptor (Grimberg & Mehlotra, 2011). This approach, either on its own or 
together with high-throughput screening, is becoming more popular in malaria drug discovery 
(Grimberg & Mehlotra, 2011).  
 
(vi) Parasite genome-based discoveries 
The entire genomes of the prevalent malaria parasites P. vivax and P. falciparum, and the 
human host are now known (Grimberg & Mehlotra, 2011). This has allowed for the 
comparison of the Plasmodium and human genomes, in an effort to identify novel, parasite-
specific molecular targets for malaria therapy and prevention (Grimberg & Mehlotra, 2011; 
Na-Bangchang & Karbwang, 2009). Ongoing drug discovery projects at the Medicines for 
Malaria Venture, using this genome-based approach, have identified several molecular targets 
in P. falciparum including falcipains, kinases and dihydrofolate reductase (Grimberg & 
Mehlotra, 2011). 
 
1.7.3.    Current methods used to screen candidate antimalarials 
The efficacy of candidate antimalarial compounds relies heavily on their capacity to kill 
malaria parasites, thereby preventing their proliferation and allowing the human immune 
system to completely clear dead and damaged parasites from the bloodstream (Noedl et al., 
2003). Conventional antimalarial susceptibility assays measure the effect of candidate 
compounds on the growth and development of the malaria parasite in in vitro cultures (Noedl 
et al., 2003). In most assays the principle is the same – the measurement of parasite growth in 
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drug-exposed cultures relative to a drug-free control (Noedl et al., 2003). However, the 
assays differ in the procedure used to quantify parasite growth and this is achieved by various 
approaches including microscopy-, isotopic-, enzymatic-, ELISA- and fluorescence-based 
methods (Co et al., 2010; Kalra et al., 2006; Noedl et al., 2003). 
 
The Giemsa-stained slide technique is an affordable means of assessing the antimalarial 
activity of a modest number of candidate drugs (Kalra et al., 2006). It involves the 
measurement of parasitaemia (i.e. percentage of infected RBCs) by light microscopy in 
Giemsa-stained thin-blood smears prepared from control and drug-treated in vitro cultures 
(Kalra et al., 2006). While the method is affordable and simple to perform, it is also time-
consuming and highly subjective since one has to distinguish between viable and non-viable 
parasites and the parasite undergoes several morphological changes during its intra-
erythrocytic development (Noedl et al., 2003). The isotopic 3H-hypoxanthine assay indirectly 
measures parasite growth by measuring the uptake of tritium-labelled hypoxanthine which is 
used by the parasite for purine salvage and DNA synthesis (Kalra et al., 2006). This is one of 
the most commonly used assays for antimalarial susceptibility testing, however, it is 
expensive, complex and relies on the use of radioactive material (Kalra et al., 2006; Noedl et 
al., 2003).  
 
Another popular assay is the colorimetric, enzymatic plasmodial lactate dehydrogenase 
(pLDH) assay which is based on the LDH-catalysed conversion of lactate to pyruvate (Kalra 
et al., 2006; Noedl et al., 2003). The assay relies on the knowledge that pLDH activity is 
distinguishable from LDH activity of the host RBC because the parasite enzyme is capable of 
utilising the cofactor APAD (3-acetylpyridine adenine nucleotide), while the human enzyme 
lacks this capability (Kalra et al., 2006; Noedl et al., 2003). The reaction produces reduced 
APAD which converts nitro blue tetrazolium to a purple formazan product which is 
spectrophotometrically measured (Noedl et al., 2003). The pLDH assay has several 
advantages over the 3H-hypoxanthine assay in that it is non-radioactive, simpler to perform 
and relies on equipment and reagents that are relatively inexpensive (Co et al., 2010).  
 
Rapid techniques using antibody-dependent ELISAs (enzyme-linked immunosorbent assays) 
for the quantification of malaria parasites in blood are also available and have been adapted 
for use in antimalarial drug susceptibility evaluations (Co et al., 2010). One such assay 
assesses parasite growth by measuring the levels of plasmodial histidine-rich protein 2 (Co et 
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al., 2010; Noedl et al., 2003). These assays are straightforward, highly sensitive and 
relatively inexpensive, however, they require long incubation times and multiple washing 
steps (Co et al., 2010; Noedl et al., 2003). Fluorescence-based assays exploit the fact that 
mature host RBCs, which are infected by the malaria parasite, lack DNA and RNA (Co et al., 
2010). Thus, parasite growth can be measured by using fluorescent nucleic acid intercalating 
stains (e.g. PicoGreen, SYBR green I, YOYO-1) together with flow cytometry to identify 
parasite-infected RBCs (Co et al., 2010). Fluorescence-based assays are fairly 
straightforward, highly sensitive and reliable, and provide a precise measurement of 
parasitaemia based on each cell rather than the population measurement which is provided by 
isotopic assays (Co et al., 2010). 
 
1.7.4.    A novel assay for malaria drug discovery 
Apart from safety, and efficacy against drug-resistant P. falciparum malaria, another key 
characteristic recommended for novel antimalarials is that they be rapid-acting (Na-
Bangchang & Karbwang, 2009; Nwaka & Ridley, 2003). According to the Medicines for 
Malaria Venture, the gold standard for the treatment of acute uncomplicated malaria should 
be a radical cure which can be administered as a single dose or, at most, a three-day regimen 
(MMV, 2010). The rationale behind this recommendation is that minimum-dose regimens 
which rapidly clear parasites from the bloodstream and relieve symptoms will improve 
patient compliance and reduce costs (MMV, 2010). This is especially important in 
impoverished areas that carry the brunt of the malaria burden and have limited access to 
clinical treatment and supervision. Furthermore, rapid cure rates reduce the risk of drug 
resistance emerging and are also essential in cases of severe malaria, particularly cerebral 
malaria, where prompt treatment is critical to avoid death (WHO, 2010a). The importance of 
rapid-acting antimalarials is further illustrated by the major contribution of ACTs to reducing 
the world malaria burden which has been largely attributed to the rapid-acting nature of the 
artemisinin component (Balint, 2001; van Agtmael et al., 1999). Hence, it is highly preferable 
that novel antimalarials be rapid-acting and thus assessing the rate of activity of candidate 
compounds is crucial to current drug discovery efforts. Although current assays used to 
screen candidate antimalarials (as discussed in section 1.7.3) give a good approximation of 
antimalarial activity of test compounds, they do not reveal an important additional property of 
candidate antimalarials – the rate at which the compounds compromise parasite viability.  
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Traditionally, this rate has been assessed by using light microscopy to observe parasite 
morphological changes in Giemsa-stained thin-blood smears prepared from in vitro cultures 
at various time-points following drug treatment (Noedl et al., 2003). At each time-point, the 
fraction of parasitised red blood cells is quantified and the parasites are examined for signs of 
aberrant morphology. While this technique is relatively simple to perform, it is time-
consuming and prone to subjective inter-operator interpretation since one has to distinguish 
between viable and non-viable parasites (Otten-Kuipers et al., 1995; Sanz et al., 2012). 
Making this distinction is particularly challenging due to the heterogeneous morphology of 
individual parasites under routine culture conditions, as well as the numerous morphological 
changes which the blood-stage parasite undergoes during its complex life cycle, as illustrated 
in Figure 1.3. 
 
 
Figure 1.3: Micrographs of the various developmental stages of blood-stage P. 
falciparum parasites. Giemsa-stained thin-blood smears were prepared from an in vitro culture over 48 
hours and photographed at 1000x magnification. Sequential parasite developmental stages are presented as 
numbered from 1-8: 1 – merozoite invasion of a RBC, 2 – newly invaded RBC, 3 – ring, 4 – early trophozoite, 5 
– late trophozoite, 6 – early schizont, 7 – schizont, 8 – mature schizont, 9 – ruptured schizont. Note: The figure 
is based on an image by Tan (2008), but is compiled from own micrographs. 
 
Another challenge is the practical difficulty of preparing uniform microscopy preparations on 
separate occasions for morphologic examination. As a result, assessing the rate of 
antimalarial action by this method is highly subjective and virtually impossible to quantitate 
with certainty, unless the drug-induced morphological anomalies are drastic and consistent. 
Quantitative procedures for assessing the rate of activity of antimalarials in in vitro cultures, 
besides subjective interpretation of morphology by light microscopy, are limited to a recently 
23 
 
reported viability-based assay (Sanz et al., 2012). This assay determines the rate of 
antimalarial drug action in in vitro cultures by directly quantifying the number of parasites 
capable of recovering from distinct periods of drug exposure. In vivo killing rates are 
subsequently estimated by calculating the parasite reduction ratio which is the ratio between 
parasitaemia at the onset of drug exposure and after one complete asexual parasite life cycle. 
Unfortunately, this method requires 3-4 weeks of monitoring re-growth in culture after drug 
exposure. Hence, there is a need for a novel, quantitative assay capable of rapidly evaluating 
the kinetics of drug action in culture, in order to more accurately compare the efficacy of 
novel antimalarials with those of existing drugs. The goal of this study was to develop such 
an assay. 
 
Energy is essential for the growth, maintenance and reproduction of all living organisms and 
the energy currency of cells is adenosine triphosphate (ATP) (Ginsburg, 2010). Chemical 
reactions convert energy from one form to another at the cellular level and the energy stored 
in chemical bonds is released as ATP when complex molecules, such as glucose, are 
degraded (Ginsburg, 2010). Hence, it is conceivable that elevated ATP levels in the malaria 
parasite may reflect increased metabolic activity to circumvent harmful drug effects, or an 
inhibition of ATP-dependent anabolic pathways. Alternatively, reduced ATP may indicate a 
significant decline in parasite energy metabolism and viability. There are two major methods 
for measuring ATP in biological samples, HPLC and the bioluminescent luciferin-luciferase 
system, with the latter being more popular (Abraham et al., 2003; Bruce, 2010). Previous 
studies have used commercially available kits based on the luciferin-luciferase assay system 
for ATP measurement in cultured P. falciparum malaria parasites (Kanaani & Ginsburg, 
1989; Peatey et al., 2012). Accordingly, it is plausible that the rate of antimalarial drug action 
may be evaluated by measuring parasite ATP levels in drug-treated cultures relative to 
control cultures using this bioluminescent system. Hence, this study has explored the use of 
the CellTiter-Glo luciferin-luciferase system (Promega) for ATP detection in cultured P. 
falciparum parasites and subsequent application of this method as a means of assessing the 
rate of antimalarial drug action.  
 
Serendipitously, a potential additional methodology for determining the rate at which 
compounds affect parasites was discovered during research conducted by the Systems 
Biology Group at CSIR Biosciences. Dr. A. C. van Brummelen successfully established 
methods for transfecting P. falciparum with expression plasmids and used these to generate 
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transgenic parasites that express luciferase. Luciferase activity in the parasites is readily 
detected using a luminescence-based kit (Bright-Glo Luciferase Assay System, Promega), 
and for the purposes of this study this procedure has been termed the Luciferase assay. 
Unexpectedly, preliminary experiments indicated that luciferase activity decreased rapidly 
and markedly in transgenic parasites exposed to the standard antimalarials artemisinin and 
mefloquine. Conceivably, measurement of luciferase activity in these transgenic parasites 
may thus be used to determine the rate of action of antimalarials.  
  
Thus, the aims of this study were as follows: 
a) develop and optimise an in vitro P. falciparum ATP assay  
b) gauge the utility of a P. falciparum ATP assay, and a Luciferase assay using 
transgenic parasites, as means of assessing the rate of antimalarial drug action 
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CHAPTER 2: DEVELOPMENT AND OPTIMISATION OF A 
PLASMODIUM FALCIPARUM ATP ASSAY 
 
2.1.    INTRODUCTION 
Apart from safety and efficacy, another essential characteristic of novel antimalarials is that 
they be rapid-acting in order to improve patient compliance, reduce costs and lower the risk 
of drug resistance emerging (MMV, 2010; Na-Bangchang & Karbwang, 2009; Nwaka & 
Ridley, 2003). Consequently, assessing the rate of activity of candidate compounds is crucial 
to current drug discovery efforts. Traditional determination of this rate by morphological 
assessments is flawed, principally due to heterogeneous morphology of individual parasites 
under routine culture conditions which results in highly subjective, operator-specific 
interpretations (Otten-Kuipers et al., 1995; Sanz et al., 2012). Hence, there is a need for a 
novel, quantitative assay for determining the kinetics of drug action in culture and the goal of 
this study was to develop such an assay. 
 
Adenosine triphosphate (ATP) serves as a primary source of energy for the growth, 
maintenance and reproduction of all living organisms (Ginsburg, 2010). Thus, it is plausible 
that elevated ATP levels in the malaria parasite may reflect increased metabolic activity to 
circumvent detrimental drug effects, while decreased ATP may indicate a significant decline 
in parasite energy metabolism and viability. The luciferin-luciferase system is a rapid and 
reliable method commonly used for measuring ATP in biological samples (Abraham et al., 
2003; Bruce, 2010). The system is based on ATP-dependent luciferin luminescence catalysed 
by firefly luciferase as outlined below (Manfredi et al., 2002). 
 
Luciferase + luciferin + ATP  luciferase-luciferyl-AMP + PPi 
Luciferase-luciferyl-AMP + O2  luciferase + oxyluciferin + AMP + CO2 + LIGHT 
 
Commercially available kits based on the luciferin-luciferase system are widely used for ATP 
quantification in cultured mammalian and bacterial cells (e.g. CellTiter-Glo Luminescent Cell 
Viability Assay, Promega; BacTiter-Glo Microbial Cell Viability Assay, Promega). Previous 
studies have also applied this ATP-based bioluminescent assay system to measure ATP levels 
in asexual (Kanaani & Ginsburg, 1989) and sexual stages (Peatey et al., 2012) of cultured P. 
falciparum parasites. Accordingly, it is conceivable that the rate of activity of antimalarial 
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drugs may be assessed by quantifying parasite ATP in drug-treated cultures relative to control 
cultures. 
 
Hence, this study has explored the use of the bioluminescent CellTiter-Glo kit (Promega) for 
ATP quantification in cultured P. falciparum parasites and subsequent application of this 
method as a means of assessing the rate of antimalarial drug action. The kit is highly 
sensitive, detecting as few as 4-15 cells which would be advantageous for measuring parasite 
ATP in samples of malaria cultures which contain a fairly minimal parasite biomass. In 
addition, the homogeneous ―add-mix-measure‖ format of the kit allows for rapid generation 
of a luminescent signal which is proportional to the amount of ATP present and has a half-life 
of more than five hours. With this in mind, a preliminary method was developed which 
allows the measurement of parasite ATP levels in control and drug-treated P. falciparum 
cultures using the CellTiter-Glo kit (Prof. H.C. Hoppe, CSIR Biosciences). The method 
requires isolation of intact parasites from host RBCs in order to remove of all traces of RBC 
ATP which would otherwise obscure the measurement of parasite-associated ATP. This 
chapter describes the optimisation of this isolation step and various other aspects of the 
experimental protocol. Additionally, application of the optimised assay for determining the 
extent to which parasite ATP levels vary as a function of parasite developmental stages is 
described. 
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2.2.    MATERIALS AND METHODS 
 
2.2.1.    Cultivation of P. falciparum parasites 
2.2.1.1.    Cell culture 
Plasmodium falciparum 3D7 parasites were cultured in human RBCs using a method adapted 
from Trager and Jensen (1976). Cultures were maintained in complete malaria culture 
medium (CMCM; Appendix 1.1) at a haematocrit (percentage of RBCs in the culture 
medium) of approximately 3%. Culture flasks were suffused with a special gas mixture (5% 
CO2, 5% O2, balance N2; Air Products, RSA), sealed and incubated at 37°C. Medium changes 
were carried out daily under aseptic conditions. The culture was transferred to a sterile 50 mL 
conical tube and centrifuged at 2000 rpm for 5 minutes before aspirating off the spent 
medium. Before adding fresh CMCM, a thin-blood smear was prepared from the infected 
RBC pellet. The smear was fixed with methanol and stained with freshly prepared Giemsa 
stain (Appendix 1.2). Parasite morphology was assessed by viewing the smear by light 
microscopy using a 100x oil-immersion objective. During its 48-hour intra-erythrocytic life-
cycle, ring-stage parasites are present for the first 20-24 hours and develop into trophozoite- 
and schizont-stage parasites during the remaining 24 hours. Thus, a typical culture alternates 
between ring- and trophozoite/schizont-stage parasites every 24 hours. Aliquots of ring-stage 
cultures were cryopreserved every 2-3 months (see section 2.2.1.3 below). The percentage of 
parasitised RBCs (parasitaemia) in the culture was maintained at approximately 5% by 
replacing 60-80% of the infected RBCs with fresh, uninfected RBCs during the 
trophozoite/schizont-stage. The parasitaemia was determined by counting infected and 
uninfected RBCs in 10-15 fields of vision. Fresh blood was obtained from healthy volunteer 
donors in EDTA vacutainer tubes every 3-4 weeks. The RBC pellet was washed twice in 
CMCM before storing at a 50% haematocrit at 4°C. Synchrony of P. falciparum cultures was 
maintained by sorbitol treatment and/or P. falciparum enrichment (see section 2.2.1.2 below).  
 
2.2.1.2.    Synchronisation of cultures  
2.2.1.2.1.    Sorbitol treatment 
The sorbitol method of synchronisation (Lambros & Vanderberg, 1979) lyses late 
trophozoite- and schizont-stage parasites. The method was applied to mixed-stage cultures of 
primarily ring-stage parasites. Firstly, the infected RBCs were pelleted from the culture by 
centrifugation at 2000 rpm for 5 minutes. The pellet was then resuspended in a 5% sorbitol 
solution (Appendix 1.3) pre-warmed at 37°C. The volume of sorbitol solution used was 10-20 
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times that of the RBC pellet. The suspension was incubated at 37°C for 10-15 minutes and 
then centrifuged at 2000 rpm for 5 minutes. The supernatant was aspirated off and the pellet 
was resuspended in fresh CMCM (Appendix 1.1) and returned to the culture flask. The flask 
was gassed (5% CO2, 5% O2, balance N2; Air Products, RSA), sealed and incubated at 37°C.  
 
2.2.1.2.2.    P. falciparum enrichment 
Synchronisation by P. falciparum enrichment was performed according to a method adapted 
from Glushakova et al. (2007). Briefly, infected RBCs from a primarily schizont-stage 
culture were pelleted by centrifugation at 2000 rpm for 5 minutes under sterile conditions. 
The packed RBCs (300 µL) were then pipetted over 1 mL of freshly prepared 60% Percoll 
solution (Appendix 1.4) in sterile microfuge tubes. Each tube was centrifuged at 10000 rpm 
for 20 minutes with slow deceleration. This resulted in the mixture separating into two layers: 
uninfected and ring-infected RBCs were pelleted at the bottom of the tube and enriched 
trophozoite/schizont-infected RBCs were located as an upper brown layer on top of the 
Percoll. The upper layer was transferred to a sterile 50 mL conical tube under aseptic 
conditions. A slide with coverslip was prepared from the suspension and viewed by light 
microscope to determine if the enrichment was successful. The unstained 
trophozoite/schizont-infected RBCs were easily identified by the haemozoin crystals of the 
parasite food vacuoles. Complete malaria culture medium (10 mL; Appendix 1.1) pre-
warmed at 37°C was added dropwise to the enriched RBCs while constantly swirling. The 
suspension was centrifuged at 2000 rpm for 5 minutes and the supernatant was aspirated off. 
The enriched RBCs were washed once more in 10 mL of CMCM before adding fresh RBCs 
in a ~1:2 ratio and resuspending the cells in CMCM at a 1% haematocrit. The suspension was 
transferred to a new culture flask, gassed (5% CO2, 5% O2, balance N2; Air Products, RSA), 
sealed and incubated at 37°C for ~4 hours. Transmission of infection was then ceased by 
destruction of the residual trophozoite and schizont stages by sorbitol treatment (detailed in 
section 2.2.1.2.1). 
 
2.2.1.3.    Cryopreservation of cultures 
Cultures were cryopreserved at the ring-stage of parasite development at a parasitaemia of at 
least 5%, using a method adapted from de Ridder (2003). Briefly, the infected RBCs were 
pelleted from the culture by centrifugation at 2000 rpm for 5 minutes and the supernatant was 
aspirated off. Ice-cold freezing solution (Appendix 1.5) was added to the infected RBCs in a 
1:1 ratio by adding one drop every 10 seconds while constantly swirling. Thorough mixing 
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was obtained by gently pipetting up-and-down followed by transfer to a cryotube and storage 
at -80°C. 
 
2.2.1.4.    Thawing of cultures 
Cultures were thawed according to the method described by de Ridder (2003). Thawing was 
achieved as quickly as possible by placing the cryotube, containing the frozen parasitised 
RBC suspension, in a water bath at 37˚C for approximately 2 minutes. The infected RBC 
suspension was transferred, under aseptic conditions, to a sterile 50 mL conical tube before 
adding the thawing solutions which were pre-warmed at 37°C. Thawing solution A 
(Appendix 1.6), at 0.2x the volume of the infected RBC suspension, was added dropwise 
while constantly swirling. Thawing solution B (Appendix 1.7), at 1.8x the volume of the 
infected RBC suspension, was added in the same manner. The solution was centrifuged at 
2500 rpm for 5 minutes and the supernatant was aspirated off. Fresh, uninfected RBCs were 
added to the infected RBC pellet in a 1:1 ratio. The pellet was resuspended in 10 mL of 
CMCM (Appendix 1.1) pre-warmed at 37°C and transferred to a T25 culture flask. The flask 
was gassed (5% CO2, 5% O2, balance N2; Air Products, RSA), sealed and incubated at 37°C.  
  
2.2.2.    ATP assay: the pilot assay 
Phosphate-buffered saline (PBS), artemisinin and chloroquine were purchased from Sigma-
Aldrich (Steinheim, Germany). The experimental pyrimidine endoperoxide, compound 4070, 
was kindly donated by Dr. C. J. Parkinson (CSIR, Biosciences). The CellTiter-Glo 
Luminescent Cell Viability Assay was purchased from Promega (Madison, WI). 
 
Plasmodium falciparum 3D7 parasites were cultured, as described in section 2.2.1 above, to a 
parasitaemia of at least 15%. An early trophozoite-stage culture was used to prepare parasite 
suspensions, adjusted to 5% haematocrit and 10% parasitaemia. The suspensions were 
prepared in the following solutions: (i) CMCM (Appendix 1.1) – untreated control; (ii) PBS – 
positive killing control; (iii) 100 nM artemisinin in CMCM; (iv) 100 nM chloroquine in 
CMCM; (v) 100 nM compound 4070 in CMCM. Each suspension was transferred to a T25 
flask, gassed and incubated for 8 and 12 hours. At each time-point, 3 x 1 mL samples were 
removed from each flask, transferred to a microfuge tube and put on ice. Each sample was 
centrifuged at 8000 rpm for 30 seconds and the supernatant was aspirated off. The RBCs 
were lysed by resuspending the pellet in 500 µL of ice-cold 0.1% saponin lysis solution 
(Appendix 2.3) and vortexing the mixture until translucent. The lysate was centrifuged at 
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8000 rpm for 30 seconds and the supernatant was aspirated off. The isolated parasites were 
washed twice in 500 µL of ice-cold 0.1% BSA in PBS (Appendix 2.1). Ice-cold PBS (100 
µL) was added and the pellet was resuspended by pipetting up-and-down. The parasite 
sample was snap-frozen in liquid nitrogen and stored frozen. The processed samples were 
thawed at room temperature and 50 µL of each sample was transferred to a white-walled, 
clear-bottomed 96-well plate (Nunc, Germany). For determination of parasite-associated 
ATP, an equal volume (50 µL) of pre-prepared CellTiter-Glo reagent (Appendix 2.4) was 
added to each well. The plate was incubated in the dark for 30 minutes at room temperature 
and luminescence measured in a multimode plate reader (Infinite F500, Tecan, Austria). 
 
2.2.3.    ATP assay: the optimised assay 
Plasmodium falciparum 3D7 parasites were cultivated as described in section 2.2.1 above. 
Parasite suspensions were prepared in CMCM (Appendix 1.1) at a 5% haematocrit and 
parasite concentration ≤ 2x106 per sample. Suspensions of uninfected RBCs were prepared at 
a 5% haematocrit to serve as background controls. Samples (500 µL) of the suspensions were 
transferred to microfuge tubes and maintained on ice. The RBCs were pelleted by 
centrifuging at 8000 rpm for 30 seconds before adding 500 µL of 0.24% saponin lysis 
solution (Appendix 2.5). Complete RBC lysis was achieved by vortexing the solution for 
approximately 45 seconds until translucent. The lysate was pipetted over 300 µL of phthalate 
oil-mix (Quashie et al., 2010; Appendix 2.6) in a microfuge tube and centrifuged at 14000 
rpm for 40 seconds. This resulted in the isolated parasites pelleting below the oil and the 
remaining aqueous lysate settling above the oil. The aqueous layer was aspirated off and the 
inner surface of the tube above the oil layer was washed with 500 µL of 0.1% BSA in PBS 
(Appendix 2.1). The oil layer was aspirated off and 150 µL of ice-cold PBS was pipetted over 
the parasite pellet without resuspending the pellet. The sample was snap-frozen in liquid 
nitrogen and stored at -20°C. Processed samples were thawed at room temperature and the 
parasite pellet was resuspended by pipetting up-and-down before transferring 50 µL to 
duplicate wells of a white Lumitrac 96-well plate (Greiner, Germany). Samples of ice-cold 
PBS (50 µL) were included as negative controls. For detection of ATP in the samples, 50 µL 
of pre-prepared CellTiter-Glo reagent (Appendix 2.4) was added to each well. The plate was 
briefly agitated and then incubated in the dark for 10 minutes at room temperature before 
measuring luminescence in a multimode plate reader (Infinite F500, Tecan, Austria).  
 
 
31 
 
2.2.4.    Data analysis 
Results were expressed as means ± SD from triplicate samples, unless otherwise stated. 
Assay precision was determined by calculating coefficients of variation (CVs) and Z‘ factors 
using the following equations: (i) Z‘ = 1 – 3*((SDsample + SDnegative/background control)/(Meansample –
Meannegative/background control)); (ii) CV = (SD/Mean)*100.  
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2.3.    RESULTS 
 
2.3.1.    The pilot ATP assay 
In order to explore parasite ATP levels as a means of assessing drug-induced parasite stress, a 
pilot assay was developed (Prof. H.C. Hoppe, CSIR Pharmacology) to measure parasite-
associated ATP in P. falciparum cultures using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Madison, WI). Trophozoite-stage parasite cultures were prepared at a 
haematocrit (percentage of RBCs in the culture medium) and parasitaemia (percentage of 
parasitised RBCs) of 5% and 10%, respectively. The cultures were incubated for 8 and 12 
hours in PBS, culture medium or in culture medium containing 100 nM of artemisinin, 
chloroquine or the experimental pyrimidine endoperoxide, compound 4070. (Note: Effective 
treatment concentrations were based on median inhibition concentrations (IC50s) and/or test 
concentrations both from the current study and previous reports (detailed in Table 5.1, 
Appendix 5). Samples (1 mL) of the cultures were taken at each time-point and the infected 
RBCs were pelleted by centrifugation. The parasites were released from RBCs by saponin 
treatment and RBC cytoplasm and debris were removed by five microfuge washing steps 
using 0.1% BSA in PBS. The intact parasites were resuspended in PBS and transferred to a 
development plate before ATP was measured using the CellTiter-Glo reagent (Figure 2.1; 
details in section 2.2.2). 
  
In control parasites, ATP levels increased by 231% between the 8 and 12 hour time-points 
(Figure 2.1b). In contrast, parasites exposed to PBS showed an 88% and 98% decline in ATP 
levels relative to controls after 8 and 12 hours, respectively (Figure 2.1a). PBS lacks glucose 
normally found in culture medium and thus presumably blocks ATP synthesis by glycolysis. 
The chloroquine treatment caused a 139% and 113% increase in ATP levels relative to 
controls after 8 and 12 hours of incubation, respectively. In comparison to controls, ATP 
levels of artemisinin-treated parasites increased by 114% and 40% after 8 and 12 hours of 
incubation, respectively. Conversely, compound 4070 caused a 22% and 33% decrease in 
ATP levels relative to controls after 8 and 12 hours, respectively.  
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Figure 2.1: The pilot ATP assay. Parasite-associated ATP in P. falciparum cultures following an 8 and 
12 hour incubation in PBS, culture medium (Control) or in culture medium containing 100 nM of chloroquine 
(CQ), artemisinin (ART) or compound 4070. Results are presented as a percentage relative to the control (Fig. 
2.1a) or as absolute values measured as relative light units (RLU) (Fig. 2.1b). Each data point represents mean ± 
SD, n = 3.  
 
Thus, the pilot assay showed that parasite ATP levels in P. falciparum cultures can be readily 
detected using a commercial luminescence assay, as demonstrated by the large difference in 
signal between control parasites and those incubated in PBS. In addition, the very significant 
alteration in signal during drug treatment suggests that ATP levels may represent a potential 
diagnostic measure of drug-induced parasite stress. This motivated the pursuit of the primary 
aim of this thesis, i.e. to develop a P. falciparum ATP assay and to explore its utility for 
assessing the kinetics of drug action in culture. The first step to achieving this goal was to 
produce an optimal protocol for measuring malaria parasite ATP by refining various aspects 
of the pilot assay, as described in the following sections. 
 
2.3.2.    Using a phthalate oil-mix to speed up washing and improve yields of isolated 
     parasites 
In the pilot experiment, saponin lysis of RBCs was followed by five microfuge washing steps 
to separate intact parasites from RBC cytoplasm (detailed in section 2.2.2). This is 
necessitated by the presence of ATP in normal and infected RBCs which would otherwise 
obscure the quantification of parasite-associated ATP. This washing process was found to be 
both time-consuming and impractical due to the numerous precise liquid handling and 
centrifugation steps. When preparing the parasite pellets, it is likely important to work 
quickly to prevent changes in parasite ATP levels during the pellet preparation. An additional 
concern was the potential for parasite lysis during the multiple centrifugation steps which, in 
Control PBS CQ ART 4070
0
50
100
150
200
250
300
a Treatments
%
 A
T
P
 R
e
la
ti
v
e
 t
o
 c
o
n
to
l
Control
0
2000
4000
6000
8000
10000
12000
b Treatment
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
8h treatment 12h treatment
34 
 
retrospect, may have been assessed by microscopic examination of the supernatant for signs 
of parasite rupture (e.g. free haemozoin crystals). Therefore, with the intention of speeding up 
isolation of intact parasites from RBC lysates and improving yield of intact parasites, the use 
of a phthalate oil-mix, as described by Quashie et al. (2010), was explored. 
 
Briefly, four samples of parasite suspension were prepared at a 5% haematocrit from a 
trophozoite-stage P. falciparum culture. The volume and parasitaemia of each sample was 
500 µL and 2% respectively, as opposed to the 1 mL, 10% parasitaemia samples used in the 
pilot assay. This amendment to the procedure allowed for more experiments to be done from 
a single parent culture. Two samples were processed as described in the pilot assay by 
removing RBC lysate through centrifugation washing steps. The remaining two samples were 
processed in the same manner with the exception that intact parasites were isolated from the 
RBC debris by centrifuging the RBC lysate through a phthalate oil-mix (dibutyl phthalate: 
dioctyl phthalate; 5:4) at 14000 rpm for 40 seconds. This resulted in the intact parasites 
pelleting below the oil and the remaining aqueous lysate, which included RBC cytoplasm and 
debris, settling above the oil – as illustrated in Figure 2.2 below.  
 
                                       
Figure 2.2: Photograph of a sample after centrifugation of the RBC lysate through the 
phthalate oil-mix. In order to measure parasite-associated ATP in P. falciparum culture samples, parasites 
were released from RBCs by saponin treatment. The intact parasites were isolated from RBC debris by 
centrifugation of the lysate through a phthalate oil-mix, as described by Quashie et al. (2010). This resulted in 
the intact parasites pelleting below the oil and the remaining aqueous RBC lysate settling above the oil. 
 
The pellet was resuspended in PBS and parasite-associated ATP was measured using the 
CellTiter-Glo reagent, with culture medium as a negative control (detailed in section 2.2.2). 
Results are shown in Figure 2.3. Parasites isolated from the RBC lysate via the phthalate oil-
Aqueous RBC lysate 
Phthalate oil-mix 
Parasite pellet 
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mix produced an average luminescence of 18878 RLU, while parasites isolated by microfuge 
washing in 0.1% BSA in PBS generated an average luminescence of 3897 RLU. When 
samples were compared to negative controls (culture medium), average Z‘ factors (indication 
of dynamic range and signal robustness – detailed in section 2.3.5) of 0.88 and 0.95 were 
obtained for the oil-mix and PBS wash samples, respectively. This suggests that 500 µL 
samples of malaria cultures at a haematocrit and parasitaemia of 5% and 2%, respectively, 
comfortably contain sufficient parasites to produce a quantifiable ATP signal which can be 
confidently distinguished from negative controls. In addition, ATP levels of parasites isolated 
via the phthalate oil-mix were approximately 5-fold greater than those of parasites isolated by 
microfuge washing, possibly due to excessive parasite rupture and non-specific adhesion of 
parasites to microfuge tube walls during repeated pelleting. Furthermore, use of the phthalate 
oil-mix was found to be far less time-consuming than repeated washing of the parasite pellet 
in 0.1% BSA in PBS. Therefore, in all future experiments parasites were isolated from RBC 
debris using the phthalate oil-mix rather than microfuge washing of the parasite pellet in 
0.1% BSA in PBS. 
 
Figure 2.3: Comparison of ATP levels in parasite samples isolated from RBC lysates via 
a phthalate oil-mix and PBS wash. Trophozoite-stage P. falciparum parasites, released from RBCs by 
saponin treatment, were isolated from the RBC lysate by: (i) Oil-mix – centrifugation of the lysate through an 
oil-mix (dibutyl phthalate: dioctyl phthalate; 5:4) (samples 1-2), or (ii) PBS wash – five microfuge washing 
steps in 0.1% BSA in PBS (samples 3-4). Parasite ATP levels, measured as relative light units (RLU), are 
presented as means ± SD, n = 2.  
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2.3.3.    Minimising contamination of the parasite pellet by RBC cytoplasm 
While exploring the phthalate oil method, it was observed that samples were occasionally 
slightly pink in colour after resuspension of the parasite pellet in PBS. This was attributed to 
possible contamination of the parasite pellet by RBC cytoplasm and/or intact RBCs that 
escaped lysis during saponin treatment. The ATP assay procedure should, ideally, remove all 
traces of RBC cytoplasm, and hence RBC ATP, during isolation of intact parasites from 
culture samples. In order to determine whether residual RBC cytoplasm may be present in 
pellets after sample processing, suspensions of uninfected RBCs were prepared at a 5% 
haematocrit and subjected to the ATP assay procedure, using the phthalate oil-method as 
described in section 2.3.2.  
 
Various adjustments were made to the experimental protocol to ensure that the final sample 
was free of RBC cytoplasm. The RBC pellet was lysed using a lysis solution with saponin 
concentration of 0.24%, as opposed to 0.1% used in previous experiments, in order to ensure 
complete RBC lysis. Subsequent centrifugation of the lysate through the phthalate oil-mix 
produced an infinitesimal, transparent ―pellet‖. The aqueous and oil layers were removed and 
150 µL of PBS was pipetted over the ―pellet‖ before the sample was snap-frozen in liquid 
nitrogen and stored frozen. Processed samples were thawed and the ―pellet‖ was resuspended 
immediately before transfer to the development plate. Resuspension was achieved either by 
vortexing the mixture or pipetting up-and-down. The ―vortexed‖ samples appeared slightly 
pink in colour while ―pipetted‖ samples were colourless. The CellTiter-Glo reagent was used 
to measure ATP levels in the samples and results are shown in Figure 2.4. The residual RBC 
ATP present in ―vortexed‖ (pink) samples (mean RLU = 152472) was 76x higher than that of 
―pipetted‖ (colourless) samples (mean RLU = 2015).  
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Figure 2.4: Comparison of residual RBC ATP levels in samples resuspended by 
vortexing and pipetting. To determine whether residual RBC cytoplasm may be present after sample 
processing, suspensions of uninfected RBCs (samples 1-4) were subjected to the ATP assay procedure. 
Resuspension of the sample ―pellet‖ in PBS was achieved either by vortexing (1 and 2) or pipetting up-and-
down (3 and 4). ATP levels, measured as relative light units (RLU), are presented as means ± SD, n = 2. 
 
The elevated ATP levels and pink colour of the vortexed samples suggests that the 
suspension may have mixed with haemoglobin-containing RBC cytoplasm, and hence RBC 
ATP, as it travelled up the sides of the tube during vortexing. This suggests that residual RBC 
cytoplasm may be present on the walls of the sample tube after removal of the aqueous and 
oil layers and may contaminate the parasite pellet during processing of P. falciparum culture 
samples. Therefore, an additional washing step was considered to remove all traces of RBC 
ATP from the walls of the sample tube. To determine the effectiveness of this washing step in 
removing residual RBC ATP, ATP levels were measured in parallel suspensions of 
uninfected and trophozoite-infected RBCs. The samples were prepared at a haematocrit and 
parasitaemia of 5%. Samples were processed in the same manner as the uninfected RBC 
samples in the previous experiment, with the following modifications: (i) after centrifugation 
of the RBC lysate through the phthalate oil-mix and removal of the aqueous layer, the inner 
surface of the sample tube and the surface of the oil layer were washed with 500 µL of 0.1% 
BSA in PBS before removing the oil layer; (ii) resuspension of all sample pellets was 
achieved by pipetting the mixture up-and-down, as opposed to vortexing. Results are shown 
in Figure 2.5.  
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Residual RBC ATP (mean RLU = 1499) was present in the uninfected RBC samples, 
however, this accounted for less than 0.5% of the ATP measured in the trophozoite parasite 
samples (mean RLU = 332876). However, inter-sample variation of uninfected RBC samples 
was substantial (CV = 57.6%), therefore uninfected RBC suspensions were included as 
background controls in all subsequent experiments.  
 
Figure 2.5: Comparison of ATP levels in samples of uninfected and trophozoite-infected 
RBCs subjected to the optimised ATP assay procedure. In order to minimise residual RBC ATP 
in the parasite sample, the ATP assay was optimised by an additional washing step and resuspension of samples 
by pipetting as opposed to vortexing. The efficacy of these modifications was assessed by comparing ATP 
levels in samples of trophozoite-infected RBCs (samples 1-3) and uninfected RBCs (samples 4-6) subjected to 
the modified procedure. ATP levels, measured as relative light units (RLU), are presented as means ± SD, n = 2.  
 
Therefore, based on the results in this section, the following adjustments were made to the 
ATP assay procedure to minimise contamination of the parasite pellet by RBC cytoplasm, 
and hence RBC ATP: 
i.  The concentration of saponin in the lysis solution was increased from 0.1% to 0.24% 
to ensure complete RBC lysis; 
ii.  After centrifugation of the RBC lysate through the phthalate oil-mix and removal of 
the aqueous layer, the inner surface of the tube was washed with 500 µL of 0.1% 
BSA. The purpose of this additional washing step was to remove any residual RBC 
cytoplasm adhering to the tube walls and surface of the oil layer, before removing the 
layer. 
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iii.  To the pellet, 150 µL of PBS was added before snap-freezing the sample. The pellet 
was resuspended immediately before transfer to the development plate by pipetting 
the mixture up-and-down, as opposed to vortexing the sample. 
 
Thus, after extensive experimental refinement, an optimised protocol for measuring parasite 
ATP levels in P. falciparum culture samples was achieved (detailed in section 2.2.3). 
Thereafter, the linearity, sensitivity and precision of the assay were assessed to gauge the 
suitability of the method. 
 
2.3.4.    Linearity and sensitivity of the ATP assay 
In order to determine the strength of the correlation between measured luminescence signals 
and parasite ATP levels, parasite suspensions were prepared from culture samples and 
serially diluted before measuring ATP levels. Briefly, 500 µL samples of parasite 
suspensions at a haematocrit and parasitaemia of 5% were prepared from trophozoite-stage P. 
falciparum cultures. The parasite pellet was isolated and resuspended in 200 µL of PBS 
before performing 5 x 2-fold serial dilutions to a final volume of 200 µL in PBS and 
measuring ATP levels (see section 2.2.3 for details). Parasite numbers in each sample were 
calculated from parasitaemia, and RBC concentration which was determined using a 
haemacytometer. The experiment was repeated on a separate occasion using higher parasite 
concentrations. Results are shown in Figure 2.6. 
 
Luminescence signals showed excellent linear correlation with parasite numbers ranging 
from 1.23x105 to 1.97x106, evident by the corresponding linear regression correlation 
coefficients (r2 values) which ranged from 0.95 to 0.99 (Figure 2.6a). When higher parasite 
concentrations were used in the assay, luminescence signals became saturated and deviated 
from linearity at parasite numbers greater than 2.19x106 (Figure 2.6b). Exclusion of the 
deviating data points produced excellent linear correlation between luminescence signals and 
parasite numbers ranging from 5.47x105 to 2.19x106 with r2 values of 0.98-1.00 (Figure 
2.6c), although care should be taken with this interpretation since only 3 data points were 
included in the linear regression. Thus, for parasite concentrations over the range 1x105–
2x106 per sample, the luminescence signals produced by the P. falciparum ATP assay 
strongly correlate with parasite-associated ATP levels. 
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Figure 2.6: Relationship between parasite ATP levels and parasite concentrations for 
the P. falciparum ATP assay. The strength of the correlation between measured luminescence signals 
and parasite ATP levels was assessed by measuring ATP levels in samples with different parasite 
concentrations. Two parasite concentration ranges were employed (i.e. 1.23x105–1.97x106 (Fig. 2.6a) and 
5.47x105–8.75x106 (Fig. 2.6b) and three (Fig. 2.6a) or two (Fig. 2.6b) samples of each parasite concentration 
were processed in parallel on each occasion. Note: Fig. 2.6c is plotted from the same data as 2.6b, with higher 
parasite numbers excluded. Each data point represents the mean ± SD, n = 2. 
 
2.3.5.    Precision and reproducibility of the ATP assay 
The ATP assay procedure involves several centrifugation and pipetting steps which increase 
the likelihood of variation among ATP levels in parallel samples. Thus, in order to determine 
the precision of results produced by the P. falciparum ATP assay, coefficients of variation 
(CVs) and Z‘ factors were calculated (detailed in section 2.2.4) for experiments performed 
during optimisation of the assay, as described in this chapter. The Z‘ factor is a unitless 
statistical parameter that indicates the useful width of the assay window (Iversen et al., 2006; 
Zhang et al., 1999a). The broader this window, the more confidently a positive signal can be 
distinguished from a background/negative signal. A Z‘ value: (i) < 0.5 = marginal assay; (ii) 
≥ 0.5 = excellent assay; (iii) = 1 = ideal assay. Results are summarised in Table 2.1. 
 
0 5 10 15 20
0
20000
40000
60000
80000 r2 = 0.95
r2 = 0.99
r2 = 0.97
a Parasites (105)
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
0 20 40 60 80 100
0
10000
20000
30000
b Parasites (10 5)
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
0 5 10 15 20 25
0
5000
10000
15000
20000
r2 = 1.00
r2 = 0.98
c Parasites (105)
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
Sample 1
Sample 2
Sample 3
41 
 
Table 2.1: Summary of coefficients of variation (CVs) and Z’ factors obtained using the 
P. falciparum ATP assay.  
Figure Parasites 
Number of 
samples 
Average % CV Average 
Z' Intra-sample Inter-sample 
   2.3 Trophozoites 4 2.8 3.2 0.91* 
   2.5 Trophozoites 3 1.5 5.0 0.95# 
   2.6a Trophozoites 15 6.0 7.6 0.81* 
   2.6b Trophozoites 10 4.7 13.3 0.86* 
   2.7 Rings 3 0.7 11.5 0.98* 
   2.8a Rings 3 1.3 28.7 0.95# 
   2.8a Trophozoites 3 0.8 18.9 0.97# 
  Total: 
41 
Average: 
2.5 
Average:  
12.6 
Average: 
0.92 
 
Note: (i) The ―Figure‖ column contains the number of the figure in this chapter which corresponds to the 
experiment from which the data was extracted to do the calculations; (ii) The ―Number of samples‖ refers to the 
number of parasite pellets that were subjected to the assay in parallel and does not take into account control 
samples presented in the figures. ATP luminescence in each pellet was read in duplicate wells (n=2); (iii) Intra-
sample CVs were calculated from results obtained from duplicate wells containing the same test sample while 
inter-sample CVs were calculated from results obtained from replicate test samples (i.e. parasite pellets prepared 
in parallel); (iv) Z‘ factors were calculated by comparing the parasite samples to negative controls (medium 
only)* or background controls (uninfected RBCs) #. 
 
The results indicated that for a total of 41 samples processed on different occasions in the 
ATP assay, the average intra-sample and inter-sample coefficients of variation were 2.5% and 
12.6%, respectively, and were deemed acceptable for a cell-based assay of this nature. In 
addition, an average Z‘ factor of 0.92 was obtained, signifying an excellent assay window. 
Hence, the P. falciparum ATP assay has a broad dynamic range and is an excellent tool for 
measuring parasite-associated ATP in culture samples with a reasonable degree of precision. 
 
Inter-assay reproducibility was assessed by determining the extent to which RLU values 
differ when the P. falciparum ATP assay was carried out on separate occasions. This was 
achieved by calculating the CV for mean RLU values of corresponding time 0 control 
samples obtained on different occasions during experiments to assess the kinetics of drug 
action, as described in Chapter 3. Results are shown in Table 2.2.  
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Table 2.2: Inter-occasional reproducibility of the P. falciparum ATP assay. 
Figure Mean RLU 
3.1a 12101 
3.2a 158882 
3.3a 221520 
3.4a 338279 
3.5a 315409 
Inter-assay 
Average 209238.2 
SD 131789.1 
CV 63.0 
 
Note: (i) The ―Figure‖ column contains the number of the figure in Chapter 3 (see section 3.3.1) which 
corresponds to the experiment from which the data was extracted to do the calculations, however, the Mean 
RLU values used in the table are not shown on the figures; (ii) The ―Mean RLU‖ column contains RLU values 
measured in corresponding time 0 control samples using the P. falciparum ATP assay. 
 
The results indicated that inter-assay RLU values of time 0 control samples varied 
considerably (CV = 63%) for reasons that have not been explored further. Therefore, absolute 
values obtained on separate occasions from analogous experiments cannot be directly 
compared except relative to internal controls, unless the purpose of the comparison is to 
assess stage variability. 
 
2.3.6.    Assessing the capacity of the assay to measure ATP levels in ring-stage parasites 
The pilot ATP assay was performed using only trophozoite-stage P. falciparum parasites 
which are characterised by rapid growth and marked metabolic activity (Lazarus et al., 2008; 
Zolg et al., 1984) and therefore, as expected, contained ATP levels that were readily 
detectable by the assay. In contrast, ring-stage parasites display low metabolic activity and 
are far less voluminous than trophozoites. Nevertheless, the measurement of ATP levels in 
ring-stage parasites was attempted (experimental details in section 2.2.2). Briefly, 500 µL 
samples of parasite suspensions at a haematocrit and parasitaemia of 5% were prepared from 
ring-stage P. falciparum cultures. The infected RBCs were lysed using a 0.1% saponin lysis 
solution and intact parasites were isolated from RBC debris using the phthalate oil-mix, as 
described before. Unlike the clearly visible dark brown pellet produced by trophozoite-stage 
parasites (see Figure 2.2), the ring-stage parasite pellet was minimal and transparent. 
Therefore, sample tubes containing ring-stage parasites were always positioned in the 
microfuge with caps facing out to ensure that the orientation of the pellet was known. The 
43 
 
pellet was resuspended in 150 µL of PBS and parasite-associated ATP was measured using 
the CellTiter-Glo reagent, with culture medium as a negative control. The results (Figure 2.7) 
indicated that luminescence signals obtained with ring-stage parasites (mean RLU = 37459) 
were considerably higher than negative controls (mean RLU = 106) by a factor of ± 355, with 
an average Z‘ factor of 0.98. 
 
Figure 2.7: ATP levels in ring-stage P. falciparum parasites. Three samples (samples 1-3) of a 
ring-stage culture were subjected to the ATP assay procedure. Parasite ATP levels, measured as relative light 
units (RLU), were measured using the CellTiter-Glo reagent, with culture medium as a negative control (sample 
4). Results are presented as means ± SD, n = 2.  
 
Thus, the ATP assay appears capable of measuring ATP levels in ring-stage parasites. 
However, the above experiment was performed before the introduction of the RBC removal 
modifications, as described in section 2.3.3. To confirm that the ATP signals attributed to the 
rings were not due to RBC contamination, the experiment was repeated using the optimised 
ATP assay procedure with uninfected RBCs as controls. Trophozoite samples were processed 
in parallel to compare the intensity of ATP signals in the two stages. Results are shown in 
Figure 2.8. 
 
As expected, ATP levels of trophozoite-stage parasites (mean RLU = 352947; Figure 2.8a) 
were more than 25x higher than the ATP levels of a corresponding number of ring-stage 
parasites (mean RLU = 13122). Luminescence signals of the ring-stage parasites were 
nonetheless considerably higher (13-fold) than those of background controls (uninfected 
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RBCs; mean RLU = 993; Figure 2.8b) with an average Z‘ factor of 0.95. This represents a 
very comfortable assay window for assessing changes in ATP levels in ring-stage parasites. 
 
 
Figure 2.8: Comparison of ATP levels in ring- and trophozoite-stage P. falciparum 
parasites. Triplicate aliquots (samples 1-3) of parallel ring- and trophozoite-stage cultures were subjected to 
the ATP assay procedure (Fig. 2.8a). Parasite ATP levels, measured as relative light units (RLU), are presented 
as means ± SD, n = 2. The ATP levels of the ring-stage parasites (n = 3) are compared to the residual RBC ATP 
of uninfected RBC controls (n = 2) in Fig. 2.8b. 
 
2.3.7.    Determining the extent to which parasite ATP levels vary as a function of   
    trophozoite development 
In order to determine the extent to which the ATP levels of trophozoite-stage parasites vary 
over time, samples of culture were taken at regular intervals and parasite-associated ATP was 
measured. Briefly, an early-mid trophozoite-stage culture synchronised by sorbitol treatment 
(detailed in section 2.2.1.2.1) was prepared at a haematocrit and parasitaemia of 5%. 
Triplicate samples (500 µL) were taken every 2 hours over a 10-hour period and subjected to 
the optimised ATP assay procedure (detailed in section 2.2.3). In addition to measuring 
parasite ATP levels, Giemsa-stained thin-blood smears were prepared at each time-point and 
assessed for morphological changes. 
 
The ATP results (Figure 2.9) indicated a substantial (62%) decrease in parasite ATP levels 
within the first 2 hours. This large decrease in ATP levels between the 0- and 2-hour time-
points was consistently observed in all time-course experiments (e.g. Figure 2.12). The 
source is not clear but likely artifactual and due to exposure of parasites to non-culture 
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conditions during preparation for the experiment which may have caused elevated ATP levels 
at time 0. This was followed by a moderate (25%) decline between the 2- and 4-hour time-
points. Parasite ATP levels remained unchanged between the 4- and 6-hour time-points and 
decreased by 39% during the last 4-hours of incubation.  
 
 
Figure 2.9: Changes in ATP levels of trophozoite-stage parasites over time in a sorbitol-
synchronised culture. Samples of a sorbitol-synchronised trophozoite-stage P. falciparum culture were 
taken every 2 hours over a 10-hour period and subjected to the ATP assay procedure. ATP levels, measured as 
relative light units (RLU), are presented as means ± SD, n = 3.  
 
Rapid growth and marked metabolic activity are characteristic of trophozoite-stage parasites 
(Lazarus et al., 2008; Zolg et al., 1984), therefore the decrease in parasite ATP levels over 
the remaining 8 hours was unexpected because the culture contained early-mid trophozoite-
stage parasites at time 0. Hence, parasite ATP levels were expected to increase as this 
developmental stage matured. Examination of the thin-blood smears prepared at each time-
point (Figure 2.10) provided some insight into these unexpected results. It was found that at 
the 6- and 8-hour time points the majority of the parasite population were schizonts, while 
mostly ring-stage parasites were observed at the 10-hour time-point.  
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Figure 2.10: Morphological changes in P. falciparum parasites over time in a sorbitol-
synchronised culture. Giemsa-stained thin-blood smears were prepared from a sorbitol-synchronised 
trophozoite-stage P. falciparum culture every 2 hours over a 10-hour period. Photomicrographs of the thin-
blood smears were taken by light microscopy with an Olympus BX41 upright microscope equipped with a 
digital camera CC-12 soft imaging system (U-CMAD3, Olympus, Tokyo, Japan) using a 100x oil-immersion 
objective and analysis LS Report software.  
 
In order to obtain a more accurate account of the different developmental stages present at 
each time-point, a total of 100 parasites were counted in each smear and the percentage of 
each parasite stage determined (Figure 2.11). The results indicated that the majority of 
parasites in the initial culture were early-mid trophozoites (74%), while the remaining 
parasite population consisted of early schizonts (26%). By the 4-hour time-point, the majority 
of parasites (66%) had reached the schizont stage and remained in this stage for the next 4 
hours. As parasites transition from the trophozoite to the schizont stage, a moderate decrease 
in metabolic activity is expected as growth ceases and the parasite undergoes four to five 
rounds of binary fission to produce daughter merozoites which proceed to infect fresh RBCs. 
Thus, the modest decrease in ATP levels between the 2- and 4-hour time-points is likely a 
result of the parasites transitioning from the trophozoite to the schizont stage. Ring-stage 
parasites are characterised by low metabolic activity (Lazarus et al., 2008; Zolg et al., 1984) 
and were observed from the 6-hour time-point onward. This developmental stage accounted 
for 21% and 76% of the parasite population at the 8- and 10-hour time-points, respectively. 
Thus, the decline in ATP levels during the last 4 hours of incubation may be attributed to the 
 
10 hours 
0 hours 
 
2 hours 4 hours 
 
6 hours 
 
8 hours 
  
47 
 
rupture of schizont-stage parasites and subsequent invasion of fresh RBCs to form rings. The 
percentage of schizonts in the parasite population declined markedly (66% to 20%) between 
the 8- and 10-hour time-points to produce the less metabolically active ring-stage parasites, 
however, overall ATP levels only decreased by about 20%. Each schizont ultimately 
produces 16-32 rings (van Agtmael et al., 1999), thus even though a large number of 
schizonts ruptured to produce less metabolically active parasites (i.e. rings), the overall 
decrease in ATP was not considerable since each schizont was replaced by multiple rings.  
 
 
Figure 2.11: The percentage of each developmental stage present in a sorbitol-
synchronised P. falciparum culture over a 10-hour incubation period. Giemsa-stained thin-
blood smears were prepared from a sorbitol-synchronised trophozoite-stage parasite culture every 2 hours over a 
10-hour period and the percentage of each developmental stage (i.e. rings, trophozoites, schizonts) was 
approximated by counting a total of 100 parasites.  
 
Thus, the results suggest that a sorbitol-synchronised early-mid trophozoite-stage culture with 
seemingly low levels (~26%) of schizont-stage parasites at time 0 will inevitably contain 
multiple developmental stages over a 10-hour period. Hence, a sorbitol-synchronised culture 
is not suitable for assessing ATP changes in trophozoite-stage parasites during a 10-hour 
incubation. In order to obtain a truer reflection of the extent to which ATP levels of 
trophozoite-stage parasites vary over time, a more tightly synchronised culture of early-
trophozoite stage parasites is required. Therefore, a Percoll-based P. falciparum enrichment 
procedure (detailed in section 2.2.1.2.2) was used to produce such a culture before repeating 
the experiment. As in the previous experiment, ATP results (Figure 2.12) indicated a major 
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(79%) decline in parasite ATP levels within the first 2 hours. This was followed by an even 
greater (108%) increase in parasite-associated ATP levels during the next 4 hours with a 
moderate (34%) decrease occurring in the remaining 4 hours.  
 
 
Figure 2.12: Changes in the ATP levels of trophozoite-stage parasites over time in a 
Percoll-synchronised culture. Samples of a Percoll-synchronised trophozoite-stage P. falciparum culture 
were taken every 2 hours over a 10-hour period and subjected to the ATP assay procedure. ATP levels, 
measured as relative light units (RLU), are presented as means ± SD, n = 3.  
 
Examination of the thin-blood smears (Figure 2.13) indicated that parasites were at the 
trophozoite stage of development throughout the experiment. Rapid growth of parasites was 
observed between the 2- and 6-hour time-points as the parasites progressed from the early- to 
mid-trophozoite stage of development, which likely explains the increase in ATP levels 
between these time-points. Late trophozoite-stage parasites were present in the last 2 hours of 
incubation, thus the decrease in ATP levels during this time may be a result of a slowing 
down in parasite growth as the parasites prepared to enter the schizont stage of development.  
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Figure 2.13: Morphological changes in trophozoite-stage parasites over time in a 
Percoll-synchronised culture. Giemsa-stained thin-blood smears were prepared from a Percoll-
synchronised trophozoite-stage P. falciparum culture every 2 hours over a 10-hour period. Photomicrographs of 
the thin-blood smears were taken by light microscopy with an Olympus BX41 upright microscope equipped 
with a digital camera CC-12 soft imaging system (U-CMAD3, Olympus, Tokyo, Japan) using a 100x oil-
immersion objective and analysis LS Report software.  
 
The results indicated that the ATP levels of trophozoite-stage parasites fluctuate considerably 
(~2-3 fold) during a 10-hour incubation, even in the absence of drug treatment. In addition, 
inter-experimental absolute RLU values obtained also display considerable differences (e.g. 
compare the luminescence values in Figures 2.9 and 2.12). Therefore, if drug-induced 
parasite stress were to be assessed by measuring parasite ATP levels in drug-treated cultures 
over a 10-hour period, an untreated control culture should be included and all results should 
be expressed relative to the control.  
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2.4.    DISCUSSION 
In an effort to develop a novel, quantitative assay for assessing drug-induced parasite stress, 
the measurement of parasite-associated ATP using the luminescence-based CellTiter-Glo 
reagent (Promega, Madison, WI) was explored as a means of diagnosing abnormal parasite 
metabolism. The pilot assay involved the measurement of parasite ATP in samples of 
trophozoite-stage P. falciparum cultures incubated for 8 and 12 hours in PBS or drug-treated 
culture medium. The ATP levels of control parasites increased more than 3-fold between the 
8 and 12 hour time-points as shown in Figure 2.1b. This was likely due to rapid growth and 
marked metabolic activity which are characteristic of trophozoite-stage parasites (Lazarus et 
al., 2008; Zolg et al., 1984). The metabolic activities of trophozoite-stage parasites include 
haemoglobin digestion and the synthesis of DNA, RNA and proteins (Lazarus et al., 2008; 
Zolg et al., 1984). There was a massive decline in the ATP levels of parasites incubated in 
PBS at both time-points, likely a result of the lack of glucose to fuel glycolysis which is the 
metabolic pathway by which the parasite anaerobically produces ATP (Olzewski & Llinás, 
2010). At both time-points, the ATP levels of chloroquine- and artemisinin-treated parasites 
increased considerably, while those of parasites exposed to compound 4070 decreased 
moderately, relative to controls. The elevated ATP levels may be a result of increased 
metabolic activity by the parasite in an effort to counteract harmful drug effects, while the 
reduced ATP levels may be indicative of compromised parasite energy metabolism and/or 
viability. These are general interpretations of the above results in light of the fact that the 
results were obtained using the pilot assay. Detailed interpretations of how parasite ATP 
levels respond to drug-induced stress are discussed in Chapter 3 with results obtained using a 
fully optimised P. falciparum ATP assay protocol.  
 
Nevertheless, results of the pilot assay have indicated that parasite ATP levels in P. 
falciparum cultures can be readily detected using a commercial luminescence assay and may 
represent a potential diagnostic measure of drug-induced parasite stress. Therefore, the 
primary aim of this study was to develop an optimised and fully functional P. falciparum 
ATP assay and to explore the utility of the assay for assessing the kinetics of drug action in 
culture. The first step to achieving this goal was to produce an optimal protocol for detecting 
malaria parasite ATP by refining various aspects of the pilot assay. 
 
In the pilot assay, five microfuge washing steps were used to isolate intact parasites from the 
RBC lysate, and hence RBC ATP, following saponin treatment. This washing process was 
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both time-consuming and impractical due to the numerous precise liquid handling and 
centrifugation steps involved. Additional concerns were the possibility of parasite lysis due to 
the multiple centrifugation steps, as well as the potential variation in parasite ATP levels 
during the lengthy exposure of the parasites to non-culture conditions. Therefore, the use of a 
phthalate oil-mix, as described by Quashie et al. (2010), was explored as an alternative 
method for parasite isolation from RBC lysates. The ATP levels of parasites isolated via the 
phthalate oil-mix were approximately 5x higher than those of parasites isolated by microfuge 
washing in 0.1% BSA in PBS. This was possibly a result of the latter method causing parasite 
loss due to excessive parasite rupture and non-specific adhesion of parasites to microfuge 
tube walls during repeated centrifugation. Furthermore, use of the phthalate oil-mix was 
found to be far less time-consuming than microfuge washing of the parasite pellet. Thus, the 
improved ATP levels may be due to reduced variation in parasite ATP levels as a result of 
shorter exposure to non-culture conditions, and/or improved yield of intact parasites as a 
result of fewer centrifugation and liquid handling steps.  
 
It was noted that samples were slightly pink in colour after resuspension of the parasite pellet 
in PBS. This was ascribed to contamination of the parasite pellet by haemoglobin-containing 
RBC cytoplasm, and/or intact RBCs which may have escaped lysis during saponin treatment. 
The ATP assay procedure should, ideally, remove all traces of RBC cytoplasm during 
isolation of intact parasites from culture samples. Therefore, several adjustments to the ATP 
assay procedure were explored in order to minimise the aforementioned contamination before 
repeating the experiment. The first amendment to the procedure was the increased saponin 
concentration of the lysis solution from 0.1% to 0.24% in order to ensure complete RBC 
lysis. The effectiveness of this modification was evaluated by subjecting uninfected RBCs to 
the ATP assay using the modified lysis solution. This resulted in a minute, transparent pellet 
which may represent RBC ―ghosts‖ i.e. post-haemolytic remains of RBCs consisting 
primarily of membrane and cytoskeletal elements and devoid of cytoplasmic components 
(Schwoch & Passow, 1973). The transparent colour of the pellet suggested that the 0.24% 
saponin lysis solution achieved complete haemolysis. Resuspension of the pellet in PBS was 
achieved by either vortexing or pipetting the sample up-and-down. ―Vortexed‖ samples were 
slightly pink in colour while ―pipetted‖ samples were colourless. The pink colour of vortexed 
samples was assumed to be a result of the suspension travelling up the sides of the tube and 
mixing with residual haemoglobin-containing RBC cytoplasm during vortexing. This 
assumption was supported by the ATP results which showed that vortexed samples (of RBC 
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material alone) contained 76x more residual RBC ATP than ―pipetted‖ samples. Therefore, 
all future experiments were carried out using the improved lysis solution (i.e. 0.24% rather 
than 0.1% saponin) and resuspension of the parasite pellet was achieved by pipetting, rather 
than vortexing, the sample immediately before transfer to the development plate. 
Furthermore, an additional washing step was included in the procedure to minimise 
contamination of the parasite pellet by RBC cytoplasm, and hence RBC ATP, during 
processing of culture samples.  
 
This additional step, performed after centrifugation of the RBC lysate through the phthalate 
oil-mix, involved washing the inner surface of the sample tube with 0.1% BSA in PBS to 
remove any residual RBC cytoplasm before removing the oil layer. The ATP levels in 
parallel suspensions of uninfected and trophozoite-infected RBCs were measured using the 
ATP assay with this additional washing step. Results indicated that residual RBC ATP was 
still present in uninfected RBC samples, even after inclusion of the washing step. Even 
though the residual RBC ATP accounted for less than 0.5% of the ATP measured in parasite 
samples, inter-sample variation of uninfected RBC samples was considerable (CV = 57.6%). 
Therefore, uninfected RBC suspensions were included as background controls in all 
subsequent experiments using the ATP assay. Thus, after extensive experimental refinement, 
an optimised protocol for measuring parasite ATP in levels in P. falciparum culture samples 
was produced. A detailed description of the protocol is given in section 2.2.3 and is 
summarised below. 
 
Infected RBCs were pelleted from in vitro cultures by centrifugation and resuspended in 
culture medium at a volume, haematocrit and parasite concentration of 500 µL, 5% and ≤ 
2x106 per sample. Uninfected RBCs were prepared in the same manner to serve as 
background controls. Triplicate 500 µL aliquots of each suspension were transferred to 
microfuge tubes and maintained on ice as samples were individually processed. Each tube 
was centrifuged to pellet the RBCs which were lysed by a 0.24% saponin solution. The RBC 
lysate was centrifuged through a phthalate oil-mix, resulting in the intact parasites pelleting 
below the oil and the remaining aqueous lysate settling above the oil. The aqueous layer was 
removed and the inner surface of the tube was washed before removing the oil layer. Ice-cold 
PBS was added to the parasite pellet before snap-freezing the sample. Processed samples 
were thawed and the parasite pellet was resuspended by pipetting up-and-down before 
transferring the suspension to a white 96-well plate. Parasite-associated ATP was detected by 
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adding CellTiter-Glo reagent and measuring the resulting luminescence in a multimode plate 
reader. 
 
Once the experimental protocol of the P. falciparum ATP assay was optimised and 
characterised, an analysis of the linearity, sensitivity and precision of the assay was 
performed. The strength of the correlation between measured luminescence signals and 
parasite ATP levels, i.e. assay linearity, was determined by measuring ATP levels in parasite 
suspensions with different parasite concentrations. Luminescence signals showed excellent 
linear correlation with parasite numbers over the range 1.23x105–2.19x106 parasites per 
sample. When higher parasite concentrations were used in the assay, luminescence signals 
became saturated and deviated from linearity. This implies that, for parasite concentrations 
over the range 1x105–2x106 per sample, the luminescence signals produced by the P. 
falciparum ATP assay strongly correlate with parasite-associated ATP levels.  
 
Assay precision represents the degree of scatter among a series of measurements obtained 
from multiple samples under identical conditions (Chesher, 2008) and is usually expressed as 
the coefficient of variation (CV). An additional means of evaluating the quality of an assay is 
to calculate the Z‘ factor which is a unitless statistical parameter that reveals the useful width 
of the assay window, i.e. the dynamic range between background/negative and positive 
control signals (Iversen et al., 2006; Zhang et al., 1999a). The wider this window, the more 
confidently a positive signal can be distinguished from a background/negative signal. A Z‘ 
value: (i) less than 0.5 indicates a marginal assay; (ii) greater than 0.5 signifies an excellent 
assay; (iii) equal to 1 is the maximum possible Z‘ value and represents an ideal assay. For a 
total of 41 samples processed on separate occasions in the ATP assay, the average intra-
sample and inter-sample CVs were 2.5% and 12.6%, respectively. These were considered to 
be acceptable given the cell-based nature of the assay. An average Z‘ factor of 0.92 was 
achieved, suggesting that the positive signals (parasite-associated ATP) can be differentiated 
from background (RBC-associated ATP) or negative controls (culture medium) with 
confidence. Hence, the P. falciparum ATP assay has a high dynamic range and is an excellent 
tool for detecting parasite ATP in culture samples with an acceptable degree of precision. 
 
During optimisation of the assay, trophozoite-stage parasites were easily tracked during 
sample processing due to haemozoin crystals in the food vacuoles which rendered the 
parasite pellet a clearly visible dark brown colour. An added advantage of working with 
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trophozoites was that these parasites produced ATP levels which were readily detectable by 
the ATP assay, likely due to marked metabolic activity which is characteristic of this 
developmental stage (Lazarus et al., 2008; Zolg et al., 1984). On the other hand, ring-stage 
parasites lack food vacuoles, are far less voluminous than trophozoite-stage parasites and 
display low metabolic activity. Nonetheless, samples of ring-stage parasite cultures were 
subjected to the ATP assay in order to ascertain whether measurement of parasite-associated 
ATP was possible in this developmental stage. The resulting parasite pellet was minimal and 
transparent, and therefore extremely difficult to track during processing of samples. Even so, 
the ring-stage parasite samples produced signals that were readily detectable.  
 
Comparison of ATP levels in parallel samples of ring- and trophozoite-stage parasites 
indicated that the ATP levels of trophozoite-stage parasites were appreciably higher than 
those of a corresponding number of ring-stage parasites. Luminescence signals of the ring-
stage parasites were nonetheless considerably higher than those of uninfected RBC 
background controls. This suggests that the P. falciparum ATP assay is capable of detecting, 
and distinguishing, ATP levels in both ring- and trophozoite-stage parasites. Thus, the ATP 
assay could potentially be used to assess drug-induced changes in the ATP levels of ring-
stage parasites. This is highly advantageous given that morphological changes in rings are 
extremely difficult to judge unambiguously by light microscopy. Even though trophozoite-
stage parasites were used for all subsequent experiments in this study, the results suggest that 
it may be possible to compare drug effects in parallel samples of ring- and trophozoite-stage 
cultures by measuring parasite ATP levels.  
 
The P. falciparum parasite undergoes rapid morphological changes and varying levels of 
metabolic activity as it proceeds through the 48-hour intra-erythrocytic phase of its life cycle. 
Ring-stage parasites are present for the first 20-24 hours and develop into trophozoite- and 
schizont-stage parasites during the remaining 24 hours. In order to determine the extent to 
which the ATP levels of trophozoite-stage parasites vary over time, parasite ATP was 
measured in samples of a sorbitol-synchronised early-mid trophozoite-stage culture taken 
every 2 hours over a 10-hour period. In addition, Giemsa-stained thin-blood smears were 
prepared at each time-point. A substantial decline in parasite ATP levels was observed within 
the first 2 hours. Exposure of parasites to non-culture conditions (i.e. removal from culture, 
centrifugation, etc.) during preparation for the experiment may have initiated a stress 
response which could explain the elevated ATP levels at time 0. Hence, the decline in ATP 
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levels may represent a return to ―normal‖ levels as culture conditions were restored. Parasite 
ATP levels showed a gradual decline over the remaining 8-hour incubation. Marked 
metabolic activity and rapid growth are characteristic of trophozoite-stage parasites (Lazarus 
et al., 2008; Zolg et al., 1984). Therefore, the decline in parasite ATP levels over the 
remaining 8 hours was unexpected, as initial cultures were at the early-mid trophozoite stage 
and parasite ATP levels were expected to increase as the parasites matured. The thin-blood 
smears prepared at each time-point were examined and the percentage of each developmental 
stage in the parasite population was approximated. The results provided an explanation for 
the unexpected ATP results. 
  
The majority of the parasite population in the initial culture consisted of early-mid 
trophozoites with the remaining parasites made up of early schizonts. Over the 10-hour 
incubation period, the mid-trophozoites present at time 0 developed into schizonts. These 
newly-developed schizonts, together with the schizonts already present at time 0, ultimately 
produced merozoites which invaded fresh RBCs and developed into rings. Unlike 
trophozoites which are characterised by marked metabolic activity, schizonts and rings 
display moderate and low metabolic activity, respectively. Accordingly, the decline in ATP 
levels over the remaining 8-hour incubation was attributed to the development of schizont 
and ring-stage parasites. Thus, the results showed that over a 10-hour period a sorbitol-
synchronised trophozoite culture inevitably contains multiple developmental stages at 
varying concentrations which significantly affect results when attempting to evaluate ATP 
changes in trophozoite-stage parasites. Therefore, to obtain a truer reflection of the extent to 
which the ATP levels of trophozoites fluctuate over time, synchronisation was achieved by P. 
falciparum enrichment. This involved the incubation of Percoll-enriched schizonts with 
uninfected RBCs, and once newly-invaded RBCs were observed residual schizonts were 
destroyed by sorbitol treatment. This produced a highly synchronised culture of early 
trophozoite-stage parasites before repeating the experiment. 
 
Examination of the thin-blood smears indicated that the parasite population was in the 
trophozoite stage throughout the experiment. As in the previous experiment, a considerable 
decline in parasite ATP levels was observed within the first 2 hours. This supports the notion 
that exposure of parasites to non-culture conditions at time 0 may trigger a stress response 
which results in elevated ATP levels. This suggests that an increase in parasite-associated 
ATP represents a rapid and sensitive indicator for parasites under stress. Parasite ATP levels 
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increased during the next 4 hours, likely due to rapid growth of the parasite as observed in the 
Giemsa-stained thin-blood smears. A moderate decrease in parasite-associated ATP levels 
occurred in the remaining 4 hours which may be attributed to a decrease in parasite growth as 
the parasites entered the late trophozoite stage of development. The results have shown that 
there is considerable variation (up to 2-3 fold) in the ATP levels of trophozoite-stage 
parasites over a 10-hour period, even in the absence of drug treatment. Thus, if the P. 
falciparum ATP assay were to be used to assess the kinetics of drug action by measuring 
parasite ATP levels in drug-treated cultures over a 10-hour period, an untreated control 
culture should be included at all time-points and all results expressed relative to the control.  
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2.5.    CONCLUSION 
After extensive experimental refinement and characterisation, a rapid and fully functional P. 
falciparum ATP assay was developed. The assay has a broad dynamic range and is capable of 
measuring parasite-associated ATP in culture samples with a high degree of precision and 
sensitivity. Furthermore, results obtained in a pilot study and during time-course experiments 
suggest that the assay may be useful in assessing the rate of activity of antimalarial drugs by 
measuring ATP levels in drug-treated cultures over time. 
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  CHAPTER 3: ASSESSING THE UTILITY OF THE  
P. FALCIPARUM ATP ASSAY FOR EVALUATING THE 
RATE OF DRUG-INDUCED PARASITE STRESS 
 
3.1.    INTRODUCTION  
Assessing the rate of activity of candidate antimalarials is crucial to current drug discovery 
efforts due to the need for novel, rapid-acting drugs, as discussed in Chapter 2 (see section 
2.1). Quantitative procedures for assessing the rate of activity of antimalarials in in vitro 
cultures, besides the time-consuming and highly subjective interpretation of morphology by 
light microscopy, are limited to a recently reported viability-based assay (Sanz et al., 2012). 
This assay directly quantifies the number of parasites capable of recovering from distinct 
periods of drug exposure in vitro, unfortunately, this involves 3-4 weeks of monitoring re-
growth. Hence, there is a need for a novel, quantitative assay which is capable of rapidly 
determining the kinetics of drug action in culture. Adenosine triphosphate (ATP) serves as a 
primary source of energy for the growth, maintenance and reproduction of all living 
organisms (Ginsburg, 2010). Our hypothesis was that parasite ATP levels may represent a 
sensitive and readily detectable means of diagnosing abnormal parasite metabolism induced 
by drug treatment. Thus, we have developed and optimised a sensitive assay for measuring 
parasite ATP levels in P. falciparum cultures using a luminescence-based kit (see Chapter 2).  
 
The utility of the assay as a means of determining the rate of antimalarial drug action was 
then explored by characterising the response of parasite ATP levels to a panel of 
antimalarials, namely chloroquine, DFMO (DL-α-difluoromethylornithine), mefloquine, 
artemisinin and ritonavir. These antimalarials were selected for their varying modes of action 
(as discussed in section 3.4. below) which, presumably, afford them different rates of activity 
that are suitable for gauging the utility of the ATP assay as a means of assessing the kinetics 
of drug action. Chloroquine, mefloquine and artemisinin are antimalarials currently in clinical 
use while DFMO and ritonavir are experimental compounds with known antimalarial 
activity. In patients receiving therapeutic doses of the clinical antimalarials, peak plasma 
concentrations achieved in vivo tend to vary from person to person (chloroquine: 39-582 nM 
(Telgt et al., 2005); mefloquine: 1.3-3 µM (Mimica et al., 1983); artemisinin: 1.1-2.7 µM 
(Räth et al., 2004)). Thus, for this study, effective treatment concentrations for each drug 
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were based on in vitro median inhibition concentrations (IC50s) and/or test concentrations 
both from the current study and previous reports (detailed in Table 5.1, Appendix 5). The 
goal was to select a concentration which causes sufficient antiplasmodial activity via direct 
drug action rather than secondary downstream effects and for this reason approximately 5 x 
IC50 was chosen as a working concentration for each drug. 
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3.2.    MATERIALS AND METHODS 
 
3.2.1.    Drugs/compounds used in this study 
Chloroquine diphosphate, mefloquine hydrochloride, artemisinin and ritonavir were 
purchased from Sigma-Aldrich (Steinheim, Germany). DL-α-difluoromethylornithine 
(DFMO) was kindly provided by P. Woster (Wayne State University, MI). Stock solutions 
were prepared as follows: chloroquine – 10 mM in water, mefloquine – 10 mM in methanol, 
artemisinin – 10 mM in DMSO, ritonavir – 100 mM in DMSO. The proteasome inhibitors 
lactacystin and MG-132 were obtained from Merck (Germany) and prepared as 10 mM 
stocks in water and DMSO, respectively. For experiments, stocks were diluted to the desired 
concentration in CMCM (Appendix 1.1).  
 
3.2.2.    Measurement of ATP levels in drug-treated parasites 
Plasmodium falciparum 3D7 parasites were cultivated as described in Chapter 2 (section 
2.2.1) and synchronised using Percoll-based P. falciparum enrichment (detailed in section 
2.2.1.2.2). An early trophozoite-stage culture was used to prepare a 32 mL, 5% haematocrit, 
2% parasitaemia suspension in CMCM (Appendix 1.1). The suspension was split into 2 x 15 
mL cultures and treated with drug and solvent control solutions, respectively. Immediately 
after treatment, 3 x 500 µL samples of the suspensions were transferred to microfuge tubes 
and maintained on ice (time 0 samples). The suspensions were then transferred to T25 culture 
flasks, gassed (5% CO2, 5% O2, balance N2; Air Products, RSA), sealed and incubated at 
37°C. Thereafter, 100 µL and 3 x 500 µL samples were taken every 2 hours over a 10-hour 
period. At each time-point, ATP levels were measured in the 500 µL samples as described in 
Chapter 2 (section 2.2.3 – optimised ATP assay). Giemsa-stained thin-blood smears were 
prepared from the 100 µL samples, as described in Chapter 2 (section 2.2.1.1), and assessed 
for morphological changes. Significant differences between the parasite-associated ATP 
levels of control and treatment samples were determined using a two-tailed, paired Student‘s 
T-test (Microsoft Excel 2007). A probability level of P ≤ 0.05 was considered statistically 
significant. Photomicrographs of the thin-blood smears were taken by light microscopy with 
an Olympus BX41 upright microscope equipped with a digital camera CC-12 soft imaging 
system (U-CMAD3, Olympus, Tokyo, Japan) using a 100x oil-immersion objective and 
analysis LS Report software. 
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3.2.3.    Plasmodial lactate dehydrogenase (pLDH) assay 
Plasmodial lactate dehydrogenase activity was measured using a method adapted from 
Makler et al. (1993). Plasmodium falciparum 3D7 parasites were cultured as described in 
Chapter 2 (section 2.2.1). A trophozoite-stage culture was used to prepare a 2% haematocrit, 
2% parasitaemia suspension in CMCM (Appendix 1.1). Drug and control solutions at twice 
the final test concentrations were added to a 96-well tissue culture plate at 100 µL per well. 
An equal volume of the parasite suspension (100 µL) was then added to each well. The 
positive and background controls comprised of untreated and chloroquine-treated (1 µg/mL) 
parasite suspensions, respectively. The plate was transferred to an airtight chamber suffused 
with a special gas mixture (5% CO2, 5% O2, balance N2; Air Products, RSA) and incubated at 
37°C for 48 hours. Following incubation, the plates were frozen before further processing. 
The plates were then thawed at room temperature and the culture wells were resuspended 
before transferring 20 µL to a clear, flat-bottomed 96-well plate pre-loaded with 100 µL of 
Malstat solution (Appendix 3.1). To each well, 25 µL of NBT/PES solution (Appendix 3.2) 
was added and air bubbles were removed with a hairdryer. The plate was left to develop in 
the dark before measuring absorbance at 620 nm in a multimode plate reader (Infinite F500, 
Tecan, Austria). Percentage parasite viability (%PV) was determined using the following 
equation: %PV = [(Absorbancesample – Mean Absorbancebackground)/(Mean Absorbancepositive – 
Mean Absorbancebackground)] x 100]. For dose-response assays, median inhibition 
concentrations (IC50s) were determined by non-linear regression analysis of log dose- 
response curves using GraphPad Prism software (v.5.02 for Windows, San Diego California, 
USA). Significant differences between IC50 values were determined using a two-tailed, 
homoscedastic Student‘s T-test (Microsoft Excel 2007). A probability level of P ≤ 0.05 was 
considered statistically significant. 
 
3.2.4.    The Recovery assay 
Plasmodium falciparum 3D7 parasites were cultured in vitro, as described in Chapter 2 
(section 2.2.1). An early trophozoite-stage culture was used to prepare a 72 mL 2% 
haematocrit, 2% parasitaemia suspension in CMCM (Appendix 1.1) which was distributed 
into 6-well plates at 2.5 mL per well. Each plate was treated with drug and solvent control 
solutions, each in triplicate. An additional plate was prepared with untreated parasite 
suspension and uninfected RBCs in triplicate wells to serve as positive and backgrounds 
controls, respectively. The plates were transferred to an airtight chamber suffused with a 
special gas mixture (5% CO2, 5% O2, balance N2; Air Products, RSA) and incubated at 37°C 
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for 6 hours. Following incubation, the contents of each well was mixed well and duplicate 
800 µL samples were transferred to sterile microfuge tubes. The first set of samples were 
transferred to a 96-well tissue culture plate at 200 µL per well (plate A) and stored frozen. 
For the second set of samples, the tubes were centrifuged at 2500 rpm for 3 minutes and the 
supernatant was aspirated off. The pellet was washed thrice in 1 mL of CMCM (Appendix 
1.1) pre-warmed at 37°C and then resuspended in fresh CMCM at a haematocrit of 1%. The 
suspensions were then transferred to a 96-well tissue culture plate at 200 µL per well (plate 
B). Plate B was placed in an airtight chamber, gassed and incubated at 37°C for 48 hours and 
thereafter stored frozen. Plasmodial lactate dehydrogenase (pLDH) activity was measured in 
plates A and B, as described in section 3.2.3 above. Significant differences between the 
parasite viability of control and treatment samples were determined using a two-tailed, paired 
Student‘s T-test (Microsoft Excel 2007). A probability level of P ≤ 0.05 was considered 
statistically significant. 
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3.3.    RESULTS 
 
3.3.1.    Assessing the utility of the ATP assay for evaluating the rate of drug-induced      
             parasite stress 
A sensitive assay for measuring parasite ATP levels in P. falciparum cultures using a 
luminescence-based kit was developed and optimised (see Chapter 2). The utility of the assay 
as a means of determining the rate of antimalarial drug action was explored by characterising 
the response of parasite ATP levels to a panel of antimalarials known to have varying rates of 
activity. This was achieved by preparing parallel control and drug-treated cultures and 
extracting samples from each culture every 2 hours over a 10-hour period. At each time-point 
the samples were used to measure parasite-associated ATP and prepare Giemsa-stained thin-
blood smears to assess parasite morphology. Note: Effective treatment concentrations for 
each drug were based on median inhibition concentrations (IC50s) and/or test concentrations 
both from the current study and previous reports (detailed in Table 5.1, Appendix 5). 
 
The results are presented in sections 3.3.1.1–3.3.1.5 below, with parasite-associated ATP 
levels presented both as absolute luminescence values and relative to controls. As in previous 
experiments (see section 2.3.7), all time 0 samples showed elevated ATP levels (data not 
shown), which were attributed to exposure of parasites to non-culture conditions during 
preparation for the experiment, and were therefore excluded from results. Furthermore, it was 
found that the pattern of ATP variation of control parasites over time differed between 
experiments (see panel ‗a‘ of Figures 3.1-3.5), even though all experiments were initiated at 
the early trophozoite stage of development on the basis of morphological assessments. 
Trophozoite-stage parasites are characterised by rapid growth and marked metabolic activity 
(Lazarus et al., 2008; Zolg et al., 1984) and previous investigations (see Figure 2.12 of 
Chapter 2) showed that the ATP levels of untreated parasites fluctuated extensively during 
trophozoite maturation. Hence, while morphological evaluations indicated that parasites were 
at the same trophozoite stage at the start of each experiment, the parasites may have been at 
different points of maturation and thus displayed different patterns of ATP variation over 
time. 
 
 
 
 
64 
 
3.3.1.1.    Chloroquine  
Results indicated that parasite-associated ATP levels of chloroquine-treated parasites closely 
matched those of control samples (P > 0.05; Table 6.1, Appendix 6) over the 10-hour 
incubation period (Figures 3.1a and 3.1b). Morphological changes in chloroquine-treated 
parasites (Figure 3.1c) were gradual with overall parasite growth appearing to slow down (i.e. 
smaller size) relative to controls from the 6-hour time-point onward, and some abnormal and 
dead parasites observed at the 10-hour time-point. 
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Figure 3.1: ATP levels and morphological changes in control and chloroquine-treated P. 
falciparum trophozoites over a 10-hour period. Samples of control and chloroquine (100 nM)-
treated cultures were taken every 2 hours over a 10-hour period and parasite-associated ATP was measured. 
ATP results are presented as absolute values (Fig. 3.1a) and relative to controls (Fig. 3.1b) with each data point 
presented as the mean ± SD, n = 3. In addition, Giemsa-stained thin-blood smears were prepared from the 
cultures at each time-point. Photomicrographs of the smears (1000x magnification) are presented in Fig. 3.1c. 
(Note: (i) Most chloroquine-treated parasites were smaller in size relative to controls from 6 hours onward; (ii) 
parasites with aberrant morphology shown at the 10 hour Treatment panel represent only a small fraction of the 
parasite population – the remaining parasites displayed normal morphology similar to controls but were smaller 
in size.) 
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3.3.1.2.    DFMO 
As with chloroquine-treated samples, parasite-associated ATP levels of DFMO-treated 
parasites were not significantly different from those of controls (P > 0.05, Table 6.1, 
Appendix 6) over the 10-hour incubation period (Figures 3.2a and 3.2b). Examination of thin-
blood smears (Figure 3.2c) indicated that morphology of DFMO-treated parasites appeared 
fairly normal throughout the 10-hour incubation. However, most DFMO-treated parasites 
were at an earlier developmental stage (judging from parasite size) than control parasites 
from the 8-hour time-point onward, suggesting a general slowing down of parasite growth 
(i.e. cell cycle delay). 
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Figure 3.2: ATP levels and morphological changes in control and DFMO-treated P. 
falciparum trophozoites over a 10-hour period. Samples of control and DFMO (10 mM)-treated 
cultures were taken every 2 hours over a 10-hour period and parasite-associated ATP was measured. ATP 
results are presented as absolute values (Fig. 3.2a) and relative to controls (Fig. 3.2b) with each data point 
presented as the mean ± SD, n = 3. In addition, Giemsa-stained thin-blood smears were prepared from the 
cultures at each time-point. Photomicrographs of the smears (1000x magnification) are presented in Fig. 3.2c. 
(Note that the majority of DMFO-treated parasites were smaller in size than the controls from 8 hours onward.) 
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3.3.1.3.    Mefloquine 
Results showed that ATP levels of mefloquine-treated parasites were increased relative to 
controls from the 4-hour time-point onward (Figures 3.3a and 3.3b). The increases at the 4-
hour (143%) and 6-hour (53%) time-points were statistically significant (P < 0.05, Table 6.1, 
Appendix 6) while those at the remaining time-points were not (P > 0.05). Even though 
parasite ATP levels were increased from the 4-hour time-point, aberrant parasite morphology 
was only observed from the 6-hour time-point. From the 6-hour time-point onward, 
mefloquine treatment resulted in an overall slowing down of parasite growth relative to 
controls (i.e. smaller size) and some abnormal parasite morphology in the form of irregularly-
shaped parasites (Figure 3.3c). Evidence of parasite death was observed during the last 2 
hours of incubation but only affected a small fraction of the parasite population.  
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Figure 3.3: ATP levels and morphological changes in control and mefloquine-treated P. 
falciparum trophozoites over a 10-hour period. Samples of control and mefloquine (100 nM)-
treated cultures were taken every 2 hours over a 10-hour period and parasite-associated ATP was measured. 
ATP results are presented as absolute values (Fig. 3.3a) and relative to controls (Fig. 3.3b) with each data point 
presented as the mean ± SD, n = 3. In addition, Giemsa-stained thin-blood smears were prepared from the 
cultures at each time-point. Photomicrographs of the smears (1000x magnification) are presented in Fig. 3.3c. 
(Note: (i) Most mefloquine-treated parasites were smaller in size relative to controls from 6 hours onward; (ii) 
aberrant parasite morphology and/or parasite death shown at the 6-10 hour Treatment panels represent only a 
small fraction of the parasite population – the remaining parasites displayed normal morphology similar to 
controls but were smaller in size.) 
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3.3.1.4.    Artemisinin 
Results indicated that the ATP levels of artemisinin-treated parasites were considerably 
(345%) higher than those of controls at the 2-hour time-point and remained elevated (80-
141% higher) during the remaining 8 hours of incubation (Figures 3.4a and 3.4b). These 
elevations were statistically significant (P ≤ 0.05, Table 6.1, Appendix 6) at all time-points 
except the 8-hour time-point (P = 0.15). As with the mefloquine treatment, even though 
elevated parasite ATP was recorded from the 2-hour time-point in artemisinin-treated 
parasites, abnormal parasite morphology, in the form of irregularly-shaped and dead 
parasites, was only observed later from the 4-hour time-point onward (Figure 3.4c). However, 
these morphological changes were only apparent in a small fraction of the parasite 
population. Furthermore, overall parasite growth of artemisinin-treated parasites was slower 
(i.e. smaller size) than that of control parasites from the 6-hour time-point onward.  
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Figure 3.4: ATP levels and morphological changes in control and artemisinin-treated P. 
falciparum trophozoites over a 10-hour period. Samples of control and artemisinin (100 nM)-
treated cultures were taken every 2 hours over a 10-hour period and parasite-associated ATP was measured. 
ATP results are presented as absolute values (Fig. 3.4a) and relative to controls (Fig. 3.4b) with each data point 
presented as the mean ± SD, n = 3. In addition, Giemsa-stained thin-blood smears were prepared from the 
cultures at each time-point. Photomicrographs of the smears (1000x magnification) are presented in Fig. 3.4c. 
(Note: (i) Most artemisinin-treated parasites were smaller in size relative to controls from 6 hours onward; (ii) 
aberrant parasite morphology and/or parasite death shown at the 4-10 hour Treatment panels represent only a 
small fraction of the parasite population – the remaining parasites displayed normal morphology similar to 
controls but were smaller in size from 6 hours onward.) 
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3.3.1.5.    Ritonavir 
Parasite-associated ATP levels of ritonavir-treated parasites were substantially decreased (≥ 
96%) relative to controls from the 2-hour time-point onward (Figures 3.5a and 3.5b). These 
decreases were statistically significant (P < 0.05, Table 6.1, Appendix 6) at all time-points 
except the 4-hour time-point (P = 0.09; n = 2). Abnormal parasite morphology, delayed cell 
cycles and parasite death were observed from the 4-hour time point onward (Figure 3.5c) and 
affected most of the parasite population.  
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Figure 3.5: ATP levels and morphological changes in control and ritonavir-treated P. 
falciparum trophozoites over a 10-hour period. Samples of control and ritonavir (100 µM)-treated 
cultures were taken every 2 hours over a 10-hour period and parasite-associated ATP was measured. ATP 
results are presented as absolute values (Fig. 3.5a) and relative to controls (Fig. 3.5b) with each data point 
presented as the mean ± SD, n = 3. In addition, Giemsa-stained thin-blood smears were prepared from the 
cultures at each time-point. Photomicrographs of the smears (1000x magnification) are presented in Fig. 3.5c. 
(Note: (i) aberrant parasite morphology and parasite death shown at the 4-10 hour Treatment panels represent 
the majority of the parasite population – the remaining parasites displayed normal morphology similar to 
controls but were smaller in size from 4 hours onward.) 
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3.3.2.    Determining whether drug-induced changes in parasite ATP levels are  
             representative of compromised parasite viability: The Recovery assay 
In order to determine whether the changes in ATP levels and parasite morphology in drug-
treated cultures, described in section 3.3.1 above, were indicative of compromised parasite 
viability, the Recovery assay (detailed in section 3.2.4) was performed. The intra-erythrocytic 
phase of the parasite‘s life cycle lasts 48-hours. Therefore the purpose of the Recovery assay 
was to determine the percentage of cells that recover from drug treatment by completing their 
life cycle. This was achieved by incubating early trophozoite-stage P. falciparum cultures for 
6 hours in control and drug-treated culture medium at concentrations equivalent to those used 
in the ATP assay (section 3.3.1). Following incubation, aliquots of the cultures were used to 
measure parasite viability by means of the pLDH assay (detailed in section 3.2.3). The 
medium in the remaining cultures was washed off and replaced with fresh medium and these 
drug-free cultures were incubated for a further 48 hours before measuring parasite viability 
via the pLDH assay. Results are shown in Figure 3.6.  
 
The results indicated that following the 6-hour incubation, drug-treated cultures showed 0%-
25% reduction in pLDH activity relative to controls. Ritonavir-treated parasites displayed the 
largest decline (25%), whilst DFMO treatment caused no decline. After the 48-hour 
incubation period, only 9% and 11% of chloroquine- and ritonavir-treated parasites, 
respectively, recovered from the 6-hour drug treatment compared to untreated controls. The 
DFMO-treated parasites showed the highest level of recovery with 85% of parasites still 
viable after the 6-hour drug treatment. In the case of mefloquine- and artemisinin-treated 
parasites, 56% and 46%, respectively, were still viable after the 6-hour drug treatment.  
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Figure 3.6: The Recovery assay: determining the extent to which a 6-hour drug 
treatment compromises parasite viability. Percentage parasite viability was measured using the 
pLDH assay in early trophozoite-stage P. falciparum cultures following a 6-hour drug treatment and 48 hours 
after washing off the drug. Viability was calculated relative to untreated control cultures. Each data point 
represents the mean ± SD, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
6h drug treatment 48h after removal of drug
Chloroquine
(100 nM)
DFMO
(10 mM)
Mefloquine
(100 nM)
Artemisinin
(100 nM)
Ritonavir
(100 M)
Drug treatment
%
 P
a
ra
s
it
e
 V
ia
b
il
it
y
76 
 
3.4.    DISCUSSION 
Adenosine triphosphate (ATP) serves as a primary source of energy for the growth, 
maintenance and reproduction of all living organisms. In most eukaryotes, ATP production 
involves the uptake of glucose followed by degradation to two pyruvate molecules through 
the process of glycolysis in the cytoplasm (Ginsburg, 2010). In the mitochondrion, pyruvate 
is converted to acetyl-CoA which enters the tricarboxylic acid cycle where it is fully oxidised 
to carbon dioxide via the process of oxidative phosphorylation (Olzewski & Llinás, 2010). 
This results in the production of 36 molecules of ATP, as well as biosynthetic precursors and 
reducing equivalents. Even though the intra-erythrocytic stages of P. falciparum possess 
mitochondria, they lack crucial complexes in the mitochondrial respiratory chain which are 
necessary to produce ATP aerobically via oxidative phosphorylation (Olzewski & Llinás, 
2010). Consequently, similar to its host RBC, the parasite metabolises glucose anaerobically 
via the glycolytic pathway whereby pyruvate is ultimately fermented to lactate, yielding just 
two ATP molecules per molecule of glucose (Olzewski & Llinás, 2010).  
 
The traditional in vitro method for evaluating the rate of antimalarial drug action by 
morphological assessments is highly subjective and time-consuming, and while a recently 
reported viability-based assay (Sanz et al., 2012) offers a quantitative alternative, it is far 
more time-consuming. Hence, there is a need for a novel, quantitative assay which is capable 
of rapidly determining this rate in order to more accurately compare the efficacy properties of 
novel antimalarials with those of existing drugs. Conceivably, parasite ATP levels may 
represent a sensitive and readily detectable means of diagnosing abnormal parasite 
metabolism brought about by drug action. Thus, a P. falciparum ATP assay was developed 
and optimised (see Chapter 2) and the utility of this assay as a means of evaluating the 
kinetics of antimalarial drug action was assessed. This was achieved by characterising the 
response of parasite ATP levels to a panel of antimalarials with varying modes of action and, 
presumably, rates of activity. A simultaneous assessment of parasite morphology was also 
carried out. 
 
3.4.1.    Effect of chloroquine on parasite ATP levels and morphology  
The first drug that was evaluated was chloroquine, a 4-aminoquinoline derivative of quinine, 
which was the most successful, cost-effective and commonly used antimalarial since the 
1940s, until the development of widespread parasite resistance rendered the drug ineffective 
in many malaria endemic regions (Grimberg & Mehlotra, 2011). It is widely accepted, on the 
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basis of several supporting studies, that chloroquine exerts its antimalarial action by 
inhibiting the detoxification of haem which is produced during haemoglobin digestion in the 
parasite‘s food vacuole (Combrinck et al., in press; Dorn et al., 1998; Egan et al., 1994; 
Ginsburg et al., 1998; O‘ Neill et al., 2006; Sullivan et al., 1996; Sullivan et al., 1998; Zhang 
et al., 1999b). 
 
During the intra-erythrocytic phase of its life cycle, the malaria parasite endocytoses 60-80% 
of the host cell cytoplasm of which 95% of the cytosolic protein is haemoglobin (Francis et 
al., 1997). The parasite degrades the haemoglobin in its food vacuole to produce amino acids 
and haem. Free haem has been shown to cause parasite lysis (Fitch et al., 1982; Orjih et al., 
1981), and must be detoxified by the parasite. The principal means of detoxification involves 
the polymerisation of haem to form the chemically inert malaria pigment, haemozoin, which 
is stored in the food vacuole (Francis et al., 1997). Alternative mechanisms of haem 
detoxification have been proposed, e.g. degradation of haem by glutathione in the cytosol 
(Famin et al., 1999; Ginsburg et al., 1998; Loria et al., 1999; Zhang et al., 1999b) and 
peroxidative degradation of haem by hydrogen peroxide in the food vacuole (Loria et al., 
1999), but haemozoin formation likely constitutes the major detoxification pathway (Egan et 
al., 2002). 
 
Investigations into the antimalarial mode of action of chloroquine have suggested that, due to 
its weak base properties, it accumulates in the parasite‘s acidic food vacuole by pH trapping 
(Aikawa, 1972; Yayon et al., 1984; Yayon et al., 1985), where it binds to haem (Bray et al., 
1999; Chou et al., 1980; Dorn et al., 1998; Sullivan et al., 1996). The binding of chloroquine 
to haem inhibits haem polymerisation (Dorn et al., 1998; Egan et al., 1994; Sullivan et al., 
1996; Sullivan et al., 1998). The chloroquine-haem complexes have been suggested to cause 
parasite lysis (Fitch et al., 1982; Orjih et al., 1981), inhibition of haemoglobin degradative 
proteases (Gluzman et al., 1994; Vander Jaqt et al., 1986), and lipid peroxidation (Sugioka et 
al., 1987). Free haem has been shown to cause parasite lysis (Fitch et al., 1982; Orjih et al., 
1981) likely due to its ability to alter the permeabilisation properties of membranes and 
disturb ion homeostasis (Chou & Fitch, 1981). In addition, Loria et al. (1999) found that 
haem displayed both peroxidase- and catalase-like activities, and therefore may play a role in 
the degradation of reactive oxygen species (ROS) which are produced during haemoglobin 
digestion in the parasite‘s food vacuole. Chloroquine was found to inhibit these enzyme-like 
activities which led the authors to suggest that this drug may cause parasite death by initiating 
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a toxic accumulation of ROS which are known to cause lipid peroxidation, DNA damage and 
oxidation of proteins (Bandyopadhyay et al., 1999). Thus, it is generally accepted that the 
antimalarial activity of chloroquine stems primarily from its accumulation in the parasite‘s 
food vacuole and inhibition of haem detoxification with a resulting toxic accumulation of 
haem and chloroquine-haem complexes. This theory is strongly supported by the studies of 
Ginsburg et al. (1998) and Zhang et al. (1999b) which showed that chloroquine treatment of 
P. falciparum-infected RBCs caused a dose-dependent inhibition of haem polymerisation 
with a concomitant increase in membrane-associated haem which correlated with parasite 
death. Similar findings were recently reported by Combrinck et al. (in press). 
 
In the present study it was found that, in comparison to controls, chloroquine-treated parasites 
showed no noticeable change in ATP levels over a 10-hour incubation period. However, an 
assessment of parasite morphology revealed delayed cell cycles and some evidence of 
parasite death at the later time-points. Thus, chloroquine appeared to exhibit a relatively slow 
rate of antimalarial action. Ginsburg et al. (1998) found that, in chloroquine-treated P. 
falciparum-infected RBCs, parasite death was only observed after membrane-associated 
haem reached a critical level. Accordingly, the slow rate of antimalarial activity observed in 
this study may be partially due to the majority of the parasite population being at the early 
trophozoite-stage during the first 4 hours of incubation, with small food vacuoles and cell 
volumes that were relatively small relative to the host RBCs (see Figure 3.1c above). This 
implies a limited degree of RBC consumption by the parasite and hence low levels of free 
haem or chloroquine-haem complexes being produced. As time passed and the parasites 
consumed RBC cytoplasm more rapidly and grew in size, the accelerating generation of free 
haem may have only reached critical levels at the later time-points. This may explain why 
evidence of abnormal parasite morphology and parasite death was only observed after 10 
hours of incubation. These morphological changes were not accompanied by variations in 
ATP levels perhaps because they did not yet translate into significant stress and an alteration 
in ATP homeostasis. In addition, only a small portion of parasites were abnormal or dead at 
the final time-point, as assessed by abnormal morphology, which may explain why a decrease 
in overall ATP levels was not observed. 
 
The observed slight cell cycle delay in chloroquine-treated parasites relative to controls may 
be a result of the accumulation of free haem and chloroquine-haem complexes which have 
been shown to inhibit the proteases involved in haemoglobin digestion. The parasite relies on 
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its digestion of host-derived haemoglobin as a source of amino acids which are essential for 
its growth and development (Francis et al., 1997). Hence, the cell cycle delay observed in 
chloroquine-treated parasites may be due to inhibition of this critical process. 
 
For the Recovery assay, P. falciparum-infected RBCs were exposed to drug-treated medium 
for 6 hours before washing off the drug and incubating parasites in drug-free medium for a 
further 48 hours. Results indicated that even though parasite viability measured immediately 
after the 6-hour chloroquine treatment was greater than 90%, only 9% of cells were truly 
viable and capable of completing their 48-hour life cycle after washing off the drug. This 
suggests that chloroquine severely compromised parasite viability during the 6-hour 
incubation, implying that it is a rapid acting antimalarial. However, this notion disagrees with 
results of the abovementioned ATP assay where an equivalent chloroquine treatment showed 
no major effect on ATP levels or overall morphology of parasites during the 10-hour 
incubation period, suggesting that chloroquine is slow-acting. These contradictory findings 
may be explained by the results of previous studies which have suggested that, due to its 
weak base properties, chloroquine is taken up by the parasite and accumulates within the 
acidic food vacuole by pH trapping (Aikawa, 1972; Yayon et al., 1984; Yayon et al., 1985). 
Accordingly, the poor performance of parasites in the Recovery assay as compared to the 
ATP assay is likely due to the accumulation and trapping of chloroquine in the parasite‘s 
food vacuole during the initial 6-hour incubation. This may have allowed the drug to escape 
removal during the subsequent washing step allowing it to remain in the parasite and continue 
to exert its toxic effects during the second 48-hour incubation, making it seem as if it acts 
more rapidly than it truly does.  
 
3.4.2.    Effect of DFMO on parasite ATP levels and morphology 
The next drug that was investigated was DFMO (DL-α-difluoromethylornithine), a derivative 
of the amino acid ornithine, which inhibits polyamine synthesis through its inhibition of 
ornithine decarboxylase, a key enzyme in the polyamine synthetic pathway (Metcalf et al., 
1978). Polyamines are low molecular weight nitrogenous bases essential to several cellular 
processes including growth, proliferation and differentiation (Clark et al., 2010; Sherman, 
2009). Polyamine metabolism has been explored as a target for antimalarial compounds for 
more than two decades, however none of these compounds have reached the stage of a 
therapeutic drug. DFMO blocks the developmental progression of P. falciparum from the 
trophozoite to the schizont stage and this effect can be reversed by exposure of parasites to 
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polyamines (Assaraf et al., 1984; Assaraf et al., 1987; Gupta et al., 2005). Consequently, 
DFMO appears to have a cytostatic rather than a cytocidal effect on P. falciparum in vitro. 
 
In the present study it was found that the ATP levels of DFMO-treated parasites closely 
matched those of controls over the 10-hour incubation period, as was the case with 
chloroquine-treated parasites. In addition, parasite morphology appeared normal throughout 
the incubation period. However, a delay in parasite growth was observed from the 8-hour 
time-point onward. Assaraf et al. (1987) found no abnormal morphology in DFMO-treated 
parasites after 47 hours of treatment. However, parasite growth was arrested in the 
trophozoite stage, which is compatible with the observations of this study. Results of the 
Recovery assay indicated that parasite viability was not significantly affected by a 6-hour 
exposure to DFMO, given that 85% of parasites were able to complete their life cycles after 
removal of the drug. Thus, the findings of this study agree with previous studies that suggest 
that DFMO has a cytostatic rather than a cytocidal effect on P. falciparum.  
 
3.4.3.    Effect of mefloquine on parasite ATP levels and morphology 
Mefloquine, a 4-quinoline methanol derivative of quinine, is an antimalarial currently used 
primarily for chemoprophylaxis, as well as in combination with artemisinin for artemisinin-
based combination therapy (Grimberg & Mehlotra, 2011). Even though mefloquine has been 
used clinically since 1975 there is still no consensus regarding its mechanism of action. 
Protease inhibitors have been shown to antagonise the antimalarial activity of mefloquine and 
chloroquine in vitro by blocking the activity of plasmepsin I which catalyses the initial 
reaction in haemoglobin degradation (Mungthin et al., 1998; Sullivan et al., 1998). This 
suggests that mefloquine, like chloroquine, may cause parasite death by interfering with 
haemoglobin metabolism which is essential for parasite growth and development. Several 
studies have reported antimalarial properties which mefloquine has in common with 
chloroquine: (i) binding to haem (Chevli & Fitch, 1982; Chou et al., 1980; Dorn et al., 1998); 
(ii) inhibition of haem polymerisation into haemozoin (Combrinck et al., in press; Dorn et al., 
1998; Sullivan et al., 1998; Zhang et al., 1999b); (iii) inhibition of glutathione-mediated 
(Zhang et al., 1999b) and peroxidative (Loria et al., 1999) degradation of haem; (iv) 
inhibition of peroxidase- and catalase-like activities of haem (Loria et al., 1999). Based on 
these findings, it appears that mefloquine may share its mode of action with chloroquine by 
causing a toxic accumulation of haem or ROS.  
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On the other hand, there is also evidence that it may possess some additional or different 
mode(s) of antimalarial action compared to chloroquine. Mefloquine displays superior 
activity against chloroquine-resistant strains of P. falciparum (Geary & Jensen, 1983; 
Mungthin et al., 1998; Zhang et al., 1999b) and Chevli & Fitch (1982) found that mefloquine 
bound to membrane and purified phospholipids with high affinity, while chloroquine lacked 
this ability. Mefloquine and chloroquine also display differential effects on the endocytosis 
and digestion of host cell cytoplasm. Famin and Ginsburg (2002) found a correlation between 
parasite death and the accumulation of haemoglobin in chloroquine-treated parasites which 
was not observed with mefloquine. Instead mefloquine was found to inhibit chloroquine-
mediated accumulation of haemoglobin. The authors proposed that chloroquine may exert its 
antimalarial effects by inhibiting haemoglobin digestion, while mefloquine may act earlier in 
haemoglobin metabolism by hindering ingestion of host cell cytoplasm. This theory was 
supported by a later study which investigated the effects of mefloquine and chloroquine on 
endocytosis in P. falciparum (Hoppe et al., 2004). Chloroquine treatment caused an 
accumulation of haemoglobin which was attributed to a block in the fusion of endocytic 
vesicles with food vacuoles. Mefloquine caused reduced haemoglobin levels, likely due to an 
inhibition of haemoglobin endocytosis. Thus, mefloquine appears to block haemoglobin 
metabolism at an earlier stage by blocking endocytosis of host cell cytoplasm, while 
chloroquine may act later by inhibiting haemoglobin digestion. This may explain 
mefloquine‘s superior antimalarial effect on chloroquine-resistant parasites, when compared 
to chloroquine. 
 
In this study, the response of parasite ATP to mefloquine treatment was assessed by exposing 
P. falciparum cultures to the drug and measuring parasite ATP levels every 2 hours over a 
10-hour period. The ATP levels of mefloquine-treated parasites were more than 2-fold higher 
than those of controls at the 4-hour time-point, with less pronounced elevations observed at 
the remaining time-points. Evidence of abnormal morphology in mefloquine-treated parasites 
was observed from the 6-hour time-point onward with an overall delay in parasite growth 
relative to controls and some irregularly-shaped parasites. Occasional parasite death was 
observed during the last 2 hours of incubation. In contrast, chloroquine-treated parasites 
showed no major change in ATP levels over the 10-hour incubation period with overall cell 
cycle delays from the 6-hour time-point and some abnormal and dead parasites observed only 
at the final time-point. These differential ATP and morphological responses imply that 
mefloquine acts at a faster rate than chloroquine and supports the notion that these drugs act 
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via different modes of action. Previous reports provide evidence that mefloquine inhibits 
endocytosis of host cell cytoplasm while chloroquine inhibits haemoglobin digestion (Hoppe 
et al., 2004). Thus, mefloquine appears to act at an earlier stage of haemoglobin metabolism 
than chloroquine which may explain why it acts at a faster rate and provokes a different ATP 
response in parasite cultures than chloroquine.  
 
Results of the Recovery assay showed that 56% of parasites recovered from a 6-hour 
mefloquine treatment suggesting that increased ATP levels may be indicative of 
compromised parasite viability. Interestingly, despite the apparent slower rate of action of 
chloroquine, chloroquine-treated parasites recover much less efficiently in the Recovery 
assay than those treated with mefloquine. As discussed previously, this may be attributable to 
an inability to wash out chloroquine due to the pH-trapping mechanism of food vacuole 
accumulation of the drug. Clearly, this does not apply equally to mefloquine, thus suggesting 
an additional difference between chloroquine and mefloquine action. 
 
It is generally accepted that the antimalarial activity of chloroquine is due to an inhibition of 
haem detoxification. Mefloquine has been proposed to share many antimalarial properties 
with chloroquine and appears to interfere with haemoglobin metabolism, but its precise mode 
of action remains a mystery. Therefore, it is difficult to fully explain the cause for increased 
ATP levels in mefloquine-treated parasites, other than to make a general assumption that it 
reflects increased metabolic activity by the parasite as part of its stress response in order to 
overcome detrimental drug effects. Any form of macromolecular damage in eukaryotic cells 
that surpasses a set limit, regardless of the cause, initiates what is known as the cellular stress 
response (Kültz, 2003). This response is intended to momentarily increase tolerance limits to 
macromolecular damage using a phylogenetically conserved array of genes and pathways that 
regulate the stabilisation and repair of macromolecules in order to promote cellular integrity 
(Kültz, 2003). Several highly conserved stress proteins are involved in this process, including 
molecular chaperones, DNA repair proteins and cell cycle regulators (Kültz, 2003). Some of 
the most well recognised stress proteins are the molecular chaperones known as heat shock 
proteins (HSPs) which mediate the correct folding, processing and functioning of proteins in 
an ATP-dependent manner (Acharya et al., 2007; Pesce & Blatch, 2009; Shonhai et al., 2007; 
Vonlaufen et al., 2008). The major chaperone classes of HSP40, HSP60, HSP70 and HSP90 
have been identified in malaria parasites and are thought to be involved in normal cell 
functioning, as well as stress responses (Acharya et al., 2007; Pesce & Blatch, 2009; Shonhai 
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et al., 2007; Vonlaufen et al., 2008). These chaperones are ATPases and hence require ATP 
to drive the folding of client proteins (Acharya et al., 2007; Pesce & Blatch, 2009; Shonhai et 
al., 2007). Hence, the increased ATP levels in mefloquine-treated parasites observed in this 
study may reflect an enhanced production of ATP to meet the requirements of the stress 
response. 
 
3.4.4.    Effect of artemisinin on parasite ATP levels and morphology 
The next drug under investigation in this study was artemisinin, a sesquiterpene trioxane 
lactone. Artemisinin and its derivatives are currently the only class of established 
antimalarials to which the parasite has not yet developed widespread resistance. These drugs 
form the cornerstone of artemisinin-based combination therapies which have significantly 
reduced the number of malaria cases worldwide since their introduction as a first-line 
treatment for uncomplicated P. falciparum malaria (Greenwood et al., 2008). A key feature 
of artemisinin treatment is that it clears blood-stage parasites far more efficiently than other 
established antimalarials (van Agtmael et al., 1999; WHO, 2010a). Despite their success, the 
precise antimalarial mode of action of artemisinins is still under discussion and numerous 
theories have been put forward.  
 
The endoperoxide bridge of artemisinin, which has the potential to produce free radicals via 
homolytic cleavage of the weak oxygen peroxide bond (Jung, 1997), is thought to play a key 
role in its antimalarial activity since artemisinin derivatives which lack this peroxide bridge 
display poor antimalarial activity in vitro (Brossi et al., 1988). Consequently, for several 
decades, oxidative stress has been thought to play a key role in the antimalarial activity of 
artemisinin due to its chemical ability to produce free radicals. This view is supported by 
findings that antioxidants antagonise the antimalarial activity of artemisinin both in vitro 
(Krungkrai & Yuthavong, 1987) and in vivo (Levander et al., 1989). Several studies have 
demonstrated the formation of artemisinin-haem adducts (Loup et al., 2007; Meshnick et al., 
1991; Paitayatat et al., 1997; Pandey et al., 1999; Robert et al., 2005; Robert & Meunier, 
1997) which would allow for cleavage of the drug‘s endoperoxide bridge by the iron centre 
of haem, thereby producing toxic free radicals. Glutathione (GSH) is an important antioxidant 
of the malaria parasite and it has been suggested that, in addition to producing free radicals, 
artemisinin may promote oxidant stress in the parasite by reducing free GSH levels due to its 
ability to form adducts with glutathione (Wang & Wu, 2000). In addition, dihydroartemisinin, 
84 
 
the active metabolite of artemisinin, has been shown to decrease the levels of GSH and other 
antioxidants in P. falciparum-infected RBCs (Ittarat et al., 2003). 
 
Evidence supporting the iron-mediated production of free radicals from artemisinin was 
provided by Meshnick and colleagues (1993) who showed that: (i) incubation of artemisinin 
with iron resulted in the production of free radicals; (ii) iron chelators antagonised the 
antimalarial effects of artemisinin in vivo and of its derivative, arteether, in vitro; (iii) a 
combination of artemisinin and hemin resulted in the oxidation of RBC membrane protein 
thiols, an effect that was reduced by iron chelators and free radical scavengers. These results, 
as well as supporting evidence from other studies, led Meshnick (1994) to suggest that the 
antimalarial action of artemisinins relies on two sequential steps, activation and alkylation. 
Activation being the iron-catalysed cleavage of the peroxide bridge to produce a free radical, 
followed by alkylation of malaria proteins through interaction with the activated drug to form 
covalent adducts. Artemisinin and dihydroartemisinin, have been shown to alkylate malarial 
proteins in culture (Asawamahasakda et al., 1994) and haemoproteins in solution (Yang et 
al., 1994), respectively.  
 
In addition to the formation of artemisinin-haem adducts resulting in a toxic accumulation of 
free radicals, this interaction may disrupt haem polymerisation in the parasite (Hong et al., 
1994; Kannan et al., 2005; Loup et al., 2007; Pandey et al., 1999). Furthermore, free 
artemisinin has been shown to degrade haemozoin (Pandey et al., 1999). Thus, in addition to 
causing a toxic accumulation of free radicals, artemisinin may exert its antimalarial activity 
by causing a toxic accumulation of haem. An additional mode of antimalarial action proposed 
for artemisinin is a disruption of haemoglobin metabolism in the parasite by inhibiting its 
ability to degrade haemoglobin (Pandey et al., 1999) and endocytose host cell cytoplasm 
(Hoppe et al., 2004). However, artemisinin is active against the intra-erythrocytic ring stages 
of P. falciparum which lack haemozoin and do not degrade haemoglobin (White, 2008; 
Woodrow et al., 2005). Therefore, an inhibition of haemoglobin metabolism is clearly not the 
only means by which artemisinin exerts its antimalarial activity.  
 
The parasite‘s mitochondrion, which is essential for pyrimidine biosynthesis (van Dooren et 
al., 2006), has recently been implicated as a potential target of artemisinin. Using a yeast 
model, Li et al. (2005) found that artemisinin inhibited growth and depolarised mitochondrial 
membrane potential. In addition, deletion and overexpression of NADH dehydrogenases, 
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which play a role in the mitochondrial electron transport chain, resulted in increased 
resistance and sensitivity to artemisinin in the respective mutant strains. The artemisinin-
resistant mutant strains produced fewer ROS than their artemisinin-sensitive counterparts, 
implying that the mitochondrial electron transport chain is involved in activating artemisinin 
to produce free radicals. Based on these observations the authors suggested that, in the 
malaria parasite, artemisinin may be activated by the mitochondrial electron transport chain 
resulting in a local production of free radicals which may damage the mitochondrial 
membrane, causing a loss in membrane potential and ultimately parasite death. A recent 
ultrastructural study of P. falciparum by Crespo et al. (2008) revealed that a 4-hour 
artemisinin treatment had no obvious effect on the membrane potential or morphology of 
mitochondria in trophozoite-stage parasites. In contrast, the mitochondria of ring-stage 
parasites displayed partially intact membrane potential and significantly disrupted membrane 
structure following a 24-hour artemisinin treatment. On the basis of these findings, the 
authors suggested that disruption of mitochondrial membrane potential may be a late-stage 
effect of artemisinin and may not be its primary mode of antimalarial action. 
 
The sarco-endoplasmic reticulum calcium ATPase (SERCA) of the malaria parasite has also 
been proposed as a specific protein target of artemisinin. Calcium is required by P. 
falciparum for RBC invasion, intracellular signalling and development within the host cell, 
and SERCAs are responsible for maintaining calcium ion concentrations by actively directing 
calcium ions into membrane-bound stores (Alleva & Kirk, 2001; Nagamune et al., 2008). 
Thapsigargin is a specific inhibitor of SERCA and based on its structural similarity to 
artemisinin, Eckstein-Ludwig et al. (2003) hypothesised that the antimalarial activity of 
activated artemisinins may involve selective and specific inhibition of the P. falciparum 
SERCA, PfATP6. Artemisinin was found to specifically eliminate the calcium-dependent 
ATPase activity of PfATP6 expressed in oocytes, while artemisinin competed with 
fluorescently tagged thapsigargin for binding to intraparasitic sites. Subsequent studies have 
both supported and opposed these findings. Jambou et al. (2005) showed that resistance to the 
artemisinin derivative, artemether, was associated with a polymorphism in the PfATP6 gene, 
thereby supporting the notion that PfATP6 may be targeted by artemisinins. A three-
dimensional docking simulation study by Jung et al. (2005) demonstrated an interaction of 
artemisinin and its derivatives with a model of the thapsigargin binding site in PfATP6, 
supporting the notion of a shared site of action for these compounds. In contrast, a similar 
docking study by Garah et al. (2009) found no correlation between the in silico binding 
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affinity of artemisinin for PfATP6 and its in vitro antimalarial activity. In addition, Crespo et 
al. (2008) found that the antimalarial activity of artemisinin was not antagonised by 
thapsigargin, thus suggesting that these two compounds act on different sites within the 
parasite. 
 
In the current study, artemisinin treatment resulted in increased parasite ATP levels 
throughout a 10-hour incubation period, as was the case with mefloquine-treated parasites. 
However, while elevated ATP levels were observed from the 4-hour time-point onward in 
mefloquine-treated parasites, in the case of artemisinin this increase was observed from the 
earlier 2-hour time-point onward. This suggests that artemisinin is a rapid-acting antimalarial 
which acts at a faster rate than mefloquine, which is agreement with previous in vitro (Gamo 
et al., 2010; Sanz et al., 2012) and in vivo (Karbwang et al., 1992; Myint & Shwe, 1987; 
White, 1994; White et al., 1992) studies that have shown artemisinins to be more rapid-acting 
than quinines. Some evidence of abnormal parasite morphology and parasite death in 
artemisinin-treated parasites was observed from the 4-hour time-point onward, while a delay 
in overall parasite growth relative to control parasites was observed from the 6-hour time-
point onward. Results of the Recovery assay indicated that close to half the parasite 
population (46%) recovered from a 6-hour exposure to artemisinin, implying that increased 
ATP levels may be indicative of compromised parasite viability, as was the case with 
mefloquine. In addition, the ATP levels of artemisinin-treated parasites were increased to a 
greater degree than those of mefloquine-treated parasites. Peak ATP levels of artemisinin- 
and mefloquine-treated parasites were 4.5-fold and 2.4-fold higher than those of controls, 
respectively, implying that artemisinin may cause a greater level of parasite stress than 
mefloquine.  
 
As discussed previously, a substantial body of evidence supports the notion that oxidative 
stress plays a key role in the antimalarial action of artemisinin, due to its capacity to produce 
free radicals via cleavage of its endoperoxide bridge (Jung, 1997; Krungkrai & Yuthavong, 
1987; Levander et al., 1989; Loup et al., 2007; Meshnick, 1994; Meshnick et al., 1991; 
Meshnick et al., 1993; Paitayatat et al., 1997; Pandey et al., 1999; Robert et al., 2005; Robert 
& Meunier, 1997). Consequently, the increased ATP levels of artemisinin-treated parasites 
observed in this study may reflect efforts by the parasite to increase its antioxidant defences 
in order to overcome oxidative stress. The malaria parasite is exposed to high levels of 
oxidant stress during the intra-erythrocytic stage of its life cycle (Müller, 2001; Sherman, 
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2009). Its haemoglobin-containing host RBC is rich in oxygen and iron which play key roles 
in the production of ROS via the Fenton reaction (Müller, 2001; Sherman, 2009). In addition, 
the parasite endocytoses much of the host cell cytoplasm and free haem is released upon 
digestion of haemoglobin within its acidic food vacuole (Francis et al., 1997). This leads to 
spontaneous oxidation of haem iron from its ferrous form to its ferric form, during which 
electrons are released which react with molecular oxygen to produce superoxide anions 
(Francis et al., 1997; Müller, 2001; Sherman, 2009). Furthermore, free haem and superoxide 
anions are prerequisites for the generation of more ROS, such as hydroxyl radicals and 
hydrogen peroxide, via the Fenton reaction (Müller, 2001; Sherman, 2009).  
 
Thus, during its intra-erythrocytic development, the malaria parasite is exposed to several 
ROS which are kept at low intracellular levels by a multiplex of enzymatic and non-
enzymatic antioxidants (reviewed by (Müller, 2001; Nickel et al., 2006; Rahlfs et al., 2002; 
Sherman, 2009)), as illustrated in Figure 3.7. Superoxide dismutase, the first line of defence 
against ROS, converts superoxide anions to hydrogen peroxide which is further reduced by 
peroxiredoxins and a GSH peroxidase-like protein which obtain reducing equivalents from 
the redox-active thioredoxin (TRX). The NADPH-dependent TRX reductase subsequently 
regenerates reduced TRX which, in turn, restores oxidised glutathione disulphide (GSSG) to 
its reduced form, GSH, thereby serving as a link between the GSH and TRX redox systems. 
Glutathione, the most abundant antioxidant in malaria parasites, has been shown to reach a 
cytosolic concentration of ~2 mM in P. falciparum trophozoites via de novo synthesis, which 
involves two ATP-dependent reactions. The GSH antioxidant system detoxifies ROS via the 
oxidation of glutaredoxin which obtains reducing equivalents from GSH which is, in turn, 
replenished via the NADPH-dependent reduction of GSSG catalysed by GSH reductase. 
Glutathione also serves as a cofactor for enzymatic antioxidants, a reductant for antioxidant 
vitamins and is capable of reducing ROS non-enzymatically. The parasites two major redox 
systems (GSH and TRX) are NADPH-dependent and reduced NADPH is regenerated via the 
pentose phosphate pathway which requires glucose-6-phosphate that is produced from 
glucose via an ATP-dependent, hexokinase-catalysed reaction (Barrett, 1997).  
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Figure 3.7: The antioxidant defence mechanisms of P. falciparum. NADPH, Nicotinamide 
adenine dinucleotide phosphate hydrogen; NADP+, oxidised NADPH; GR, glutathione reductase; GSH, 
glutathione; GSSG, glutathione disulphide; ROS, reactive oxygen species; GST, glutathione-S-transferase; 
SOD, superoxide dismutase; H2O2, hydrogen peroxide; H2O, water; O2, oxygen; TRX, thioredoxin; TR, 
thioredoxin reductase. 
 
Hence, the elevated ATP levels of artemisinin-treated parasites observed in this study may 
reflect efforts by the parasite to overcome oxidative stress induced by the drug. This likely 
necessitates increased production of ATP to fuel synthesis of the enzymes, substrates and co-
factors involved in its various antioxidant defence systems. In particular, its most abundant 
antioxidant GSH is synthesised de novo via two ATP-dependent reactions and the 
regeneration of NADPH relies on the ATP-dependent production of glucose-6-phosphate.  
 
An alternative justification for the increased ATP levels in artemisinin-treated parasites may 
be associated with the proposed artemisinin-mediated inhibition of the P. falciparum 
SERCA, PfATP6 (Eckstein-Ludwig et al., 2003; Jambou et al., 2005; Jung et al., 2005). The 
SERCA regulates intracellular calcium stores by transporting two molecules of calcium from 
the parasite‘s cytoplasm to the lumen of the endoplasmic reticulum with the concomitant 
hydrolysis of an ATP molecule (Nagamune et al., 2008). Large bursts of calcium ions are 
involved in intracellular signalling, therefore SERCAs are essential to parasite survival 
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because they allow for recurring events of intracellular signalling by rapidly restoring 
calcium concentrations (Alleva & Kirk. 2001; Haynes & Krishna, 2004; Nagamune et al., 
2008). During drug exposure the parasite attempts to overcome detrimental drug effects and it 
is likely that there is an increase in intracellular signalling and hence a concomitant increase 
in ATP production in order to fuel the activity of the SERCA. Thus, the increased ATP levels 
in artemisinin-treated parasites may be due to inhibition of the P. falciparum SERCA, 
PfATP6, which would prevent its ATP-mediated function resulting in an accumulation of 
ATP.  
 
Finally, the increased ATP levels may reflect increased ATP production by the parasite in 
order to fuel an increased production and function of stress proteins in response to drug 
stress, in particular the HSPs which are ATP-dependent (as discussed previously for 
mefloquine). 
 
3.4.5.    Effect of ritonavir on parasite ATP levels and morphology 
In addition to characterising the ATP response of P. falciparum to conventional antimalarials 
(i.e. chloroquine, mefloquine and artemisinin) and a cytostatic drug (i.e. DFMO), ritonavir, a 
compound which is not used clinically as an antimalarial but displays potent antimalarial 
activity, was also investigated. Ritonavir is a protease inhibitor developed to target the 
aspartyl protease of HIV type-1 and has significantly contributed to improving the outcome 
of HIV disease in developed countries (Chandwani & Shuter, 2008). In 2003, the WHO 
launched its ―3 by 5‖ initiative aimed at providing antiretrovirals to 3 million individuals 
infected with HIV-1, particularly in developing countries, by 2005. In most developing 
countries malaria is co-endemic with HIV, hence this initiative resulted in many malaria-
infected individuals being exposed to antiretrovirals. This prompted Skinner-Adams et al. 
(2004) to investigate the in vitro effects of antiretroviral protease inhibitors on P. falciparum, 
and ritonavir was found to directly inhibit parasite growth at clinically relevant 
concentrations. Later studies confirmed the antimalarial activity of ritonavir against P. 
falciparum in vitro (Andrews et al., 2006; He et al., 2010; Parikh et al., 2005; Parikh et al., 
2006) and demonstrated its in vivo activity against P. chabaudi in mice (Andrews et al., 
2006). Despite evidence of its antimalarial activity, ritonavir is unlikely to become a first-line 
antimalarial due to its high cost, potential toxicity and limited knowledge with regard to 
interactions with established antimalarial drugs (Skinner-Adams et al., 2004). 
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In this study, it was found that ritonavir almost completely depleted the ATP levels of P. 
falciparum parasites. This effect was seen from the 2-hour time-point and persisted for the 
remainder of the 10-hour incubation. Abnormal parasite morphology, delayed cell cycles and 
parasite death were observed from the 4-hour time point onward in the majority of the 
parasite population. Furthermore, it was observed during sample processing that, relative to 
controls, the parasite pellet isolated from ritonavir-treated culture samples was minimal up to 
the 4-hour time-point, and barely visible at the remaining time-points. These observations 
suggested that the depleted ATP levels were likely due to severely compromised parasite 
viability, and parasite death. This was confirmed by results of the Recovery assay which 
showed that only 11% of parasites were truly viable and capable of completing their intra-
erythrocytic life cycle after a 6-hour exposure to ritonavir.  
 
The exact mechanism of antimalarial action of ritonavir is unclear, however, based on the fact 
that it was developed to target an aspartyl protease of HIV-1, Andrews et al. (2006) 
hypothesised that the drug targets the parasite‘s plasmepsins (PMs) which are also aspartyl 
proteases. Ten different PM isoforms have been identified in P. falciparum and the most 
well-characterised are PM-I, PM-II, PM-IV and histoaspartic protease (HAP) which are 
involved in haemoglobin digestion (Sherman, 2009). Andrews et al. (2006) used modelling 
and ligand docking methods to show that ritonavir has the potential to bind to the active sites 
of P. falciparum plasmepsins, PM-II and PM-IV. In addition, they found that ritonavir 
inhibited the activity of these enzymes in vitro. In contrast, Parikh et al. (2006) found that 
there was no significant difference between the antimalarial activity of ritonavir against P. 
falciparum wildtype parasites and those with PM-I, PM-II, HAP or PMI/IV knocked out. The 
very rapid action of ritonavir, as reported here, also makes an inhibition of haemoglobin 
digestion as the primary mode of action unlikely. During its intra-erythrocytic development 
the malaria parasite exports hundreds of proteins which alter cytoadherence, nutrient uptake 
and structural integrity of its host cell in order to support parasite survival (Sherman, 2009). 
Plasmepsin V was recently identified as an essential enzyme in this process (Boddey et al., 
2010) and ritonavir was found to inhibit its activity. Hence it is possible that the antimalarial 
effects of ritonavir observed in this study may have been due to a disruption of the parasite‘s 
protein trafficking ability through inhibition of PM-V. 
 
 
 
91 
 
3.5.    CONCLUSION  
Taken together, the ATP results suggest that chloroquine and DMFO are slow-acting 
antimalarials, mefloquine and artemisinin have moderate rates of antimalarial action, and 
ritonavir is a rapid-acting antimalarial. With regard to chloroquine, mefloquine and 
artemisinin which are established antimalarials, these findings are in agreement with the 
expected rates of activities of these drugs. This supports the notion that measurement of 
parasite ATP levels may be a potential tool for assessing the rate of antimalarial drug action. 
The results of this study suggesting that ritonavir is a rapid-acting antimalarial are, to our 
knowledge, the first reports of the rate of activity of this antimalarial. 
 
With chloroquine and DFMO, parasite ATP levels did not differ significantly from untreated 
controls over a 10-hour treatment period. This agrees with the very minor morphological 
changes observed and, in the case of DFMO, with the Recovery assay results. The marked 
activity of chloroquine in the Recovery assay is likely due to its entrapment in the parasite‘s 
food vacuole and prolonged exposure of the parasites to the drug beyond the 6-hour treatment 
window, and thus not a true reflection of its rate of action. In the case of artemisinin and 
mefloquine treatments, which caused rapid increases in overall parasite ATP levels, the 
Recovery assay showed that more or less half the parasite population was viable following a 
6-hour drug exposure. This implies that elevated parasite ATP levels may be diagnostic of 
some degree of eventual loss of viability. Ritonavir caused a rapid and considerable decrease 
in overall parasite ATP accompanied by morphological evidence of parasite death in the 
majority the parasite population. These observations agreed with the Recovery assay results 
which showed that only about a tenth of ritonavir-treated parasites remained viable following 
a 6-hour exposure. These findings suggest that depleted ATP levels may be indicative of 
severely compromised parasite viability.  
 
Based on the above discussion, the current working hypothesis would thus be that unchanged 
ATP levels reflect a lack of significant drug action, increased ATP levels a stress response to 
drug action and indicative of some loss of viability, while significantly reduced ATP is 
indicative of severe loss of parasite viability. Cell cycle delays observed in the drug-treated 
parasites relative to controls may be a survival mechanism whereby the parasite slows down 
its metabolism, resulting in a decrease in potential metabolic drug targets, such as haem 
(Veiga et al., 2010). This reduced metabolism may also allow for the specific induction of 
drug transporters to extrude the drug, thereby averting its toxic effects. 
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Examination of Giemsa-stained thin-blood smears is the traditional method of assessing the 
rate of antimalarial activity. In the case of mefloquine- and artemisinin-treated parasites, 
rapid increases in ATP levels were observed implying that these drugs are rapid-acting. 
While cell cycle delays were observed in the majority these parasites, instances of abnormal 
morphology and parasite death were only observed in a small fraction of the parasite 
population. Thus, examination of parasite morphology without concurrent measurement of 
parasite ATP may have led to the erroneous conclusion that these antimalarials are more 
slow-acting than is actually the case. This further illustrates the subjective and unreliable 
nature of this traditional method of assessing the kinetics of drug action. In addition, even 
though morphological abnormalities affected the majority of the parasite population in the 
ritonavir treatments, initial changes in ATP levels were not accompanied by immediate 
changes in parasite morphology, which were only observed at later time-points. These 
findings imply that measuring parasite ATP levels provides a more appropriate reflection of 
the earliest parasite responses to drug action than examining parasite morphology, 
particularly in the case of fast-acting antimalarials.  
 
By contrast, parasite ATP levels do not appear to be as sensitive to cell cycle delays. For 
example, in comparison to controls, both chloroquine- and DFMO-treated parasites displayed 
morphological cell cycle delays with fairly unchanged ATP levels. In addition, occasional 
parasite death was observed in chloroquine-treated parasites after 10 hours of treatment 
without any change in parasite ATP in comparison to controls. Hence, in the case of a slow-
acting antimalarial where parasite death may only affect a fraction of the parasite population, 
or where drug action results in a slow inhibition of parasite growth, measuring parasite ATP 
alone may not provide a complete representation of parasite response to drug action. 
Therefore, we conclude that the best approach for assessing the rate of antimalarial drug 
action would be a simultaneous evaluation of parasite ATP levels and parasite morphology to 
take advantage of their complimentary roles vis-à-vis rapid- and slow-acting drugs. 
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CHAPTER 4: EXPLORING A LUCIFERASE ASSAY USING 
TRANSGENIC PARASITES AS AN ALTERNATIVE 
METHODOLOGY FOR EVALUATING THE RATE OF 
DRUG-INDUCED PARASITE STRESS 
 
4.1.    INTRODUCTION 
Transfection involves the transfer of exogenous nucleic acid sequences into an organism 
(Waterkeyn et al., 1999). The development of transient and stable transfection technologies 
for blood-stage P. falciparum parasites has allowed for the expression of transgenes and 
aided the functional study of parasite proteins via the disruption, modification or substitution 
of the genes that encode them (de Koning-Ward et al., 2000; O‘Donnell et al., 2001). This, in 
turn, leads to a better understanding of parasite biology, thereby revealing novel drug targets 
and vaccine candidates (de Koning-Ward et al., 2000; O‘Donnell et al., 2001). Luciferase is 
commonly used as a reporter for promoter characterization and transcriptional regulation 
studies in transfected mammalian cells (Kim et al., 2009; Yee et al., 2009) and Plasmodium 
parasites (Helm et al., 2010; Sunil et al., 2008). Thus, in order to investigate transcriptional 
regulation in P. falciparum, the Systems Biology Group at CSIR Biosciences successfully 
established methods for transfecting P. falciparum with expression plasmids and used these 
to generate luciferase-expressing transgenic parasites. Luciferase activity in these parasites is 
readily detected using a luminescence-based kit. Unexpectedly, preliminary experiments 
indicated that luciferase activity decreased rapidly and markedly in the transgenic parasites 
when exposed to the standard antimalarials artemisinin and mefloquine (data not shown). 
Conceivably, luciferase activity measurements in these transgenic parasites may thus be used 
to assess the rate of action of antimalarials. To investigate this further, these parasites were 
made available for this study and the luciferase system was explored as an alternative to the 
ATP assay (see Chapters 2 and 3) as a means of evaluating the rate of antimalarial drug 
action using a panel of antimalarials with varying mechanisms of action and, presumably, 
rates of activity. 
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4.2.    MATERIALS AND METHODS 
 
4.2.1.    Transfection 
Frozen stocks of transgenic P. falciparum parasites stably transfected with episomal 
luciferase expression plasmids were kindly donated by Dr. A.C. van Brummelen (CSIR 
Biosciences). The transfection protocol used to prepare the parasites is described in Appendix 
4.1. Two luciferase-expressing parasite lines were acquired, each with a different 5‘ promoter 
region: (i) HSP-Luc (heat shock protein 86 promoter), (ii) LYS-Luc (lysophospholipase 
promoter, PlasmoDB gene ID: PF14_0017).  
 
The plasmid construct (Figure 4.1) was comprised of Photinus pylaris (firefly) luciferase and 
human dihydrofolate reductase (hDHFR) expression cassettes in a head-to-head orientation in 
a pHTK (Duraisingh et al., 2002) backbone. The luciferase coding region was flanked by the 
5‘ promoter region and the Plasmodium berghei 3‘ termination region. The hDHFR coding 
region was flanked by the 5‘ calmodulin promoter and the histidine-rich protein 2 3‘ 
termination region. By generating resistance to the antifolate WR99210, hDHFR acted as a 
selection marker that allowed transgenic parasites to be obtained from transfected parasite 
populations. The frozen parasite stocks were thawed and cultured, as described in Chapter 2 
(section 2.2.1), using CMCM (Appendix 1.1) supplemented with 5 nM WR99210. 
 
 
 
Figure 4.1: Diagram of the plasmid construct used to generate transgenic luciferase-
expressing parasites. Pb 3‘ – Plasmodium berghei 3‘ termination region; Luc – Photinus pylaris (firefly) 
luciferase; CAM 5‘ – 5‘ calmodulin promoter; hDHFR – human dihydrofolate reductase; hrp2 3‘ – histidine-rich 
protein 2 3‘ termination region. 
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4.2.2.    The Luciferase assay 
Luciferase activity in parasites was measured using a luminescence-based kit (Bright-Glo 
Luciferase Assay System, Promega, Madison, WI). Briefly, parasite suspensions with 5% 
haematocrit, 2% parasitaemia were prepared in CMCM (Appendix 1.1) supplemented with 5 
nM WR99210. A suspension of uninfected RBCs (5% haematocrit) was prepared as a 
background control. Samples (200 µL) of the suspensions were transferred to microfuge 
tubes and centrifuged at 8000 rpm for 30 seconds. The supernatant was aspirated off and the 
infected RBC pellet was resuspended in 100 µL of Glo lysis buffer (Promega, Madison, WI) 
pre-warmed at 22°C. The sample was incubated for 5 minutes at room temperature before 
mixing the lysate and transferring 100 µL to a white Lumitrac 96-well plate (Greiner, 
Germany). Pre-prepared Bright-Glo reagent (100 µL, Appendix 4.2), pre-warmed at ≤ 25°C, 
was added to each well and luminescence was measured in a multimode plate reader (Infinite 
F500, Tecan, Austria).  
 
4.2.3.    Measurement of luciferase activity in drug-treated transgenic parasites 
Transgenic luciferase-expressing HSP-Luc parasites were prepared and maintained as 
described in section 4.2.1 above. An early trophozoite-stage culture was used to prepare a 5% 
haematocrit, 2% parasitaemia suspension in CMCM (Appendix 1.1) supplemented with 5 nM 
WR99210. Five identical test plates were prepared as follows: (i) parasite suspension (200 
µL) was added to triplicate wells of each plate before adding the drug or solvent control 
solution; (ii) uninfected RBCs at 5% haematocrit (200 µL) were added to triplicate wells as 
background controls. The plates were then transferred to an airtight chamber suffused with a 
special gas mixture (5% CO2, 5% O2, balance N2; Air Products, RSA) and incubated at 37°C. 
At 2-hour intervals, one plate was carefully removed from the chamber without disturbing the 
settled RBCs and 150 µL of supernatant was removed from all wells and discarded. 
Luciferase activity was then measured as described in section 4.2.2 above. Significant 
differences between the luciferase activity of control and treatment samples were determined 
using a two-tailed, paired Student‘s T-test (Microsoft Excel 2007). A probability level of P ≤ 
0.05 was considered statistically significant. 
 
 
 
 
 
96 
 
4.3.    RESULTS 
Apart from the ATP assay discussed in Chapter 3, the Luciferase assay was investigated as an 
alternative means of assessing the rate of antimalarial activity. The assay relies on transgenic 
luciferase-expressing P. falciparum parasites which were kindly prepared and donated by Dr. 
A. C. van Brummelen of the CSIR Systems Biology group (see Appendix 4.1 for details of 
the transfection protocol). The Luciferase assay involves the rapid detection of luciferase 
activity of the transgenic parasites using the luminescence-based Bright-Glo Luciferase 
Assay System (Promega, Madison, WI). Briefly, samples of trophozoite-stage transgenic 
cultures were prepared at a 5% haematocrit and 2% parasitaemia. Infected RBCs were lysed 
using the Glo lysis buffer (Promega, Madison, WI) and luciferase activity in the lysate was 
detected using the Bright-Glo reagent (details in section 4.2.2 above). Linearity and 
sensitivity of the assay were analysed before testing the suitability of the assay as a means of 
assessing the rate of antimalarial drug action.  
 
4.3.1.    Linearity and sensitivity of the Luciferase assay 
With the aim of gauging the strength of the correlation between measured luminescence 
signals and parasite luciferase activity, HSP-Luc parasite suspensions were prepared from 
culture samples and serially diluted before measuring luciferase activity. Briefly, an 800 µL 
suspension of trophozoite-stage transgenic parasites was prepared at a haematocrit and 
parasitaemia of 5%. The haematocrit was maintained while performing 8 x 2-fold serial 
dilutions to a final volume of 800 µL before measuring luciferase activity (as described in 
section 4.2.2). Parasite numbers in each sample were calculated from the parasitaemia, and 
RBC concentration which was determined using a haemacytometer. Results are shown in 
Figure 4.2. Luminescence signals correlated excellently with parasite numbers ranging from 
55x103 to 70x105, evident by the corresponding linear regression correlation coefficient (r2 
value) of 0.98. Thus, for parasite numbers ranging from 55x103 to 70x105 per sample, the 
luminescence signals produced by the Luciferase assay strongly correlate with parasite 
luciferase activity. However, the connecting line in Figure 4.2 could suggest a modest 
deviation from linearity at the highest parasite concentrations, which may indicate substrate 
limitation and/or upper limits of luciferase detection being approached at these parasite 
numbers. In addition to analysing the linearity and sensitivity of the Luciferase assay, the 
precision and reproducibility of the assay were also assessed. 
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Figure 4.2: Relationship between parasite luciferase activity and parasite concentrations 
for the Luciferase assay. The strength of the correlation between measured luminescence signals and 
parasite luciferase activity was assessed by measuring luciferase activity in samples with different 
concentrations of HSP-Luc parasites. Each data point represents the mean ± SD, n = 2. 
 
4.3.2.    Precision and reproducibility of the Luciferase assay 
As with the ATP assay, the precision of results obtained with the Luciferase assay was 
assessed by calculating coefficients of variation (CVs) and Z‘ factors (details in section 2.2.4 
of Chapter 2) for experiments described in this chapter. Results are summarised in Table 4.1. 
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Table 4.1: Summary of coefficients of variation (CVs) and Z’ factors obtained using the 
Luciferase assay.  
Figure 
Number of 
samples 
Average 
% CV 
Average 
Z' 
     4.2 8 2.3 0.93 
     4.3a 10 1.6 0.95 
     4.4a 10 1.0 0.97 
     4.5a 10 2.4 0.93 
     4.6a 10 2.6 0.92 
     4.6c 10 2.6 0.92 
     4.7a 10 4.5 0.86 
     4.9 2 1.9 0.94 
     4.12 10 2.3 0.93 
 
Total: 
80 
Average: 
2.4 
Average: 
0.93 
Note: (i) The ―Figure‖ column contains the number of the figure in this chapter which corresponds to the 
experiment from which the data was extracted to do the calculations; (ii) The ―Number of samples‖ refers to the 
number of parasite samples that were subjected to the assay in parallel and does not take into account control 
samples presented in the figures. Luciferase activity in each pellet was read in duplicate wells (n=2); (iii) CVs 
were calculated from results obtained from replicate test samples; (iv) Z‘ factors were calculated by comparing 
samples to background controls (uninfected RBCs).  
 
The results showed that for a total of 80 samples processed on separate occasions in the 
Luciferase assay, an excellent overall CV of 2.4% was achieved. Furthermore, the average Z‘ 
factor of 0.93 indicates an excellent assay window. Therefore, the Luciferase assay has a 
broad dynamic range and is an appropriate means of measuring luciferase activity in culture 
samples with a reasonable level of precision. 
 
Inter-occasional reproducibility of the Luciferase assay was analysed by establishing the 
degree to which RLU values varied when the assay was performed on separate occasions. 
This was accomplished by calculating the CV for mean RLU values of corresponding (i.e. 2-
hour time-point) control samples obtained on different occasions during experiments to 
assess the kinetics of drug action, as described later in this chapter (see section 4.3.3). Results 
are shown in Table 4.2 below.  
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Table 4.2: Inter-occasional reproducibility of the Luciferase assay. 
Figure Mean RLU 
4.3a 1139813 
4.4a 1151288 
4.5a 1099264 
4.6a 1986252 
4.6c 1148399 
4.7a 799961 
Inter-assay  
Average 1220829.5 
SD 398604.0 
CV 32.7 
 
Note: (i) The ―Figure‖ column contains the number of the figure in this chapter from which the experimental 
data was extracted to do the calculations; (ii) The ―Mean RLU‖ column contains RLU values measured in 
corresponding (i.e. 2-hour time-point) control samples using the Luciferase assay (detailed in section 4.3.3). 
 
The results indicated that inter-assay RLU values of corresponding control samples varied 
considerably (CV = 32.7%) for reasons that have not been investigated further. Therefore, 
absolute values recorded on different occasions from corresponding experiments cannot be 
directly compared except relative to internal controls, unless the purpose of the comparison is 
to assess stage variability. 
 
4.3.3.    Assessing the utility of the Luciferase assay for evaluating the rate of drug-    
     induced parasite stress 
As with the ATP assay (see Chapter 3), the effectiveness of the Luciferase assay as a means 
of assessing the kinetics of antimalarial drug action was tested by characterising the response 
of parasite luciferase activity to a panel of antimalarial drugs with varying rates of activity. In 
the case of the ATP assay, parasites were isolated from RBCs before measuring ATP in order 
to exclude RBC ATP. However, isolation of parasites from RBCs was unnecessary for the 
Luciferase assay since the RBCs lack luciferase activity. Consequently, the experimental 
protocol of the Luciferase assay required fewer liquid handling steps and was thus 
considerably more amenable to multiple sample processing than the ATP assay (see sections 
4.2.3 and 3.2.2 for details of the respective protocols). This allowed for the Luciferase assay 
to be performed in a 96-well plate format with several drugs assayed in a single experiment. 
Five identical test plates containing parallel control and drug-treated HSP-Luc cultures were 
prepared and luciferase activity was measured every 2 hours over a 10-hour period by 
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subjecting one plate to the Luciferase assay, as described in section 4.2.3. Treatment 
concentrations for each drug were the same as those used for the ATP assay (see Chapter 3), 
except in the case of artemisinin to which the transgenic HSP-Luc parasites displayed 
resistance. Results are presented both as absolute values and relative to controls in sections 
4.3.3.1–4.3.3.5 below.  
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4.3.3.1.    Chloroquine 
Results indicated that the luciferase activity of control parasites increased throughout the 
incubation period with an overall increase of 115% between the 2- and 10-hour time-points 
(Figure 4.3a). The time-dependent increase in the luciferase activity of chloroquine-treated 
parasites occurred at a slower rate than that of controls (Figure 4.3a). Consequently, the 
luciferase activity of treated parasites was progressively lower than that of controls with an 
average decline of 5% between time-points (Figure 4.3b). At the final time-point luciferase 
activity of treated parasites was 20% lower than that of control parasites (P < 0.05; Table 7.1, 
Appendix 7.1).  
 
 
Figure 4.3: Luciferase activity in control and chloroquine-treated HSP-Luc parasites 
over a 10-hour period. Luciferase activity was measured in samples of control and chloroquine (100 nM)-
treated cultures every 2 hours over a 10-hour period. Results are presented as absolute values (Fig. 4.3a) and 
relative to controls (Fig. 4.3b) with each data point presented as the mean ± SD, n = 3.  
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4.3.3.2.    DFMO 
The response of parasite luciferase activity to DFMO treatment was similar to that seen in 
chloroquine-treated parasites. Both control and DFMO-treated parasites showed an increase 
in luciferase activity with time. However, from the 6-hour time-point onward, luciferase 
activity of DFMO-treated parasites increased at a slower rate than that of controls (Figure 
4.4a). Over the 10-hour incubation period, the overall increase in the luciferase activity of 
control and treated parasites was 106% and 69%, respectively. As with chloroquine, the 
luciferase activity of DFMO-treated parasites gradually decreased relative to controls with an 
average decline of 5% between time-points (Figure 4.4b). Luciferase activity of DFMO-
treated parasites was 17% lower than that of controls at the final time-point (P < 0.05; Table 
7.1, Appendix 7.1). 
 
 
Figure 4.4: Luciferase activity in control and DFMO-treated HSP-Luc parasites over a 
10-hour period. Luciferase activity was measured in samples of control and DFMO (10 mM)-treated 
cultures every 2 hours over a 10-hour period. Results are presented as absolute values (Fig. 4.4a) and relative to 
controls (Fig. 4.4b) with each data point presented as the mean ± SD, n = 3.  
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4.3.3.3.    Mefloquine 
Luciferase activity of control parasites increased throughout the 10-hour incubation period 
with an overall increase of 120% (Figure 4.5a). Unlike the moderate effect on parasite 
luciferase activity seen with chloroquine and DFMO treatments, mefloquine had a far more 
pronounced effect on the transgenic parasites. Luciferase activity of mefloquine-treated 
parasites was 44% lower than that of controls at the 2-hour time-point (P < 0.05; Table 7.1, 
Appendix 7.1) and remained relatively unchanged at the remaining time-points (Figure 4.5a). 
Consequently, the luciferase activity of treated parasites was, on average, 66% below that of 
controls during the last 6 hours of incubation (Figure 4.5b; P < 0.05, Table 7.1, Appendix 
7.1). 
 
 
Figure 4.5: Luciferase activity in control and mefloquine-treated HSP-Luc parasites 
over a 10-hour period. Luciferase activity was measured in samples of control and mefloquine (100 nM)-
treated cultures every 2 hours over a 10-hour period. Results are presented as absolute values (Fig. 4.5a) and 
relative to controls (Fig. 4.5b) with each data point presented as the mean ± SD, n = 3.  
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4.3.3.4.    Artemisinin 
The luciferase activity of control parasites did not increase throughout the 10-hour incubation 
period (Figure 4.6a), as was the case in previous experiments (see Figures 4.3a, 4.4a and 
4.5a). This may be due to a higher degree of synchronisation of the developmental stages of 
the parasite population in the previous experiments. Luciferase activity of HSP-Luc parasites 
treated with 100 nM artemisinin closely matched that of untreated parasites throughout the 
10-hour incubation period (Figures 4.6a and 4.6b). This was unexpected since the 100 nM 
artemisinin treatment had caused significantly elevated ATP levels in the wildtype parasites 
used in the ATP assay (see section 3.3.1.4 of Chapter 3). Consequently, the IC50s of 
artemisinin against the wildtype and HSP-Luc parasites were compared and it was found that 
the transgenic parasites were less sensitive to artemisinin (see section 4.3.4 below). 
Accordingly, the Luciferase assay was repeated using a higher concentration of artemisinin 
(500 nM). 
 
The 500 nM artemisinin treatment was found to have a significant effect on parasite 
luciferase activity, similar to that obtained with mefloquine. The luciferase activity of control 
parasites increased throughout the 10-hour incubation period with an overall increase of 
111% (Figure 4.6c). In contrast, the luciferase activity of artemisinin-treated parasites 
decreased by 71% between the 2- and 4-hour time-points and remained relatively unchanged 
during the remainder of the incubation (Figure 4.6c). As a result, the luciferase activity of 
treated parasites was 67% below that of controls at the 2-hour time-point and, on average, 
96% lower than that of controls at the remaining time-points (Figure 4.6d; P < 0.05, Table 
7.1, Appendix 7.1). This pattern of decreasing luciferase activity in artemisinin-treated 
parasites, relative to controls, was similar to that observed with mefloquine, however, the 
artemisinin treatment caused more pronounced decreases.  
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Figure 4.6: Luciferase activity in control and artemisinin-treated HSP-Luc parasites 
over a 10-hour period. Luciferase activity was measured in samples of control and artemisinin-treated 
cultures every 2 hours over a 10-hour period in two separate experiments with respective artemisinin 
concentrations of 100 nM and 500 nM. Results are presented as absolute values (Fig. 4.6a and 4.6c) and relative 
to controls (Fig. 4.6b and 4.6d) with each data point presented as the mean ± SD, n = 3.  
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4.3.3.5.    Ritonavir 
The luciferase activity of control parasites increased substantially (256%) during the first 8 
hours of incubation before decreasing by 23% during the last 2 hours (Figure 4.7a). In 
contrast, the luciferase activity of ritonavir-treated parasites decreased by 16% between the 2- 
and 4-hour time-points, with a further decrease of 92% during the remaining 6 hours of 
incubation (Figure 4.7a). As a result, the luciferase activity of treated parasites was 34% and 
64% lower than that of controls at the 2- and 4-hour time-points, respectively and, on 
average, 95% below that of controls at the remaining time-points (Figure 4.7b; P < 0.05, 
Table 7.1, Appendix 7.1). This pattern of luciferase activity was similar to parasites treated 
with 500 nM artemisinin. 
 
 
Figure 4.7: Luciferase activity in control and ritonavir-treated HSP-Luc parasites over 
a 10-hour period. Luciferase activity was measured in samples of control and ritonavir (100 µM)-treated 
HSP-Luc cultures every 2 hours over a 10-hour period. Results are presented as absolute values (Fig. 4.7a) and 
relative to controls (Fig. 4.7b) with each data point presented as the mean ± SD, n = 3.  
 
 
 
 
 
 
 
 
 
 
2 4 6 8 10
0
5.0105
1.0106
1.5106
2.0106
2.5106
3.0106
3.5106
Untreated control 100 M Ritonavir
 a Time Elapsed (hours)
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
2 4 6 8 10
0
20
40
60
80
100
120
Untreated control
 b
100 M Ritonavir
Time Elapsed (hours)
R
e
la
ti
v
e
 L
u
m
in
e
s
c
e
n
c
e
107 
 
4.3.4.     Investigating drug resistance in luciferase transgenic parasites 
Even though a 100 nM artemisinin treatment had caused significantly elevated ATP levels in 
wildtype parasites (see section 3.3.1.4 of Chapter 3), it had a negligible effect on the 
luciferase activity of luciferase transgenic HSP-Luc parasites (see section 4.3.3.4 above). 
Therefore, in order to ascertain whether there was a difference in the sensitivity of wildtype 
and HSP-Luc parasites to artemisinin, the IC50s of artemisinin against these parasite lines 
were determined. This was achieved using a standard pLDH assay (detailed in section 3.2.3 
of Chapter 3) with a final concentration range of 1.00x100–1.52x10-4 µM. The results of two 
independent experiments (Figures 4.8a and 4.8b) showed that the IC50 of artemisinin against 
HSP-Luc parasites was significantly higher than that obtained against wildtype parasites (P < 
0.05; Table 7.4, Appendix 7.2). This suggested that the HSP-Luc parasites were less sensitive 
to artemisinin than the wildtype parasites. 
 
 
Figure 4.8: Comparing the IC50 of artemisinin against wildtype and HSP-Luc parasites. 
Trophozoite-stage cultures were exposed to two-fold serial dilutions of the drug (final concentration range: 
1.00x100–1.52x10-4 µM) for 48 hours. Percentage parasite viability was determined using the pLDH assay and 
the IC50 was determined from a log dose-response curve using GraphPad Prism software. The results of two 
independent experiments (a-b) are shown, with each data point representing the mean ± SD, n = 2. 
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The next step was to determine whether the apparent resistance of HSP-Luc parasites to 
artemisinin may be linked to their expression of luciferase. This was achieved by assessing 
the sensitivity of LYS-Luc parasites, which displayed luciferase activity 31x lower than that 
of HSP-Luc parasites (Figure 4.9), to artemisinin.  
 
Figure 4.9: Comparing the luciferase activity of transgenic luciferase parasites with 
different promoters. To determine the effect of different promoters on the level of parasite luciferase 
activity, parallel samples of trophozoite-stage HSP-Luc and LYS-Luc cultures were subjected to the Luciferase 
assay. Uninfected RBCs served as negative controls. Luciferase activities, measured as relative light units 
(RLU), are presented as means ± SD, n = 2.  
 
The results of IC50 determinations from two independent experiments (Figures 4.10a and 
4.10b) once again showed that the IC50 of artemisinin against HSP-Luc parasites (IC50s = 
64.5 nM, 50.9 nM) was substantially higher than that against wildtype parasites (IC50s = 
35.8 nM, 37.5 nM). In contrast, it was found that the IC50 of artemisinin against LYS-Luc 
parasites (IC50s = 35.6 nM, 39.3 nM) was not significantly different (P > 0.05; Table 7.4, 
Appendix 7.2) from that of wildtype parasites. These findings suggest that, in comparison to 
wildtype parasites, HSP-Luc parasites and LYS-Luc parasites are less and equally sensitive to 
artemisinin, respectively. Since luciferase activity of LYS-Luc parasites is significantly lower 
(P < 0.05; Table 7.2, Appendix 7.1) than that of HSP-Luc parasites, and wildtype parasites 
lack luciferase activity, the results suggest that reduced sensitivity of HSP-Luc parasites to 
artemisinin may be associated with luciferase expression. 
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Figure 4.10: Comparing the IC50 of artemisinin against wildtype and luciferase 
transgenic parasites. Trophozoite-stage cultures were exposed to two-fold serial dilutions of artemisinin 
(final concentration ranges: 4.10a = 1.00x100–1.52x10-4 µM; Fig. 4.10b = 3.00x100–4.57x10-4 µM) for 48 hours. 
Parasite viability was determined using the pLDH assay and the IC50 was determined from a log dose-response 
curve using GraphPad Prism software. The results of two independent experiments (a-b) are shown, with each 
data point representing the mean ± SD, n = 2. 
 
In order to ascertain whether the transgenic HSP-Luc parasites used in the Luciferase assay 
were resistant to the other established antimalarials used in this study (i.e. chloroquine and 
mefloquine), IC50 determinations were performed for these drugs as well. The results (Figure 
4.11) showed no significant difference (P > 0.05; Table 7.4, Appendix 7.2) in the IC50s of 
chloroquine and mefloquine against wildtype and HSP-Luc parasites, suggesting that these 
parasite lines were equally sensitive to these respective drugs. 
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Figure 4.11: Comparing the IC50s of chloroquine and mefloquine against wildtype and 
HSP-Luc parasites. Trophozoite-stage cultures were exposed to two-fold serial dilutions of the drugs (final 
concentration ranges: Fig. 4.11a-b = 3.33x10-1–1.5210-4 µM; Fig. 4.11c-d = 3.00x100–1.37x10-3 µM) for 48 
hours. Parasite viability was determined using the pLDH assay and the IC50 was determined from a log dose-
response curve using GraphPad Prism software. Each data point represents the mean ± SD, n = 2. 
 
4.3.5.    Determining whether drug-induced decreases in luciferase activity are a result  
             of proteasomal degradation 
Overall results of the Luciferase assay indicated that, over a 10-hour incubation period, the 
luciferase activity of drug-treated parasites remained fairly unchanged and/or decreased 
relative to controls (see section 4.3.3 above). Several cellular processes, including the cellular 
stress response, rely on the correct balance of various cellular proteins, and protein 
degradation plays a major role in the maintenance of this balance (Myung et al., 2001). The 
eukaryotic cell possesses two proteolytic mechanisms, the non-specific lysosomal pathway 
and the ubiquitin-proteasome pathway (Myung et al., 2001). The involvement of proteasomal 
degradation in the antimalarial-mediated decreases of HSP-Luc luciferase activity was 
assessed by determining whether proteasome inhibitors could prevent these decreases. This 
was achieved using proteasome inhibitors Lactacystin (LC) and MG-132 (MG), and the 
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antimalarial mefloquine (MQ) which had decreased luciferase activity of HSP-Luc parasites 
by 66% after a 6-hour 100 nM treatment (see section 4.3.3.3 above). Briefly, trophozoite-
stage HSP-Luc parasites were prepared at a 5% haematocrit and 2% parasitaemia. Cultures 
were incubated for 6 hours with MQ (100 nM), LC (5 µM) or MG (300 nM) alone, or a 
combination of MQ+LC or MQ+MG, before measuring luciferase activity via the Luciferase 
assay, as described in section 4.2.2 above. The results are presented in Figure 4.12. Note: 
Treatment concentrations for LC and MG were based on their IC50s against HSP-Luc 
parasites (Figure 8.1, Appendix 8) determined using a standard pLDH assay.  
 
The MQ and LC treatments both caused a 58% decrease in luciferase activity while the MG 
treatment caused a 28% decrease, relative to controls (P < 0.001; Table 7.3, Appendix 7.1). 
Mefloquine treatment in the presence of the proteasome inhibitors LC or MG resulted in 
decreased luciferase activity that was 25% and 4% lower, respectively, than that observed 
with MQ alone. This suggests that the decreased luciferase activity of HSP-Luc parasites in 
the presence of antimalarials is likely not due to proteasomal degradation since this decrease 
persisted even in the presence of proteasome inhibitors. 
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Figure 4.12: The effect of proteasome inhibitors on luciferase activity in control and 
drug-treated HSP-Luc parasites. To determine whether proteasomal degradation was involved in 
antimalarial-mediated decreases of HSP-Luc luciferase activity, samples of trophozoite-stage cultures were 
incubated for 6-hours in culture medium or culture medium containing mefloquine or a proteasome inhibitor, 
either alone or in combination. Samples were subjected to the Luciferase assay and luciferase activities, 
measured as relative light units (RLU), are presented as means ± SD, n = 3. 
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4.4.    DISCUSSION 
In addition to our investigations of the P. falciparum ATP assay (see Chapter 3) as a novel, 
quantitative means of assessing the rate of antimalarial drug action in in vitro cultures, the 
Luciferase assay was explored as a potential additional methodology. The assay uses a 
luminescence-based kit (Bright-Glo Luciferase Assay System, Promega) to detect parasite 
luciferase activity in luciferase-expressing P. falciparum transfectants. The transfectants were 
generated by the CSIR Systems Biology Group, and preliminary experiments by the group 
showed that luciferase activity in these parasites decreased rapidly and markedly during 
exposure to artemisinin and mefloquine (data not shown). Conceivably, measurements of 
luciferase activity in these transgenic parasites may thus be used to evaluate the rate of 
antimalarial drug action. To explore this further, the luciferase-expressing parasite line was 
made available for this study.  
 
Firstly, the correlation of luciferase activity in culture samples with varying parasite 
concentrations was determined. The results indicated that, for 55x103 to 70x105 parasites per 
sample, the luminescence signals produced by the Luciferase assay correlated strongly with 
parasite numbers. This appears to be an advantage over the ATP assay (see section 2.3.4 of 
Chapter 2) where luminescence signals became saturated and diverged from linearity at 
parasite numbers greater than 22x105.  
 
The utility of the Luciferase assay as a means of assessing the rate of antimalarial drug action 
was evaluated in the same manner as for the ATP assay, i.e. by characterising the response of 
parasite luciferase activity to a panel of antimalarial drugs with varying modes of action and, 
presumably, rates of activity. The results are discussed below. Note: Since luciferase activity 
at each time-point was measured using a separate aliquot of pre-prepared Bright-Glo reagent, 
the discussion below focuses on the ‗relative to control‘ data rather than the absolute values. 
 
4.4.1.    Characterising the response of parasite luciferase activity to a panel of     
   antimalarial drugs 
The results of this study revealed that the luciferase activities of chloroquine- and DFMO-
treated parasites were progressively lower than that of controls with maximum decreases of 
20% and 17%, respectively, at the final time-point. This modest variation between the 
luciferase activities of control and treated parasites suggests that chloroquine and DFMO are 
slow-acting antimalarials. The luciferase activity of mefloquine-treated transgenic parasites 
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was found to be significantly (44%) lower than that of controls within 2 hours of treatment, 
with even lower (± 66%) levels observed during the remainder of the 10-hour incubation 
period. This is in contrast to the mild decreases caused by DFMO and chloroquine treatments, 
which suggests that mefloquine acts at a faster rate than these drugs.  
 
The luciferase activity of transgenic parasites in the presence of 100 nM artemisinin closely 
mirrored that of the controls throughout the 10-hour incubation period. This was unexpected 
since the same 100 nM treatment had caused greatly elevated ATP levels in the wildtype 
parasites used in the ATP assay (see section 3.3.1.4 of Chapter 3). Comparison of the IC50s 
of artemisinin against the wildtype and transgenic HSP-Luc parasites revealed that the 
transgenic parasites were less sensitive to artemisinin. Consequently, the Luciferase assay 
was repeated using a higher concentration of artemisinin (500 nM). The results of this second 
experiment showed that the luciferase activity of the artemisinin-treated transgenic parasites 
was significantly lower (67%) than that of controls after 2 hours of incubation with even 
lower (± 96%) levels detected during the remaining 8 hours. This response appears to be 
similar to that observed with mefloquine-treated parasites, but the decreases in the luciferase 
activity of artemisinin-treated parasites were more pronounced. This suggests that the rate of 
antimalarial action of artemisinin may be faster than that of mefloquine which agrees with 
previous in vitro (Gamo et al., 2010; Sanz et al., 2012) and in vivo (Karbwang et al., 1992; 
Myint & Shwe, 1987; White, 1994; White et al., 1992) studies that have shown artemisinins 
to be more rapid-acting than quinines. However, care must be taken in evaluating the relative 
rates of action of artemisinin and the other drugs, considering the higher dose of artemisinin 
required due to its increased IC50 in HSP-Luc parasites, and thus the increased risk of 
secondary drug effects unrelated to the primary mode of action. Taken together, the 
Luciferase assay results suggest that chloroquine and DFMO are slow-acting antimalarials, 
mefloquine has a moderate rate of activity and artemisinin is rapid-acting, which is consistent 
with the findings of the ATP assay discussed in Chapter 3. 
 
In addition to the traditional (i.e. chloroquine, mefloquine and artemisinin) and cytostatic (i.e. 
DFMO) antimalarials used in this study, a potent antimalarial compound which is not used 
clinically (i.e. ritonavir) was also analysed. Ritonavir-treated P. falciparum parasites were 
found to display luciferase activity that was significantly lower than that of controls within 2 
(34% lower) and 4 (64% lower) hours of treatment, and ± 95% below that of controls during 
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the remaining 6 hours of incubation. This implies that ritonavir, like artemisinin, is a rapid-
acting antimalarial which agrees with the findings of the ATP assay discussed in Chapter 3. 
 
4.4.2.    Possible explanations for the luciferase activity decreases observed in drug- 
   treated HSP-Luc parasites  
Note: Since the proposed modes of action of each drug were discussed at length in Chapter 3 
(section 3.4), only information pertinent to the Luciferase assay results are mentioned here. 
 
Due to the parasite‘s limited capacity for de novo amino acid synthesis, digestion of host-
derived haemoglobin is critical to parasite survival as it releases amino acids which may be 
used for energy metabolism or incorporated into parasite proteins (Francis et al., 1997). A 
number of the drugs used in this study have been suggested to exert their antimalarial action 
by interfering with haemoglobin metabolism in the parasite. Chloroquine, due to its weak 
base properties, is believed to accumulate in the parasite‘s acidic food vacuole by pH 
trapping (Aikawa, 1972; Yayon et al., 1984; Yayon et al., 1985) where it binds to haem 
(Bray et al., 1999; Chou et al., 1980; Dorn et al., 1998; Sullivan et al., 1996) forming 
chloroquine-haem complexes which have been implicated in the inhibition of haemoglobin 
degradative proteases (Gluzman et al., 1994; Vander Jaqt et al., 1986). Artemisinin and 
mefloquine have been proposed to disrupt haemoglobin metabolism in the parasite by 
inhibiting endocytosis of the haemoglobin-rich host RBC cytoplasm (Famin & Ginsburg, 
2002; Hoppe et al., 2004) and by blocking haemoglobin degradation (Mungthin et al., 1998; 
Pandey et al., 1999; Sullivan et al., 1998). Ritonavir has been suggested to impede 
haemoglobin metabolism in the parasite by binding to and inhibiting plasmepsins, the 
parasite‘s haemoglobin degradative proteases (Andrews et al., 2006). Based on this 
discussion, the lower levels of luciferase activity in parasites treated with chloroquine, 
mefloquine, artemisinin or ritonavir relative to controls observed in this study may be 
associated with the proposed ability of these drugs to interfere with haemoglobin metabolism. 
By disrupting this critical process these drugs may have limited the parasite‘s source of 
amino acids, thus impairing the production of parasite proteins, including luciferase which 
the transgenic HSP-Luc parasites used in the Luciferase assay were modified to express. 
 
While the aforementioned plasmepsin-inhibitor theory of antimalarial action, based on its 
inhibition of HIV aspartic acid protease, may seem plausible for ritonavir, its very rapid 
action against P. falciparum, as reported here, makes an inhibition of haemoglobin digestion 
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as the principle mode of action unlikely. Furthermore, Parikh et al. (2006) showed that the 
antimalarial activity of ritonavir against wildtype and plasmepsin knockout P. falciparum 
parasites was not significantly different, which further opposes the plasmepsin-inhibitor 
theory of antimalarial action. Therefore, it is difficult to fully explain the decline in the 
luciferase activity of ritonavir-treated parasites observed in this study. 
 
The slow rate at which the luciferase activity of chloroquine-treated parasites decreased 
relative to controls in this study may be partly due to the fact that most parasites were in the 
early trophozoite-stage of development at time 0. During this early phase of development, 
endocytosis and digestion of host cell cytoplasm by the parasite is limited and consequent 
release of haem is comparatively limited. Consequently, at the earlier time-points there may 
have been minimal production of chloroquine-haem complexes. As time passed, parasite 
consumption of host cell cytoplasm may have increased in order to create space and provide 
amino acids for the growing parasite. This may have led to an increased production of free 
haem and chloroquine-haem complexes which may explain why, in comparison to controls, 
the decrease in luciferase activity of chloroquine-treated parasites, though still modest, was 
more pronounced at the later time-points. 
 
Studies by Famin and Ginsburg (2002) and Hoppe et al. (2004) suggest that mefloquine 
blocks parasite endocytosis of the haemoglobin-rich host cell cytoplasm, while chloroquine 
may act later by inhibiting haemoglobin digestion in the food vacuole. Thus, in this study, the 
speedier action of mefloquine relative to chloroquine on parasite luciferase activity may be 
because it is proposed to target an earlier stage of haemoglobin metabolism than chloroquine. 
Interestingly, studies have shown that mefloquine is active against chloroquine-resistant 
strains of P. falciparum (Geary & Jensen, 1983; Mungthin et al., 1998; Zhang et al., 1999b), 
suggesting that it may possess some additional or different mode(s) of antimalarial action 
compared to chloroquine. The results of this study which show a more pronounced decrease 
in parasite luciferase activity in mefloquine-treated parasites as compared to that seen in 
chloroquine-treated parasites supports the notion that these drugs may differ in their modes of 
action. In comparison to DFMO which has a cytostatic effect on malaria parasites (Assaraf et 
al., 1984; Assaraf et al., 1987; Gupta et al., 2005), mefloquine has a cytotoxic mode of 
antimalarial action which may explain why its effect on parasite luciferase activity in this 
study was more rapid and more potent than that of DFMO. 
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DFMO is proposed to inhibit the synthesis of polyamines which are essential to several 
cellular processes, including protein synthesis (Metcalf et al., 1978). Assaraf et al. (1984) 
found that DFMO treatment blocked the developmental progression of P. falciparum 
parasites from the trophozoite to the schizont stage, with a concomitant inhibition of nucleic 
acid and protein synthesis. Thus, the decreased luciferase activity of DFMO-treated parasites 
seen in this study was likely due to DFMO inhibiting polyamine synthesis, which may have 
led to an inhibition in the synthesis of proteins, such as luciferase which the HSP-Luc 
parasites were modified to express. The results also showed that the luciferase activity of 
DFMO-treated parasites only decreased relative to controls from the 6-hour time-point 
onward. This may be partially due to the majority of the parasite population being in the early 
trophozoite-stage of development at time 0. Assaraf et al. (1984) showed that in untreated P. 
falciparum parasites, the synthesis and accumulation of polyamines peaked during the early 
trophozoite stage of development, while protein synthesis peaked once trophozoites matured. 
Thus, in this study, DFMO-mediated inhibition of polyamine synthesis may have only 
manifested as a decrease in protein synthesis once the trophozoites had matured, i.e. from the 
6-hour time-point onward.  
 
Regarding artemisinin, the most popular notion is that its antimalarial action may be centred 
on oxidative stress due to its chemical ability to produce free radicals upon iron-mediated 
cleavage of its endoperoxide bridge (Jung, 1997). An additional means by which artemisinin 
may promote oxidative stress is by forming adducts with glutathione, thereby decreasing 
levels of this major antioxidant in the parasite (Wang & Wu, 2000). Free radicals are 
notorious for causing lipid peroxidation, DNA damage and oxidation of proteins 
(Bandyopadhyay et al., 1999). Artemisinin and its active metabolite, dihydroartemisinin, 
have been shown to alkylate malaria proteins in P. falciparum cultures (Asawamahasakda et 
al., 1994). This effect is believed to be due to the formation of covalent adducts upon 
interaction of malaria proteins with the free radicals produced from artemisinin. Conceivably, 
the decreased luciferase activity of artemisinin-treated transgenic parasites observed in this 
study may be due to artemisinin-mediated production of free radicals and alkylation of 
parasite proteins, such as luciferase. Alkylation of luciferase may have impaired its function 
as a catalyst for the luminescence-producing reaction which forms the basis of the Luciferase 
assay, as illustrated in Figure 4.13.  
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Figure 4.13: The Luciferase reaction. The Luciferase assay used in this study rapidly detects the 
luciferase activity of transgenic parasites using the luminescence-based Bright-Glo Luciferase Assay System 
which is based on the luciferase-catalysed mono-oxygenation of luciferin in the presence of magnesium, ATP 
and molecular oxygen (Promega, Madison, WI). 
 
Another means by which the panel of drugs used in this study may have decreased parasite 
luciferase activity is by eliciting a cellular stress response, a common phenomenon in 
eukaryotic cells under threat of macromolecular damage (Kültz, 2003). An often typical 
feature of this response is a reduction in the global translation of non-essential proteins, 
thereby conserving cellular energy for use in the production of stress proteins, such as DNA 
repair and heat shock proteins, which help to restore cellular homeostasis (Holcik & 
Sonenberg, 2005). Furthermore, the correct balance of various cellular proteins is critical to 
several cellular processes, including the stress response, and protein degradation (i.e. 
proteolysis) may also play a role in ensuring that this balance is maintained (Myung et al., 
2001). Amino acids released during proteolysis of non-essential proteins can be re-used in 
biosynthetic processes. Luciferase was not essential to the survival of the HSP-Luc parasites 
used in this study and its expression was under the control of an exogenous promoter in the 
episomal plasmid. The promoter used was a heat shock promoter (hsp86) which typically is 
upregulated during periods of cellular stress. Indeed, using unrelated promoters in episomal 
constructs, it was found that luciferase mRNA transcript levels actually increase during drug 
treatment of transgenic parasites, despite a rapid decline in luciferase enzyme activity (A.C. 
van Brummelen, unpublished results). It is therefore unlikely that the decline in luciferase 
activity during drug exposure is due to transcriptional suppression. More likely it reflects 
either inhibition of luciferase mRNA translation, or increased degradation and/or misfolding 
of the enzyme due to drug-induced cellular stress. 
 
In addition to their previously described detrimental drug effects, chloroquine, mefloquine 
and artemisinin may have initiated a stress response in the parasite via their proposed ability 
to inhibit haem detoxification. Haem is the toxic byproduct of haemoglobin digestion in the 
parasite‘s food vacuole and is detoxified primarily via its polymerisation to inert haemozoin 
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(Francis et al., 1997). Several studies have shown that the aforementioned drugs bind haem 
(Bray et al., 1999; Chou et al., 1980; Dorn et al., 1998; Sullivan et al., 1996; Chevli & Fitch, 
1982; Loup et al., 2007; Meshnick et al., 1991; Paitayatat et al., 1997; Pandey et al., 1999; 
Robert et al., 2005; Robert & Meunier, 1997) and inhibit haemozoin formation (Combrinck 
et al., in press; Dorn et al., 1998; Egan et al., 1994; Hong et al., 1994; Kannan et al., 2005; 
Loup et al., 2007; Pandey et al., 1999; Sullivan et al., 1996; Sullivan et al., 1998; Zhang et 
al., 1999b) thereby causing a toxic accumulation of haem in the parasite which may elicit a 
cellular stress response, resulting in increased luciferase degradation/misfolding or decreased 
translation. 
 
4.4.3.    Investigating drug resistance in the luciferase-expressing HSP-Luc parasites 
While investigating the response of parasite luciferase activity to artemisinin treatment it was 
found that a 100 nM treatment, which had caused greatly elevated ATP levels in the wildtype 
parasites (see section 3.3.1.4 of Chapter 3), barely affected the luciferase activity of HSP-Luc 
parasites. Comparison of the IC50s of artemisinin against these parasite lines revealed that 
the luciferase-expressing HSP-Luc parasites were less sensitive to artemisinin than the 
wildtype parasites, which likely explains the contradictory results of the ATP and Luciferase 
assays. Additionally, IC50 determinations of chloroquine and mefloquine against these 
parasite lines indicated that wildtype and HSP-Luc parasites were equally sensitive to 
mefloquine and chloroquine, respectively. 
 
To ascertain whether the reduced sensitivity of HSP-Luc parasites to artemisinin may be 
associated with luciferase expression, artemisinin sensitivity of an alternative luciferase-
expressing parasite line, the LYS-Luc parasites, was investigated. The only genetic difference 
between the HSP-Luc and LYS-Luc parasites is their respective promoters, i.e. the heat shock 
protein 86 promoter and the lysophospholipase promoter. The results of IC50 determinations 
indicated that, relative to wildtype parasites, the HSP-Luc parasites were less sensitive to 
artemisinin while the LYS-Luc parasites were equally sensitive. Measurements of luciferase 
activity showed that the ―artemisinin-resistant‖ HSP-Luc parasites displayed activity that was 
markedly (31x) higher than that of the ―artemisinin-sensitive‖ LYS-Luc parasites and, as 
expected, the ―artemisinin-sensitive‖ wildtype parasites lacked activity. Taken together, these 
results suggest that the reduced sensitivity of HSP-Luc parasites to artemisinin, relative to 
that of wildtype parasites, may be associated with luciferase expression, which can reach 
substantial levels in these transgenic parasites. The exact mechanism by which luciferase 
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expression may lead to artemisinin resistance in these parasites (e.g. competition for drug 
targets by adduct formation, altered parasite metabolism to compensate for artemisinin 
action, etc.) needs to be investigated further. This does raise doubts, however, that luciferase-
expressing parasites can be used to perform assays with all classes of drugs. 
 
4.4.4.    Does the proteasome play a role in decreasing the luciferase activity of drug- 
    treated HSP-Luc parasites? 
Overall results of the Luciferase assay showed that the luciferase activity of drug-treated 
parasites remained fairly unchanged and/or decreased relative to controls (see section 4.3.3 
above). The cellular stress response relies on the correct balance of various cellular proteins 
and proteolysis plays a major role in the maintenance of this balance (Myung et al., 2001). 
Thus, the decrease in the luciferase activity of HSP-Luc parasites following drug treatment 
may be due to the parasite degrading foreign and unnecessary proteins, such as luciferase, as 
part of its stress response. The eukaryotic cell possesses two proteolytic mechanisms: (i) the 
non-specific lysosomal pathway where proteins are engulfed within endocytic vesicles and 
transported to the lysosome where degradation is carried out by a collection of proteolytic 
enzymes and, (ii) the highly specific ubiquitin-proteasome pathway where the protein 
destined for destruction is targeted for proteasomal degradation by the attachment of multiple 
ubiquitin molecules (Myung et al., 2001). The P. falciparum genome has 14 genes encoding 
protein subunits of the proteasome, as well as a single gene encoding the ClpQ/hsIV ortholog, 
the prokaryotic precursor of the proteasome (Gille et al., 2003). 
 
The contribution of proteasomal degradation to the antimalarial-mediated decreases of HSP-
Luc luciferase activity observed in this study was assessed by determining whether 
proteasome inhibitors could abrogate these decreases. This was achieved using the 
antimalarial mefloquine (MQ), which in previous experiments had decreased parasite 
luciferase activity considerably, and the proteasome inhibitors Lactacystin (LC) and MG-132 
(MG). The results showed that, relative to controls, the MQ and LC treatments decreased 
luciferase activity considerably (58%) while the MG treatments caused a less pronounced 
(28%) decrease. The fact that parasite luciferase activity decreased substantially when only 
proteasome inhibitors were present suggests that these decreases were likely not a result of 
proteasomal degradation of luciferase. The proteasome regulates the turnover of most 
eukaryotic proteins and thus plays a central role in several cellular processes, including 
protein quality control and signal transduction (Kreidenweiss et al., 2008). Therefore, it is 
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likely that proteasome inhibitors may threaten parasite survival and trigger a stress response, 
reflected by a marked reduction in luciferase activity. Furthermore, when MQ was used in 
combination with LC or MG, parasite luciferase activity decreased relative to controls, 
however, these decreases were more pronounced than those observed with MQ alone, 
particularly with LC. This further supports the notion that decreased luciferase activity of 
HSP-Luc parasites in the presence of antimalarials, is likely not due to proteasomal activity 
since the presence of proteasome inhibitors failed to abrogate this decrease. This makes it 
more likely that the activity decreases are due to either an inhibition of luciferase translation 
or increased misfolding/denaturation of the enzyme during cellular stress. 
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4.5.    CONCLUSION 
Overall, the Luciferase assay results imply that chloroquine and DFMO have a slow rate of 
antimalarial action, mefloquine has a moderate rate of activity, and artemisinin and ritonavir 
are rapid-acting antimalarials. For the established drugs, chloroquine, mefloquine and 
artemisinin, as well as the polyamine inhibitor DFMO, these observations agree with the 
expected rates of activity of these antimalarials, thereby supporting the use of the Luciferase 
assay as a potential means of evaluating the rate of antimalarial drug action. In addition, the 
rates of activity of the abovementioned antimalarials indicated by the Luciferase assay are in 
agreement with those suggested by the ATP assay discussed in Chapter 3. The findings of 
this study which suggest that ritonavir acts rapidly on parasite ATP and luciferase levels are, 
to our knowledge, the first account of this antimalarial‘s rate of activity.  
 
From a technical point of view, the Luciferase assay has several advantages over the ATP 
assay. It is far easier to perform than the ATP assay since isolation of transgenic parasites 
from RBCs is unnecessary due to the lack of luciferase activity in RBCs and thus only three 
pipetting steps are required after drug exposure (i.e. removal of medium, addition of lysis 
buffer to infected RBCs and addition of luciferase reagent to the lysate). By contrast, parasite 
isolation is essential during the ATP assay in order to remove RBC ATP. Consequently, 
when 2-hour time-points are employed when assessing the rate of antimalarial activity, the 
Luciferase assay can be performed in a 96-well plate format and multiple drugs can be 
assayed in a single experiment. In contrast, due to the multiple pipetting steps involved in the 
ATP assay during isolation of parasites from RBCs, only a single drug can comfortably be 
analysed per experiment. An additional advantage of the Luciferase assay is that luciferase 
activity can be accurately detected in samples with parasite concentrations as high as 7x106, 
as opposed to the ATP assay where the limit of detection is 2x106 parasites per sample.  
 
This practical advantage of the Luciferase assay should be seen in the context of some 
additional considerations. A major difference between the Luciferase and ATP assays is that 
the former assay measures the activity of a foreign protein (i.e. luciferase) which the parasites 
were modified to express, while the latter assay measures the natural energy source of 
multiple cellular processes (i.e. ATP). The results of this study showed that, relative to 
controls, parasite ATP levels were relatively unchanged, increased or decreased in response 
to drug stress. The role of ATP in metabolic processes, plus Recovery assay and 
morphological evaluations, led to the hypothesis that unchanged ATP levels reflect poor drug 
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action, increased ATP levels indicate a stress response to drug action and some loss of 
parasite viability, while a major decline in ATP reflects severely compromised viability. In 
contrast, parasite luciferase activity always decreased in response to drug stress, relative to 
controls, and this was broadly interpreted as a reflection of a stress response to drug action. 
Thus, an advantage of the ATP assay over the Luciferase assay is that more information 
regarding the status of parasite health may potentially be inferred from the results. 
Additionally, since the Luciferase assay relies on transgenic parasites, it is possible that 
expression of a foreign protein (i.e. luciferase) may have unanticipated effects on the parasite 
that affect drug sensitivity. Possible interactions of luciferase with the antimalarials used in 
this study are also unknown. As an example, the transgenic HSP-Luc parasites used in the 
Luciferase assay were less sensitive to artemisinin than the wildtype parasites. Potential 
resistance of these transgenic parasites to compounds under investigation would thus 
necessitate the performance of IC50 determinations prior to use of the Luciferase assay in 
order to select effective treatment concentrations. Since the ATP assay makes use of wildtype 
parasites, the potential shortcomings associated with the use of transgenic parasites are not a 
factor in this assay. Furthermore, the ATP assay may be rapidly applied to parasites isolated 
from the field, without the necessity of having to first generate transgenic parasites which is a 
time-consuming process and may alter the wild-type characteristics of the field strains. 
 
In comparison to controls, parasite luciferase activity generally decreased in response to drug 
stress. Numerous cellular processes, such as the cellular stress response, rely on the correct 
balance of various cellular proteins and proteolysis has a leading role in the preservation of 
this balance (Myung et al., 2001). Eukaryotic cells have two proteolytic mechanisms – the 
non-specific lysosomal pathway and the highly specific ubiquitin-proteasome pathway 
(Myung et al., 2001). Interestingly, significant decreases in the luciferase activity of 
mefloquine-treated parasites persisted even in the presence of proteasome inhibitors. This 
suggests that proteasomal degradation of luciferase may not have contributed to the decreases 
in the luciferase activity of drug-treated parasites observed in this study. Instead, these 
decreases may be due to a decline in the translation of non-essential proteins such as 
luciferase, as part of a stress response initiated by drug treatment. 
 
One aspect that was not investigated is whether altered parasite ATP levels in drug-treated 
parasites may influence the luciferase activity results, bearing in mind that luciferase uses 
ATP and luciferin as substrates. ATP is added exogenously as part of the luciferase assay 
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reagents. However, no attempt is made to remove/deplete parasite ATP before conducting the 
luciferase assay, so an effect on the read-outs is a formal possibility that may be investigated 
in future. 
 
In conclusion, the results of this study suggest that the Luciferase assay may serve as a useful 
indicator of the rate of antimalarial action. However, possible resistance of the transgenic 
parasites used in the assay to the drugs being tested may be a complication which has to be 
taken into account. 
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CHAPTER 5: GENERAL CONCLUSION 
 
The Medicines for Malaria Venture endorses a ―single dose radical cure‖ as the ideal 
treatment for uncomplicated malaria since rapid clearance of blood-stage parasites and 
symptom relief improves patient compliance, reduces costs and limits drug resistance (WHO, 
2010c). This call for rapid-acting antimalarials makes assessing the rate of activity of 
candidate compounds critical to malaria drug discovery. Traditional determination of this rate 
by morphological assessments is flawed, primarily due to heterogeneous morphology of 
individual parasites under routine culture conditions which result in highly subjective, 
operator-specific interpretations. In addition, an in vitro viability-based assay which 
determines this rate by directly quantifying the number of parasites capable of recovering 
from distinct periods of drug exposure was recently reported (Sanz et al., 2012). However, 
this method is very time-consuming, requiring 3-4 weeks of monitoring re-growth in culture 
following drug exposure. Hence, the aim of this study was to develop a novel, quantitative 
assay capable of rapidly determining the kinetics of drug action in culture. 
 
A rapid protocol for detecting ATP in P. falciparum parasites using a luminescence-based kit 
was developed and optimised, and luciferase-expressing transgenic parasites, from which 
luciferase activity is readily detected using a similar kit, were acquired. The utility of both 
methods as potential means of assessing the rate of antimalarial drug action were investigated 
using a panel of antimalarials with varying modes of action and, presumably, rates of activity. 
The results indicated that parasite ATP remained unchanged, increased or decreased in 
response to drug stress. Assessments of parasite morphology and a recovery assay were used 
to aid interpretation. The results of these assessments suggested that, generally, during drug 
exposure unchanged parasite ATP levels reflect poor drug action, elevated ATP levels 
indicate a stress response and partially compromised viability, while marked decreases in 
ATP reflect severely compromised viability. With regard to the Luciferase assay, parasite 
luciferase activity decreased during drug treatment. The observed responses of parasite ATP 
and luciferase activity to established (i.e. chloroquine, mefloquine and artemisinin) and 
cytostatic (i.e. DFMO) antimalarials occurred at rates that agreed with the expected rates of 
activity of these compounds. Hence, measurement of parasite ATP and/or luciferase activity 
show potential as novel means of evaluating parasite health and the kinetics of antimalarial 
action. With further validation and characterisation, these assays may benefit drug discovery 
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as tools for comparing candidate compounds with established antimalarials in order to 
identify rapid-acting ―hit‖ compounds. 
  
Additionally, the results suggested that the potent antimalarial, ritonavir, is rapid-acting 
which, to our knowledge, is the first report regarding the rate of activity of this drug. Another 
interesting observation was that, even though chloroquine-treated parasites showed relatively 
no change in ATP or luciferase activity, they failed to recover from a 6-hour drug treatment 
after removal of drug pressure. This supports the notion that pH entrapment in the parasite‘s 
food vacuole, which would allow for prolonged drug pressure, is involved in chloroquine‘s 
mode of action. 
 
Decreases in the luciferase activity of the drug-treated transgenic parasites persisted in the 
presence of proteasome inhibitors, opposing the involvement of proteasomal degradation. 
The molecular basis for these decreases may be investigated further by determining the half-
life of luciferase in the transgenic parasites by blocking protein translation and assessing the 
rate at which luciferase levels decline. A rapid decline would suggest that luciferase has a 
high turnover rate and that drug-induced decreases may be attributable to a global decrease in 
the translation of non-essential proteins, which is a characteristic feature of the eukaryotic 
stress response (Holcik & Sonenberg, 2005). By contrast, a gradual decline would suggest a 
long half-life and thus that the drug-induced decreases may be the result of selective 
proteasome-independent protein digestion. It should be noted, however, that changes in the 
levels of luciferase are being inferred from measuring its enzymatic activity. The luciferase 
protein used in this study (i.e. firefly luciferase) is innately unstable and thermolabile which 
may lead to denaturation and subsequent loss of activity under stress conditions (Tisi et al., 
2002). Thus, western-blotting using anti-luciferase antibodies would be necessary to confirm 
that the observed activity decreases correspond to changes in the levels of the actual protein 
and not just a loss of enzymatic function due to protein denaturation or irreversible 
damage/inhibition during drug-induced stress. Alternatively, a more stable reporter protein 
may be employed such as green fluorescent protein which has a high degree of resistance to 
denaturation by heat and chemical denaturants, although its detection by fluorimetry is much 
less sensitive than luciferase (Ripp et al., 2011). 
 
Regardless of the molecular basis of luciferase activity decreases, the results presented here 
support the use of the Luciferase assay as a justifiable means of assessing malaria parasite 
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stress. Further work may include evaluating the luciferase and ATP assays with an expanded 
set of drug or experimental compounds, to determine if there are exceptions of compound 
classes for which the assays do not detect rates of action. It is also important to note that the 
assays in their current form may be useful for ranking compounds relative to each other with 
regards to rate of action. But they have not been characterised sufficiently to unambiguously 
determine the absolute killing rates of compounds, i.e. the time-points where all parasites in 
the culture have been irretrievably compromised. For example, despite a near complete 
depletion of detectable ATP and luciferase with some of the drug treatments, some parasites 
were still able to recover in the recovery assay, albeit at a highly reduced rate. Further work 
will need to be carried out to firmly establish the correlates between total parasite inhibition 
and the changes in ATP or luciferase levels. 
 
Additionally, the transgenic luciferase-expressing parasites were found to be less sensitive to 
artemisinin than wildtype parasites. An alternative transgenic parasite line, with lower levels 
of luciferase activity than that used for the Luciferase assay, did not display artemisinin 
resistance. This suggested that resistance may be due to an interaction between artemisinin 
and luciferase. Possible interactions of luciferase with the antimalarials used in this study are 
unknown and need to be investigated further. Another potential weakness of the Luciferase 
assay system is that the transgenic parasites upon which it relies carry episomal plasmids 
which may segregate unevenly into daughter parasites during cell division (O‘ Donnell et al., 
2001). Consequently, these transgenic parasite populations may easily lose their plasmids and 
therefore lose their luciferase-expressing ability, unless selective pressure is maintained (O‘ 
Donnell et al., 2001). In order to avoid this situation, parasites carrying integrated copies of 
the luciferase expression cassettes may be used. These are generated by subjecting the 
episomally transformed parasites to a drug cycling process whereby drug pressure is removed 
for 2 weeks before being reinstated until only integrated forms of the transgenic parasites are 
present in the parasite population (O‘ Donnell et al., 2001). 
  
The panel of antimalarials used in this study did not include any antibiotics which are 
currently used as second-line antimalarial treatments (WHO, 2010a). This class of drugs 
targets the apicoplast of the malaria parasite resulting in a ―delayed-death‖ phenotype where 
the progeny of the treated parasites are killed as opposed to the treated parasites themselves 
(Dahl et al., 2006; Goodman et al., 2007). The asexual life cycle of the malaria parasite lasts 
48 hours, thus in order to investigate the response of parasite ATP levels and luciferase 
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activities to antibiotics, the end-point of the ATP and Luciferase assays will need to be 
extended beyond the 10-hour time-point used in this study.  
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APPENDICES 
 
APPENDIX 1: CULTIVATION OF P. FALCIPARUM PARASITES 
 
1.1. Complete malaria culture medium (CMCM) 
RPMI 1640 medium with 25 mM Hepes, 2 mM L-glutamine (500 mL; Lonza, Belgium) 
Glucose (Sigma-Aldrich, Germany) 
Albumax II (Invitrogen, USA) 
Hypoxanthine (Sigma-Aldrich, Germany) 
NaOH (1 M; Sigma-Aldrich, Germany) 
Gentamicin (50 mg/mL; Lonza, Belgium) 
 
Under aseptic conditions:  
Transfer 2 g of glucose and 2.5 g of albumax to a sterile 50 mL centrifuge tube and add 20 
mL of the RPMI medium. Weigh out 44 mg of hypoxanthine in a microfuge tube and 
dissolve in 1 mL of NaOH before adding to the mixture. Add 600 µL of gentamicin to the 
mixture and vortex until the glucose and albumax are completely dissolved. Filter sterilise 
(0.22 µm) the solution into the remaining 450 mL of RPMI medium and store at 4°C. 
 
1.2. Giemsa stain 
Giemsa solution (Sigma-Aldrich, Germany) 
Phosphate buffered saline, 1X (Lonza, Belgium) 
 
Prepare immediately before use by mixing 1 part of Giemsa solution with 10 parts of 
phosphate-buffered saline (v/v). 
 
1.3. 5% Sorbitol solution 
Dissolve 5 g of D-sorbitol (Sigma-Aldrich, Germany) in 100mL of autoclaved ddH20 and 
filter sterilise (0.22 µm) filter. Store at 4°C. 
 
1.4. 60% Percoll solution 
Firstly, prepare 2.5X RPMI/12.5% sorbitol solution by dissolving 1.045 g of RPMI 1640 
powder (Sigma-Aldrich, Germany) and 5 g of D-sorbitol (Sigma-Aldrich, Germany) in 20 
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mL of sterile water. Adjust the pH to 7.0 and make up volume to 40 mL. Filter sterilise (0.22 
µm) and store at 4°C. Thereafter, prepare 60% Percoll solution by mixing 6 mL of Percoll 
(GE Healthcare, Sweden) and 4 mL of 2.5X RPMI/12.5% sorbitol solution. Prepare on the 
day of use and store at 4°C. 
 
1.5. Freezing solution (28% glycerol in CMCM) 
Add 280 µL of glycerol (Sigma-Aldrich, Germany) and 720 µL of CMCM (see 1.1.) to a 
microfuge tube and mix well. Prepare on the day of use and store at 4°C. 
 
1.6. Thawing solution A (12% NaCl)  
Dissolve 120 mg of NaCl (Sigma-Aldrich, Germany) in 1 mL of sterile water and filter 
sterilise (0.22 µm). Store at 4°C. 
 
1.7. Thawing solution B (1.6% NaCl) 
Dissolve 80 mg of NaCl (Sigma-Aldrich, Germany) in 5 mL of sterile water and filter 
sterilise (0.22 µm). Store at 4°C 
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APPENDIX 2: THE ATP ASSAY 
 
2.1. 0.1% BSA in PBS  
Bovine serum albumin (BSA, Albumax II, Invitrogen, USA) 
Phosphate buffered saline (PBS; Sigma-Aldrich, Germany) 
 
Dissolve 0.1 g of BSA in 100 mL of PBS and store at 4°C.  
 
2.2. 5% Saponin solution 
Dissolve 60 mg of saponin (Fluka, Germany) in 1.2 mL of 0.1% BSA in PBS (see 2.1.) and 
store protected from light at 4°C.  
 
2.3. 0.1% Saponin lysis solution (0.1% saponin, 0.1% BSA in PBS) 
Prepare the lysis solution on the day of use. For 10 mL of lysis solution, mix 200 µL of 5% 
saponin (see 2.2.) and 9800 µL of 0.1% BSA in PBS. Store protected from light at 4°C.  
 
2.4. CellTitre-Glo reagent  
CellTitre-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI) stored at -20°C. 
 
Thaw the buffer and lyophilised substrate to room temperature, combine and aliquot. Store 
aliquots protected from light at -20°C for up to 21 weeks. 
 
2.5. 0.24% Saponin lysis solution (0.24% saponin, 0.1% BSA in PBS) 
Prepare the lysis solution on the day of use. For 10 mL of lysis solution, mix 476 µL of 5% 
saponin (see 2.2.) and 9524 µL of 0.1% BSA in PBS. Store protected from light at 4°C.  
 
2.6. Phthalate oil-mix (Quashie et al., 2010) 
Dibutyl phthalate (Merck, Germany) 
Dioctyl phthalate (Sigma-Aldrich, Germany) 
 
Prepare the oil-mix by combining 5 parts of dibutyl phthalate with 4 parts of dioctyl 
phthalate. Store protected from light at room temperature. 
 
 
132 
 
APPENDIX 3: THE pLDH ASSAY 
 
3.1. Malstat solution 
L-lactate (Sigma-Aldrich, Germany) 
Trizma base (Sigma-Aldrich, Germany) 
3-acetylpyridine nicotinamide adenine dinucleotide (APAD; Sigma-Aldrich, Germany) 
Triton X-100 (Fluka, Germany) 
 
Dissolve 4 g of L-lactate, 1.32 g of Trizma base and 22 mg of APAD in 100 mL of ddH2O 
and adjust pH to 9. Add 400 µL of Triton X-100 and make up to a final volume of 200 mL 
and store 4°C.  
 
3.2. NBT/PES solution 
Nitro blue tetrazolium salt (NBT; Sigma-Aldrich, Germany) 
Phenazine ethosulphate (PES; Sigma-Aldrich, Germany) 
 
Dissolve 160 mg of NBT and 8 mg of PES in 100 mL of ddH2O and store protected from 
light at 4°C. 
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APPENDIX 4: THE LUCIFERASE ASSAY 
 
4.1. Stable transfection of P. falciparum parasites with luciferase expression  
            plasmids  
Transfection of parasites was performed by Dr. A.C. van Brummelen (CSIR Biosciences) 
using methodology adapted from the following laboratory protocols: 
 
(i)  Stable transfection of P. falciparum parasites, Fidock Lab, Department of Microbiology 
and Immunology, Albert Einstein College of Medicine, Yeshiva University, NY, USA 
 
 (ii) Transfection of P. falciparum, Llinàs Lab, Department of Molecular Biology, Princeton 
University, NJ, USA 
 
Note: Complete malaria culture medium (CMCM; Appendix 1.1) was used with the 
exception that Albumax II was replaced with 10% human serum. 
 
4.1.1. Preparation of parasites 
a. Culture P. falciparum parasites as described in Chapter 2 (section 2.2.1). For each 
transfection, 80-100 µL of healthy ring-stage parasites at 5% parasitaemia is required.  
b. The day before transfecting: (i) In the morning, adjust the parasitaemia to 1.8 - 2.5% 
by the addition of fresh uninfected RBCs, in order to produce ~5% rings the next day; 
(ii) In the late afternoon, replace medium maintaining a 3% haematocrit. 
c. Transfection day: (i) About 3 hours before transfection, prepare smears and replace 
medium; (ii) Determine whether the cells are healthy, at the correct stage (primarily 
large, healthy rings) and ideal parasitaemia (~5%) for transfection. 
  
4.1.2. Preparation of the DNA: 
a. Prepare plasmid constructs in NEB5α Escherichia coli cells (New England BioLabs, 
Ipswich, MA) using standard molecular biology techniques. 
b. Purify plasmid DNA using the QIAGEN Plasmid Maxi Kit – 50-100 µg of DNA is 
required per transfection. 
c. Have all plasmids in cytomix and ready for transfection stored at 4 C, so that 
whenever parasites are ready, transfection can be performed. Equilibrate isolated 
plasmid DNA in cytomix (120 mM KCl (anhydr); 0.15 mM CaCl2; 10 mM KH2PO4 
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(anhydr); 25 mM HEPES; 2 mM EGTA; 5 mM MgCl2; adjust pH to 7.6 with KOH 
and filter sterilise (0.2µm)) for transfection using Amicon Centricon columns. 
 Columns hold a maximum volume of 2.5 mL. Load up to 300 µg DNA/column and 
exchange buffer with cytomix for transfection.  
 Parafilm the top of the column and puncture the parafilm with a sterile needle several 
times.  
 Centrifuge the column at 3000 rpm until there is less than 300 µL of cytomix in the 
column. For 300 µg of DNA, start with 45 minutes, check and then add time as 
needed. 
 Add cytomix to the column to bring up the volume to 300 uL and pipette up and down 
a few times without touching the filter. Thus, the final DNA concentration will be 1 
µg/µL. Flip upside down into collection tube and centrifuge at 3000 rpm for 5 minutes 
to recover DNA from the column. 
 Measure the volume of eluted DNA and determine the volume required to transfect 
the parasites with 100 µg of plasmid DNA (i.e. 100 µL/transfection for DNA 
concentration of 1 µg/µL). 
 
4.1.3. Transfection 
Note: Try and finish the entire transfection procedure in about 30 minutes from the time the 
parasites are harvested from the incubator to when the transformed parasites are returned to 
the incubator. Adhere to sterile technique. 
 
a. Label all electroporation cuvettes, tissue culture plates and microfuge tubes and pre-
set electroporator to required settings (0.31 kV, 950 F and max capacitance) before 
beginning transfection.  
b. Pre-prepare uninfected RBCs at 4% haematocrit in CCM and aliquot into the wells of 
a 6-well tissue culture plate at 3.5 mL per transfection per well. 
c. Harvest 2.5 mL culture/transfection into a sterile 15 ml conical tube and centrifuge at 
1300 rpm for 4 minutes at room temperature (RT).  
d. Remove and discard all the supernatant and resuspend the cell pellet in excess 
cytomix. 
e. Centrifuge the cells at 1300 rpm for 3 minutes at discard all supernatant. The cell 
pellet should be about 80-100 µL.   
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f. Add DNA and then cytomix to final volume of 400 µL. Assuming the cell pellet is 80 
µL and DNA concentration is 1µg/µL, add 100 l of DNA and 220 µL of cytomix. 
Make sure there are no bubbles. 
g. Carefully transfer the suspension into electroporation cuvettes without creating 
bubbles. Insert cuvette into shocking chamber and slide into place. Press both Pulse 
buttons and release as soon as beep is heard. Record time constant – time constants 
between 7 and 11 msec are good. You will always hear a slight ―pop.‖ If you chill the 
cuvettes briefly (< 30 secs) immediately before zapping, they will not pop as much 
into the top of the cuvette.  
h. Immediately after electroporating, add 1 mL of CCM gently down the side of each 
cuvette, aseptically on the bench. When all electroporations are complete, transfer 
them back to the laminar flow hood. 
i. Resuspend the cells by pipetting gently up/down in cuvette to remove all/most cells 
and transfer to the pre-prepared wells of the tissue culture plates, but do not take any 
of the lysed and dried culture around the top of cuvette. Wash cuvette with another 1 
mL of CCM and add to well before transferring the plates to an airtight chamber. 
Suffuse the chamber with the special gas mixture (5% CO2, 5% O2, balance N2; Air 
Products, RSA) and incubate at 37°C – this is Day 0.  
j. Three to four hours post-transfection, remove cultures from wells and centrifuge at 
1300 rpm for 4 minutes at RT. Discard supernatant and gently resuspend cells in 5 mL 
fresh CCM before transferring to a new plate and returning to incubator in gassed 
chamber.  
 
4.1.4. Continuing care of transfection cultures: 
a. Keep cultures stationary for the first 7 days and thereafter shake at 50 rpm until 
parasites come up. 
b. Adding drug on Day 2: Spin down the cultures and prepare smears. The parasitaemia 
should be between 1-2%. If the parasitaemia is > 3%, cut the culture at 1:2 with fresh 
RBCs or split into 2 wells because the drug will not kill the parasites quickly enough 
before they crash. Resuspend in CCM supplemented with the appropriate drug – 2.5 
nM WR9210 or 2.5 µg/mL blasticidin.  
c. Medium changes/Smearing: Change the media every day for the first 6 days on a 
regular schedule. Smear on day 6 to make sure that all the parasites are dead. 
WR99210 kills by day 4 and blasticidin by day 6. If there are a lot of gametocytes (> 
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1%) in days 6-10, the culture is very stressed and it may take longer for parasites to 
appear. After day 6, feed every other day and smear once or twice a week to check for 
parasites. 
d. Most important: Between days 10-14 cultures must be cut at 3:5 to 1:2 to add fresh 
RBCs and remove old lysing cells, and then every 7-8 days. Cultures are about to lyse 
if they are very dark despite having low parasitaemia, > 50% of the RBCs on the 
smear are blebby, or if there is a layer of reddish colour immediately over the cells 
(from the side view).  
 
4.1.5. When parasites come up: 
a. Smear once or twice a week, scanning the slide for evidence of life (rings!). Parasites 
should appear between day 20-30, but transfections may come up as early as day 10, 
or as late as day 45, depending on how quickly your parasite strain grows, and how 
well the transfection went (health of starting cultures, stress during transfection, 
parasitaemia on day 2, care of transfections in first 10 days, etc.). 
b. As soon as parasitaemias reach ~2 % with > 50 % rings, cultures should be frozen 
down – two aliquots should be frozen on separate days (see Chapter 2, section 2.2.1.3 
for details). Remaining culture should be expanded and harvested for genomic DNA 
extraction (for microsatellite analysis, plasmid rescue and PCR screening for 
integration). 
c. At some point between days 45 - 90 integration of the plasmid into the genome may 
occur. These integrant parasites will grow quicker than episomally transformed 
parasites. When growth rates increase, genomic DNA should be extracted and PCRs 
performed to confirm integration of the plasmid into the genome. Genomic DNA can 
be extracted every 3-4 weeks to screen for integration. Integration can occur as early 
as day 24, and as late as day 150. 
d. Once genomic DNA is extracted, the remaining culture can be down-sized to 1 or 2 
ml cultures and should be kept at lower parasitaemias, such that they will only need 
cutting twice per week (i.e. Monday and Friday) and medium changes every other 
day. Note that the growth rate of episomally transformed cultures are slower than 
normal. 
e. Stably transfected cultures are maintained in the same manner as wildtype cultures 
(see Chapter 2, section 2.2.1) with the exception that CCM is supplemented with 
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WR99210. Two aliquots of transfection cultures should be frozen down once a month 
(see Chapter 2; section 2.2.1.3 for details). 
   
4.2. Bright-Glo reagent  
Bright-Glo Luciferase Assay System (Promega, Madison, WI) stored at -20°C. 
 
Thaw the buffer and lyophilised substrate to room temperature (≤ 25°C), combine and 
aliquot. Store aliquots protected from light at -80°C for up to 1 month. 
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APPENDIX 5: DETERMINING EFFECTIVE TREATMENT CONCENTRATIONS  
                        FOR THE PANEL OF ANTIMALARIAL DRUGS USED IN THIS  
   STUDY 
 
Based on the data in Table 5.1 below, the following treatment concentrations were selected 
for the ATP assay: chloroquine, artemisinin, mefloquine = 100 nM; DFMO = 10 mM; 
ritonavir = 100 µM. 
 
Table 5.1: Previously reported IC50 values against P. falciparum for the panel of 
antimalarials used in this study. 
Drug 
P. falciparum 
strain 
IC50 
Test 
concentration 
Reference 
Chloroquine 
3D7 8.5 nM - Amewu et al., 2006 
3D7 9.7 nM - Vivas et al., 2008 
3D7 10.6 nM - Biot et al., 2006 
3D7 11.3 nM - Aunpad et al., 2009 
3D7 14 nM - Penali et al., 2007 
3D7 22.2 nM - He et al., 2010 
3D7 31 nM - Jansen et al., 2010 
3D7 38.8 nM - Bero et al., 2009 
DFMO 
3D7 1 mM 5 mM van Brummelen et al., 2009 
FCR-3 - 5-10 mM Assaraf et al., 1984 
FCR-3 - 10 mM Assaraf et al., 1987 
FCD-3 1.8 mM - Das et al., 1995 
3D7 1.25 mM - Gupta et al., 2005 
Mefloquine 
3D7 6.11 nM - Vivas et al., 2008 
3D7 18.2 nM - Aunpad et al., 2009 
3D7 19.3 nM - Wong et al., 2011 
3D7 26.8 nM - Varotti et al., 2008 
3D7 38.7 nM - Biot et al., 2006 
3D7 50 nM - Veiga et al., 2010 
Artemisinin 
3D7 3.5 nM - Wong et al., 2011 
3D7 9.5 nM - Amewu et al., 2006 
3D7 14.1 nM - Sanella et al., 2007 
3D7 15.2 nM - O‘ Neill et al., 2005 
3D7 23.7 nM - Jansen et al., 2010 
3D7 35.4 nM - Bero et al., 2009 
Ritonavir 
3D7 1.7 µM - Andrews et al., 2006 
3D7 5.62 µM - He et al., 2010 
3D7 10.9 µM - Nsanzabana & Rosenthal, 2011 
3D7 12.2 µM - Parikh et al., 2006 
3D7 15 µM - This study, Figure 5.1 below 
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Figure 5.1: IC50 determination of ritonavir against P. falciparum. Trophozoite-stage cultures 
were exposed to two-fold serial dilutions of ritonavir (final concentration ranges: 3.00x102–5.08x10-3 µM) for 
48 hours. Percentage parasite viability was determined using the pLDH assay (section 3.2.3) and the IC50 was 
determined from a log dose-response curve using GraphPad Prism software. Each data point represents the 
mean ± SD, n = 2. 
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APPENDIX 6: STATISTICAL ANALYSES (ATP ASSAY) 
 
Table 6.1: T-test results for comparing ATP levels (measured as relative light units, 
RLU) of control and drug-treated parasites over a 10-hour period. 
  Time 
(h) 
Luminescence (RLU) 
P-value 
 Untreated control Treatment 
C
H
L
O
R
O
Q
U
IN
E
 0 15646 8555   7443 17381   0.9767 
2 34519 35930 39134 68756 58600 39266 0.1980 
4 103377 92133 118010 121291 100728 78276 0.8281 
6 222592 209588 189911 199055 152017 118829 0.0697 
8 262559 277111 257590 328202 261676 180959 0.8505 
10 139663 182308 137045 191697 144871 137301 0.8662 
D
F
M
O
 
0 180287 157005 139355 203531 202217 158971 0.0668 
2 26093 41075 40764 64920 82394 46114 0.1333 
4  75647 69944  55578 77958 0.7419 
6  63764 68167  73962 59680 0.9418 
8 82042 65484 102541 115685 99430 115298 0.0622 
10 240758 228520 212982 268358 223592 246120 0.2577 
M
E
F
L
O
Q
U
IN
E
 0 203621 257406 203532 254061 279652 213624 0.1472 
2 52559 63060 38879 101457 60111 82379 0.2117 
4 43626 100731 84531 196533 166645 192639 0.0492 
6 111475 144281 139064 178044 221681 204247 0.0031 
8 129744 236478 169154 228093 185399 249172 0.4624 
10 158935 192220 112165 177915 198484 250367 0.3242 
A
R
T
E
M
IS
IN
IN
 0 347735 300378 366726 273371 408822 316418 0.9335 
2 48136 29660 41057 152743 170442 206194 0.0161 
4 107912 135300 113482 237751 231683 253011 0.0113 
6 84468 145851 106442 216911 201695 199913 0.0512 
8 61654 101993 136782 204447 177762 158262 0.1501 
10 118667 123605 117779 321068 280007 265112 0.0101 
R
IT
O
N
A
V
IR
 0  313160 319906  214484 256773 0.1377 
2 95504 90450 86436 1125 6120 2310 0.0015 
4  116703 153628  3221 2916 0.0891 
6 175473 106107 140248 937 1713 2286 0.0206 
8 168103 176646 150786 2217 750 5018 0.0030 
10 157966 170946 139063 1358 2645 3211 0.0038 
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Table 6.2: T-test results for comparing percentage parasite viability of control and 
drug-treated parasites: (i) after a 6-hour treatment and (ii) 48 hours after removal of 
the drug. 
  
Drug 
% Parasite Viability 
P-value 
  Control Treatment 
F
ol
lo
w
in
g 
a 
6-
ho
ur
 d
ru
g 
tr
ea
tm
en
t 
CQ 101.98 103.64 94.38 87.24 92.44 92.69 0.1419 
DFMO 86.57 97.95 115.48 108.24 94.35 103.34 0.8636 
MEF 100.63 100.52 98.85 86.03 82.07 87.41 0.0182 
ART 90.29 107.06 102.65 82.96 82.44 84.62 0.0805 
RIT 105.24 98.39 96.37 70.54 73.90 80.33 0.0433 
48
 h
ou
rs
 a
ft
er
 
re
m
ov
al
 o
f 
dr
ug
 
CQ 109.37 98.41 92.22 0.40 4.07 22.99 0.0159 
DFMO 110.11 93.39 96.50 82.77 82.36 89.84 0.1398 
MEF 99.77 101.80 98.43 57.95 51.13 59.40 0.0063 
ART 98.14 96.18 105.68 47.33 53.07 36.94 0.0191 
RIT 101.59 101.84 96.56 6.75 10.11 15.07 0.0020 
 
Note: CQ – 100 nM chloroquine; DFMO – 10 mM DL-α-difluoromethylornithine; MEF – 100 nM mefloquine; 
ART – 100 nM artemisinin; RIT – 100 µM ritonavir. 
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APPENDIX 7: STATISTICAL ANALYSES (LUCIFERASE ASSAY) 
 
7.1. Luciferase assays 
Table 7.1: T-test results for comparing luciferase activity (measured as relative light 
units, RLU) of control and drug-treated transgenic parasites over a 10-hour period. 
 
Time 
(h) 
Luminescence (RLU) 
P-value 
  Untreated control Treatment 
C
H
L
O
R
O
Q
U
IN
E
 
2 1122792 1135220 1161427 1114444 1131018 1154462 0.0334 
4 1624619 1565411 1550456 1470395 1470118 1476366 0.0460 
6 1843140 1919962 1876667 1668529 1677102 1673088 0.0090 
8 2255781 2270968 2280419 1939037 1899480 1846652 0.0081 
10 2424750 2463256 2472402 2005687 1978203 1892323 0.0088 
D
F
M
O
 
2 1151942 1175345 1126576 1169837 1171990 1173610 0.2951 
4 1548971 1517604 1521085 1493519 1478117 1486485 0.0206 
6 1882597 1883848 1877151 1707241 1704277 1725099 0.0026 
8 2175676 2201653 2197486 1883984 1897428 1920885 0.0008 
10 2314402 2391607 2405235 1967261 1959193 2005835 0.0040 
M
E
F
L
O
Q
U
IN
E
 
2 1068543 1103156 1126093 592811 618868 619048 0.0004 
4 1525561 1536325 1534993 569568 564547 567318 0.0000 
6 1876207 1876098 1875251 560900 677688 656483 0.0008 
8 2163910 2153942 2193879 662591 731057 726984 0.0002 
10 2359820 2432798 2447317 753132 755304 755427 0.0003 
10
0 
nM
 
 R
T
E
M
IS
IN
IN
 
2 1955654 1998676 2004426 1847839 1788982 1812592 0.0326 
4 2213200 2095381 2130932 1912448 2211172 2158983 0.7200 
6 3188196 3130931 3050952 2971665 2953970 2891520 0.0083 
8 2713456 2634770 2507764 2573214 2511762 2459613 0.0668 
10 2678600 2665420 2588218 2797483 2827012 2815603 0.0330 
50
0 
nM
 
A
R
T
E
M
IS
IN
IN
 
2 1173540 1137779 1133876 368864 390675 383248 0.0006 
4 1539472 1530216 1532835 111012 109447 106320 0.0000 
6 1898968 1898183 1896089 73621 71271 66768 0.0000 
8 2311966 2266280 2264829 55235 53918 51062 0.0000 
10 2365821 2431478 2458806 47208 42305 42071 0.0002 
R
IT
O
N
A
V
IR
 2 799676 801699 798510 522527 537373 527696 0.0002 
4 1240990 1234286 1239954 447811 455675 427037 0.0002 
6 2117281 2034637 2021813 145794 170474 192287 0.0005 
8 3026346 2780699 2734315 102593 104139 109030 0.0011 
10 2192257 2206089 2169329 40117 38903 30587 0.0000 
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Table 7.2: T-test results for comparing luciferase activity (measured as relative light 
units, RLU) of HSP-Luc and LYS-Luc transgenic parasites. 
Luminescence (RLU) 
P-value 
HSP-Luc  LYS-Luc 
1496187 1467729 46657 48277 0.0067 
 
Table 7.3: T-test results for comparing the luciferase activity (measured as relative light 
units, RLU) of untreated transgenic HSP-Luc parasites with those of parasites treated 
with antimalarials and/or proteasome inhibitors. 
Sample 
Luminescence (RLU) 
P-value 
Control Treatment 
Mefloquine (MQ) 520115 535073 536490 226040 225260 220702 0.0004 
Lactacystin (LC) 511996 519286 529460 511996 519286 529460 0.0001 
MG-132 (MG) 514856 522357 532573 214440 220974 223318 0.0000 
MQ+LC 511657 514973 517905 514856 522357 532573 0.0000 
MQ+MG 524843 525538 535510 365164 375438 384686 0.0002 
 
 
7.2. pLDH assays 
Table 7.4: T-test results for comparing the IC50s of artemisinin, chloroquine and 
mefloquine against wildtype parasites with those against luciferase transgenic parasites. 
Figure Drug 
IC50s P-value 
WT HL LL WT vs. HL WT vs. LL 
4.8a Artemisinin 14.16 13.42 37.08 28.56 - - 0.0470 - 
4.8b Artemisinin 35.58 26.30 85.26 77.05 - - 0.0149 - 
4.10a Artemisinin 34.02 37.52 60.93 47.06 37.75 33.85 0.1256 0.9919 
4.10b Artemisinin 37.04 38.03 51.70 49.85 39.51 39.23 0.0062 0.0704 
4.11a,b Chloroquine 30.09 34.48 33.50 34.48 - - 0.5275 - 
4.11c,d Mefloquine 19.32 19.12 20.11 15.94 - - 0.6248 - 
 
Note: (i) The ―Figure‖ column contains the number of the figure in this chapter from which the experimental 
data was extracted to do the calculations, (ii) WT, wildtype parasites; HL, HSP-Luc parasites; LL, LYS-Luc 
parasites. 
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APPENDIX 8: DETERMINING EFFECTIVE TREATMENT CONCENTRATIONS   
                           FOR THE PROTEASOME INHIBITORS USED IN THE  
                           LUCIFERASE ASSAY 
 
In order to determine effective treatment concentrations for the proteasome inhibitors used in 
the Luciferase assay (see section 4.3.5 above), median inhibition concentrations (IC50s) were 
determined for lactacystin and MG-132 against luciferase transgenic P. falciparum parasites. 
Based on the IC50s obtained, the following treatment concentrations were chosen for the 
assay: lactacystin = 5 µM; MG-132 = 300 nM. 
 
 
Figure 8.1: IC50 determinations of proteasome inhibitors against HSP-Luc parasites. 
Trophozoite-stage cultures were exposed to two-fold serial dilutions of the drugs (final concentration ranges: (i) 
lactacystin = 1.00x102–1.69x10-3 µM; (ii) MG-132 = 1.00x100–5.08x10-5 µM) for 48 hours. Percentage parasite 
viability was determined using the pLDH assay (section 3.2.3) and the IC50s were determined from a log dose-
response curve using GraphPad Prism software (Fig. 8.1a, Lactacystin IC50 = 0.84 µM; Fig. 8.1b, MG-132 
IC50 = 58.5 nM). Each data point represents the mean ± SD, n = 2. 
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